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ABSTRACT
Despite advances in care for individuals with insulin-dependent diabetes mellitus 
(IDDM) over the last seventy five years the management of diabetic pregnancy still 
presents a challenge to the medical profession with perinatal morbidity and mortality, 
and maternal morbidity remaining higher than in normal pregnancy. One cause of 
this is pre-eclampsia which is twice as common in IDDM pregnancy.
Blood pressure control is multi-factorial. Among systems involved are the 
calcium/phosphate/magnesium homeostatic mechanisms and the 
renin/angiotensin/aldosterone system. These are disordered in non-pregnant IDDM 
but have only been studied minimally in IDDM pregnancy. This thesis describes 
studies performed on normal and IDDM women during and after pregnancy:
• Assessment of dietary calcium
• A prospective, randomized, double-blind, placebo-controlled trial on the effect on 
blood pressure of a daily 1.5g calcium supplement, given from 20 weeks until 
delivery
• A longitudinal study of the short term effects o f a standard meal and lg  oral 
calcium load on calcium homeostasis and plasma renin and substrate 
concentrations
Results presented show that both groups o f women received adequate dietary calcium 
during pregnancy and that calcium supplementation did not affect blood pressure. 
Pregnancy-induced changes in blood pressure are different in IDDM women who 
have no mid-trimester fall. In IDDM, compared with normal pregnancy serum 
ionized calcium and urinary calcium excretion are identical, serum magnesium does 
not fall and intact parathyroid hormone concentrations are lower. Phosphate excretion 
is increased in pregnant and non-pregnant IDDM women.
Plasma renin concentration correlates negatively with serum ionized calcium in 
normal but not IDDM women; during pregnancy plasma renin concentration rises in 
normal but not IDDM women . Plasma renin substrate rises throughout normal
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pregnancy, in IDDM pregnancy there is no further rise beyond 20 weeks. These 
observations suggest impaired synthesis or release of renin in IDDM with additional 
inhibitory factors acting in IDDM pregnancy.
The observed differences between normal and IDDM pregnancy, whilst interesting in 




This thesis will investigate the hypothesis that pregnant insulin-dependent diabetic 
(IDDM) women have abnormalities in both calcium metabolism and the renin- 
angiotensin system (RAS) which predispose them to the development o f pre-eclampsia 
(PE). It will also look in detail at the effect o f calcium supplementation on these 
systems and on arterial blood pressure in normal and IDDM pregnancy. The remainder 
of this chapter provides an overview introduction to these various components, linking 
them where the current state o f knowledge allows.
1.1 Historical perspective
Before the introduction of insulin in 1922 the only treatment for diabetes was “planned 
undemutrition”, a system o f dietary manipulation which verged on starvation. If young 
women survived they tended to be amenorrhoeic and therefore infertile.
One of the first reported cases of diabetic pregnancy described a woman who 
developed intense thirst and polyuria in her fourth pregnancy and subsequently 
delivered a stillborn infant weighing 12 pounds (Bennewitz, 1824). In 22 cases of 
diabetic pregnancy, presented to the London Obstetrical Society in 1882, perinatal 
mortality was 43%, 4 women died in coma at the time o f delivery and 7 more died 
within the next 2 years. American figures were similar with maternal mortality for 
diabetic women in the Joslin Clinic between 1889 and 1917 being 34% and perinatal 
loss 60% (Hare & White, 1977).
With the introduction of insulin more diabetic women survived and became pregnant. 
Maternal mortality fell to 9.3% but fetal loss remained high at 45.2% (Skipper, 1933). 
Throughout the twentieth century regimes o f tight maternal glucose control and 
improved paediatric care, including early feeding, for the infant have continued to 
improve these figures. In 545 diabetic pregnancies at King’s College Hospital, London 
between 1971 and 1986 there was only one maternal death, in a woman with advanced 
diabetic nephropathy, and the perinatal mortality rate was 2.8% (Brudenell, 1989). 
More recently the Northern Diabetic Pregnancy Audit reported a perinatal mortality
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rate o f 38/1000 for diabetic pregnancy compared to the background rate of 9/1000 
(Hawthorne, Robson, Ryall, Sen, Roberts & Ward-Platt, 1996). As this illustrates all 
the problems attending diabetic pregnancy have not been solved and they continue to 
have an increased complication rate when compared with non-diabetic pregnancies.
The measurement o f arterial blood pressure is an integral part o f the examination of 
every pregnant woman mainly because it is used both to detect and define PE and 
eclampsia. These pregnancy-specific disorders remain common, poorly understood, 
serious and sometimes fatal. Between 1994 and 1996 PE and its sequelae were 
responsible for 20 direct maternal deaths, a rate o f 9.1 per 1 000 000 maternities, 
making it the second commonest cause of maternal mortality in the United Kingdom 
after thromboembolism (21.8 per 1 000 000); the overal direct maternal mortality rate 
for the same period was 74 per 1 000 000 (HMSO, 1998).
The incidence of PE is difficult to determine because of a lack of uniformity of 
definition between authors (see below). It is, however, generally accepted to be 
approximately twice as common in diabetic pregnancy as in non-diabetic pregnancy 
(Brohman, 1983; Gamer, D’Alton, Dudley, Huard & Hardie, 1990) but the reason for 
this as well as the aetiology of PE remains unknown. Angiotensin II (Ang II) is one of 
the most potent vasoconstrictors known to man and it is now well established that 
sensitivity to this substance is reduced in normal pregnancy (see below). In non­
diabetic women abnormalities in the RAS have been demonstrated in hypertensive 
pregnancy (Symonds & Broughton Pipkin, 1978) and subsequently Broughton Pipkin 
showed that in diabetic pregnancy the plasma renin and aldosterone concentrations are 
higher than in non-diabetic pregnancy and the plasma renin substrate (PRS) is lower 
(Broughton Pipkin, Hunter, Oats & O’Brien, 1982). It is possible that abnormalities 
within the RAS system o f diabetic subjects may increase the frequency o f pregnancy- 
induced hypertension and PE.
For many years it has been known that the renal excretion of calcium is reduced in PE. 
Recently much interest has been focused on calcium supplementation in the prevention 
o f pre-eclampsia (Belizan, Villar, Zalazar, Rojas, Chan & Bryce, 1983a; Belizan, Villar, 
Gonzalez, Campodonico & Bergei, 1991; Lopez-Jaramillo, Narvaez, Weigel & Yepez,
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1989; Villar, Repke, Belizan & Pareja, 1987). Non-pregnant diabetic individuals have 
been shown to have multiple abnormalities in calcium metabolism - low levels of serum 
ionized calcium (iCa2+) have been reported (Fogh-Anderson, McNair, Moller-Petersen 
& Madsbad, 1982 & 1983), intact parathyroid hormone (iPTH) is low in diabetic 
subjects (Thalassinos, Hadjiyanni, Tzanela, Alevizaki & Philokiprou, 1993), urinary 
calcium excretion is increased (McNair, Madsbad, Christensen, Christiansen, Faber, 
Binder & Transb0 l, 1979) and there is reduced bone mineralization in insulin- 
dependent diabetes (McNair, Madsbad, Christiansen, Faber, Transb0 l & Binder, 
1978a).
Four years after work on this thesis began the results of the National Institutes of 
Health trial o f calcium supplementation to prevent PE have been published and show 
no beneficial effect of calcium supplements in normal healthy nulliparous women 
whose diet already contains adequate calcium, in preventing either PE or pregnancy- 
induced hypertension (PIH) (Levine, Hauth, Curet, Sibai, Catalano, Morris, 
DerSimonian, Esterlitz, Raymond, Bild, Clemens & Cutler, 1997). However IDDM 
women were excluded from this trial and for the reasons, alluded to above, and dealt 
with more fully later, their response to calcium supplementation may well differ from 
the normal response. To the author’s knowledge this has not been investigated before.
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1.2 CALCIUM HOMEOSTASIS
Calcium is the fifth most abundant element in the human body with an average 70kg 
adult containing 1 lOOg of calcium. Calcium plays essential roles in muscle contraction, 
neural transmission, blood coagulation, membrane transport and enzyme activity, while 
as calcium phosphate it provides skeletal strength (Guyton, 1986).
Calcium metabolism consists of several intricate and interrelated mechanisms which 
normally operate to maintain the concentration of iCa2+ in the extracellular fluid (ECF) 
within narrow physiological limits. The metabolism of other minerals such as Mg (Mg) 
and inorganic phosphate (PO4) are linked with calcium metabolism. Like calcium Mg 
is a divalent cation among the transition elements and so it is almost impossible to 
think of the physiology of one in isolation from the other. Hormonal control is exerted 
by parathyroid hormone (PTH), calcitonin (CT) and the vitamin D group of steroid 
hormones.
Serum calcium (normal range 2.25 - 2.65 mmol/1) is present in three different forms: 
approximately 40% is bound to plasma proteins, especially albumin; about 9% forms 
complexes with citrates and phosphates in such a way that it is not ionized and the 
remainder is ionized Ca2+ and can difliise through the capillary membrane (Guyton, 
1986). Anything which causes the concentration of albumin to rise or fall will have a 
parallel effect on the total serum calcium but the iCa2+ remains unchanged, controlled 
by the mechanisms described below.
1.2A Calcium absorption
In the non-pregnant state the recommended minimum adult daily intake o f calcium is 
900mg and in pregnancy 1250mg (Committee On Medical Aspects of food policy, 
1991). The majority o f this comes from dairy products as the calcium content o f the 
non-dairy part of an average diet rarely exceeds 500mg. A pint of milk contains 
700mg of calcium. Of note, this is in the whey not the curds, and so a low-fat diet 
containing skimmed or semi-skimmed milk contains marginally more calcium per pint. 




190mg daily is lost via intestinal secretions, overall only about one sixth of the total 
daily intake is utilized (Guyton, 1986).
Dietary absorption of calcium occurs in the small intestine by active transport and 
facilitated diffusion, both regulated by the 1,25-dihydroxycholecalciferol (DHCC) 
component of vitamin D -  see below. The active transport mechanism is saturable 
whilst the rate of diffusion of calcium from the lumen of the intestine into the mucosal 
cells depends directly on the calcium concentration in the gut lumen, in other words the 
dietary calcium intake. In conditions of relatively high calcium intake and in areas of 
the intestine where the intra-luminal concentration o f calcium is high the passive 
diffusion process predominates. However when calcium intake is low and the intra­
luminal calcium concentration is less than 6mmol/L the active transport process is most 
important (Bringhurst & Potts, 1979). The same authors, on reviewing the evidence, 
suggest that “the greatest proportion of intestinal calcium absorption is accomplished 
in the ileum, especially under natural conditions where calcium is ingested along with 
solid food. The active transport process seems to predominate in the duodenum and 
jejunum and [predominates].. ..when the calcium content o f the diet is low”.
In addition to vitamin D physiological control o f intestinal absorption of calcium is 
influenced by PTH but this is an indirect effect mediated by increased synthesis of 
1,25-DHCC as discussed below.
1.2B Vitamin D
Several vitamin D compounds exist and are obtained either from the diet or by the 
action o f ultraviolet on 7-dehydrocholesterol in the skin. The latter reaction produces 
vitamin D3 or cholecalciferol which is hydroxylated in the liver to 25- 
hydroxycholecalciferol (HCC) and this is then hydroxylated again, at the 1 position, in 
the kidneys to the biologically active 1,25-DHCC. Alternatively the 25-HCC can be 
hydroxylated at the 24 position to 24,25-DHCC. It appears that in vitamin D deficient 
states the major conversion is to the active 1,25-DHCC (Boyle, Gray & deLuca, 1971) 
whereas when the diet contains high levels of calcium and a source of vitamin D then 
the predominant conversion is to 24,25-DHCC (Holick, Schnoes, deLuca, Gray, Boyle
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& Suda, 1972). The latter compound is rapidly metabolized in the liver and excreted in 
bile and so is unlikely to have a significant physiological role (Holick, Baxter & 
Schraufrogel, 1976).
The second hydroxylation from 25-HCC to 1,25-DHCC is the rate limiting step and so 
renal-1-hydroxylase activity, is the major determinant of intestinal calcium absorption 
in the non-pregnant state. Renal-1-hydroxylase is stimulated by PTH (Garabedian, 
Holick, deLuca & Boyle, 1972; Henry, 1979); low calcium (probably via PTH) and 
directly by low phosphate levels (Baxter & deLuca, 1976); various peptide hormones 
including growth hormone and prolactin (Spanos, Brown, Stevenson & MacIntyre, 
1981); and oestrogen (Kenney, 1976; Castillo, Tanaka, deLuca & Sunde, 1977). The 
stimulatory effect o f PTH on renal-1-hydroxylase is impaired in diabetes and this 
impairment is corrected by insulin replacement (Wongsurawat & Armbrecht, 1985). 
Conversely renal-1-hydroxylase is inhibited by negative feedback by 1,25-DHCC and 
low levels of PTH.
1.2C Parathyroid hormone
PTH is a small protein with a molecular weight of approximately 9 500, made up of 84 
amino acids, secreted by the chief cells of the parathyroid glands. The human form 
was first isolated in small quantities by O’Riordan and colleagues in 1971. Subsequent 
work which extracted larger quantities of a more highly purified form of the hormone 
allowed its amino acid sequence to be established (Keutmann, Barling, Hendy, Segre, 
Niall, Aurbach, Potts & O’Riordan, 1974). Smaller compounds with some PTH 
activity have also been isolated from the parathyroid glands but this activity is always 
less than that o f intact PTH and it seems likely that these compounds are breakdown 
products of PTH (Segre, 1979).
PTH secretion is regulated predominantly by the ionized fraction of serum calcium 
being increased by hypocalcaemia and suppressed by hypercalcaemia but the 
relationship is not linear; instead it is sigmoid so that changes in PTH secretion occur 
over a narrow range o f serum iCa2+ which corresponds with the lower end of the 
physiological range (fig. 1.2i). Thus if serum iCa2+ is falling and serious hypocalcaemia
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is threatened then scretion of PTH is maximal and so serum iCa2+ is maintained, 
whereas if serum iCa2+ is well within the physiological range PTH secretion is minimal.
PTH secretion 
rate
Serum ionized calcium concentration
Fig.l.2i The relationship between serum iCa2+ and PTH secretion (after several 
authors)
Additional factors also regulate PTH secretion. As mentioned above PTH influences 
vitamin D metabolism and it appears that there is a reciprocal relationship with 
metabolites of vitamin D such as 24,25-DHCC, which are produced in conditions of 
calcium plenty, having an inhibitory effect on PTH secretion (Bates, Care, Peacock, 
Mawer, & Taylor, 1975). Mg deficiency also impairs PTH release (Anast, Winnacker, 
Forte & Bums, 1976). Secretion of PTH is increased by adrenergic agonists via p 
receptors (Kukreja, Hargis, Bowser, Henderson, Fisherman & Williams, 1975) and by 
intravenous infusion of saline (Zemel, Bedford, Standley & Sowers, 1989). Plasma 
inorganic phosphate does not have a direct effect on PTH secretion although it 
indirectly increases plasma concentration of PTH by causing a fall in iCa2 
concentration.
1.2D Calcium excretion
As early as 1946 Elizabeth Knapp showed that in over 600 people studied, from age 1 
to 80, urinary calcium excretion (UCE) increased with increasing calcium intake per 
unit weight. She also postulated that UCE was under the influence of an, as yet, 
unrecognised endocrine factor. Subsequently this factor was identified as PTH.
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At normal glomerular filtration rates about 215 mmol of calcium is filtered daily but the 
average daily UCE is around 4mmol; this corresponds to 0.16g (Lemann, Adams & 
Gray, 1979). From this it can be seen that virtually all of the calcium filtered by the 
kidney is reabsorbed. This reabsorption is distributed throughout the kidney with 
approximately 60% occurring in the proximal tubule, 20 -25% in the Loop o f Henle 
and the remainder in the distal tubule and collecting ducts (Bringhurst & Potts, 1979). 
No calcium is secreted by the kidney tubules.
In the proximal tubule calcium is reabsorbed actively and this process is closely linked 
to sodium reabsorption in dogs (Beck & Goldberg, 1973). In humans acute 
administration of sodium chloride has much less effect on UCE (Lemann et al, 1979). 
The active transport mechanism is voltage dependent but is not affected by PTH. The 
mechanism for calcium reabsorption in the Loop of Henle is controversial.
It is in the distal tubule and collecting ducts that calcium reabsorption is finely 
controlled depending on the calcium concentration of the blood. At low serum 
concentrations virtually no calcium is excreted but if the serum concentration rises 
above the normal range then urinary calcium excretion (UCE) increases markedly. 
Distal reabsorption of calcium is increased by raised levels of PTH which acts via 
cyclic adenosine monophosphate (cAMP); PTH also increases renal excretion of 
phosphate (Agus, Gardner & Beck, 1973).
The normal range of UCE is wide (Knapp, 1946 and Lemann et al, 1979) and it is 
difficult to set an upper limit of normal. Early studies suggested that it was mainly 
dependent on skeletal weight and dietary calcium intake (Knapp, 1946; MacFadyen, 
Nordin, Smith, Wayne & Rae, 1965; Peacock, Hodgkinson & Nordin, 1967). 
Subsequently a non-hospital based study on factors influencing UCE concluded that it 
“is determined more by the absorption of calcium from the intestine than by the intake 
of calcium, and that the efficiency o f absorption decreases in men and women as they 
grow older” (Davis, Morgan & Rivlin, 1970).
UCE rises with ingestion or infusion of glucose (Lindeman, Adler, Yiexgst & Beard, 
1967; Lemann, Lennon, Piering, Prien & Riccannati, 1970). In the study by Lemann
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and colleagues serum ultrafiltrable calcium and Mg were measured and were shown 
not to be affected by an oral glucose load. The subjects then stood, a manoeuvre 
which had previously been shown to decrease inulin clearance and therefore the GFR. 
Despite this reduction in GFR the urinaiy excretion of both calcium and Mg rose 
suggesting that glucose is affecting the net tubular reabsorption of these cations. PTH 
was not thought to be likely to be responsible for this change in tubular function partly 
because the effect was too rapid and also because a similar effect was observed in 
individuals known to have deficient PTH secretion. Lemann concluded that “the 
inhibition of net reabsorption o f calcium and Mg after glucose appears more likely to 
be a consequence of an alteration by glucose of renal tubular cell metabolism”.
Increased protein intake increases the UCE (Lindemann et al, 1967; Kerstetter & 
Allen, 1990) as does a metabolic acidosis produced by administration of ammonium 
chloride, (Lemann et al, 1979). The latter is probably the mechanism by which a high 
protein intake increases the UCE. Alcohol also increases UCE (Lindemann et al, 
1967). Numerous studies by Lemann and colleagues over twenty years looked at the 
effect o f dietaiy phosphate on UCE and concluded that except in cases of extreme 
phosphate deprivation, when UCE rose, it had little effect (Lemann et al, 1979).
1.2E Bone and its relationship to extracellular calcium
This aspect o f calcium metabolism was not studied in detail in this thesis. Therefore a 
brief summary only of this important topic is given below.
The majority of the calcium present in the body is found in bone where it combines 
with phosphate to produce crystalline salts known as hydroxyapatites:
Ca2+,o-x(H30 +)2x . (P04)6(0H-)2
The relative ratio of calcium to phosphorus in these long, flat crystals varies markedly 
under different nutritional conditions.
If  the iCa2+ concentration of the blood is raised or lowered acutely it rapidly returns to 
normal. This is achieved by there being exchangeable calcium which is always in
equilibrium with the serum calcium. The majority of this exchangeable calcium is 
found in bone and accounts for 0.4 - 1% of the total bone calcium. This buffering 
effect of bone on serum calcium acts almost instantaneously and is not dependent on 
any hormones. Hormonal activity comes into play within a few minutes of a change in 
serum iCa2+ concentration. PTH increases serum calcium by promoting the resorption 
of bone, while the reverse activity is controlled by CT. CT acts mainly in the short 
term and is eventually over-ridden by the PTH control mechanism. Over a prolonged 
period of time it is the PTH system that sets the long-term level o f iCa2+ in the ECF. 
As the buffering capacity of bone on the serum iCa2+ is vast PTH mainly acts via bone. 
However if the skeleton becomes saturated with calcium then the slight rise in serum 
iCa2+ which occurs leads to a fall in the secretion of PTH and so the intestinal and renal 
absorption of calcium is reduced and therefore serum calcium returns to normal 
(Guyton, 1986).
1.2F Calcium metabolism in pregnancy
Pregnancy creates great demands on maternal calcium stores; the mineral content of an 
average mature baby is about 28g (700mmol) of calcium and 16g o f phosphorus, with 
99% and 85% respectively in the skeleton. The combination of progressive skeletal 
mineralization and exponential growth means that some 70% o f this calcium is 
deposited in the third trimester; the net flux o f calcium into the fetus towards the end 
of pregnancy is about 250mg (6.25mmol) per day (Misra & Anderson, 1990). The 
control of this process is achieved by integration and collaboration between the fetal 
and maternal endocrine systems.
Maternal calcium physiology
Total calcium levels in the maternal serum decline during pregnancy paralleling a fall in 
albumin concentration produced by an increase in plasma volume (Pitkin, Reynolds, 
Williams & Hargis, 1979). This rise in plasma volume is approximately 1 250ml in 
healthy first pregnancies and more in subsequent pregnancies and mainly takes place 
before 32 -34 weeks gestation (Letsky, 1987). There is no consensus as to what 
happens to serum iCa2+ during pregnancy. Some report it as falling slightly (Tan,
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Reman & Sinnathyray, 1972; Pitkin & Gebhardt, 1977; Pitkin et al, 1979), others have 
found that it rises (Reitz, Daane, Woods & Weinstein, 1977) and further studies have 
found no change (Gertner, Coustan, Kliger, Mallette, Ravin & Broadus,1986; 
Roelofsen, Berkel, Uttendorfsky & Siegers, 1988; Seely, Brown, DeMaggio, Weldon 
& Graves, 1997). Another group reported a more complex picture with an overall rise 
in pregnancy compared with 12 months post-partum but a slight fall in the latter part of 
the third trimester (Rasmussen, Frolich, Homes & Hegedus, 1990). These 
discrepancies cannot simply be explained by variation in analysis technique, for 
example Tan et al (\912), Pitkin et al (1979) and Reitz et al (1977) all used the same 
calcium flow-through electrode. Only three of these studies (Pitkin et al, 1979; Seely 
et al, 1997; Rasmussen et al, 1990) used the same women throughout the study so that 
each woman gave repeated blood samples and acted as her own non-pregnant control; 
the others used groups o f different women at different gestations and this may partly 
account for the discrepancy in their results.
Although the longitudinal studies are likely to give a more accurate picture of 
pregnancy-induced changes in serum iCa2+ the post-partum data in the studies o f both 
Pitkin et al (1979) and Seely et al (1997), are confused by the fact that some o f the 
women were still lactating (20 of 30 women and 8 of 23 women respectively) when the 
blood samples were drawn. Pitkin compared iCa2+ levels in the lactating and non- 
lactating women and found no difference between the groups but this work has not 
been repeated with larger numbers (Pitkin et al, 1979). The study by Rasmussen et al 
(1990) did not mention whether or not the women were lactating when they gave 
blood samples.
Despite the increased demand for calcium in pregnancy the UCE rises markedly during 
normal pregnancy (Howarth, Morgan & Payne 1977; Gertner, Coustan, Kliger, 
Mallette, Ravin & Broadus, 1986; Roelofsen, Berkel, Uttendorfsky & Siegers, 1988; 
Macintosh, Hutchesson & Duncan, 1990; Seely et al, 1997). A highly significant 
correlation between calcium excretion and creatinine clearance has been shown in 
pregnant women and it is likely that this hypercalciuria of pregnancy is caused by the 
increase in glomerular filtration rate which occurs during pregnancy (Howarth et al, 
1977).
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The increased renal loss of calcium in pregnancy may be partly compensated for by an 
increased oral intake of calcium but more significantly the proportion of dietary 
calcium which is absorbed rises in pregnancy (Heaney & Skillman, 1971; Gertner et al, 
1986). Levels of 1,25-DHCC rise during pregnancy (Kumar, Cohen, Silva & Epstein, 
1979; Whitehead, Lane, Young, Campbell, Abeyasekera, Hillyard, MacIntyre, Phang 
& Stevenson, 1981; Reddy, Norman, Willis, Goltzman, Guyda, Solomon, Philips, 
Bishop & Mayer, 1983; Gertner et al, 1986; Verhaeghe & Bouillon, 1992; Ardawi, 
Nasrat & A’Aqueel, 1997; Seely et al, 1997) and these higher levels mediate an 
increase in intestinal absorption o f calcium. Thus it can be seen that pregnant women 
utilize available calcium more efficiently then non-pregnant women. This explains why 
repeated pregnancies are usually not associated with osteopenia (Walker, Richardson 
& Walker, 1971) although this is not the case for Asian immigrants to the West who 
are relatively vitamin D deficient because, for cultural reasons, they expose their skin 
less to sunlight than their Caucasian neighbours. Marya, Rathee & Manrow (1987) 
studied a group o f 50 Hindu women, half o f whom received vitamin D supplements. 
They found that the unsupplemented women were actually hypocalciuric compared 
with non-pregnant, non-lactating Hindu women controls, while those who received 
600,000iu vitamin D showed the hypercalciuria of pregnancy previously demonstrated 
in Caucasian women.
The rise in circulating levels o f 1,25-DHCC does not seem to be related to PTH 
concentration. Data on PTH concentrations in pregnancy are contradictory with some 
reporting an increase (Cushard, Creditor, Canterbury & Reiss, 1972; Pitkin et al,
1979), others a decrease (Reddy et al, 1983; Davis, Hawkins, Rubin, Posillico, Brown 
& Schiff, 1988) and some no change (Gillette, Insogna, Lewis & Baran, 1982). Much 
of the conflicting data on PTH concentration during pregnancy can be explained by 
discrepancies between the different assays used by different research groups. 
Immunoreactive assays measure not only the intact, and presumably bioactive, PTH 
molecule but also smaller, non-bioactive fragments o f the complete hormone. 
Therefore if the ratio of intact PTH (iPTH) to breakdown fragments o f PTH differs 
between the pregnant and non-pregnant states discrepant results will be obtained. 
Newer assays which measure iPTH have shown either no change in pregnancy 
(Mimouni, Tsang, Hertzberg, Neumann & Ellis, 1989; Saggese, Baroncelli, Bertelloni
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& Cipolloni, 1991) or lower values during pregnancy, compared to postpartum 
(Rasmussen et al, 1990; Ardawi et al, 1997). Despite agreeing that iPTH was lower 
overall during pregnancy the latter authors disagreed about changes in serum iPTH 
during the course of pregnancy with Rasmussen et al (1990) reporting a rise between 
the second and third trimesters and Ardawi et al (1997) reporting a fall. Both were 
prospective longitudinal studies but the latter looked at twice as many women (40 vs 
20) and so may be more indicative of the true state of affairs.
Much o f the additional vitamin D found in pregnancy is produced in the placenta. The 
ability of human decidual tissue to generate 1,25-DHCC and o f human placenta to 
generate both 1,25-DHCC and 24,25-DHCC in vitro was first reported in 1979 
(Weisman, Harell, Edelstein, David, Spirer & Golander). Subsequently (1981) 
Whitsett, Ho, Tsang, Norman & Adams showed that human placenta could also 
synthesize 1,25-DHCC in vitro. As well as directly producing vitamin D the placenta 
secretes a protein hormone, placental lactogen (PL), which increases in vitro renal 1- 
alpha-hydroxylase activity (Spanos et al, 1981). Additionally PL stimulates the 
production of insulin-like growth factor 1 (IGF-1) in the mother and the fetus and this 
also increases renal 1,25-DHCC production (Caverzasio, Montessuit & Bonjour, 
1990). Oestrogen, as mentioned above (section 1.2B, p i3) also stimulates renal 1- 
alpha-hydroxylase activity and is a further cause of the raised levels of vitamin D found 
in pregnancy.
Levels of CT in human pregnancy have generally been reported as being higher than 
non-pregnant values in both animal studies (Reynolds, Williams & Pitkin, 1981) and 
humans (Whitehead et al, 1981; Sgambata, Passariello, Buoninconti, Caserta & 
Paolisso, 1986; Ardawi et al, 1997). It has been speculated that elevated CT protects 
the maternal skeleton from excessive resorption of calcium but this has not been 
proven. As in the non-pregnant state the exact physiological role o f CT is still 
speculative.
Placental transport of calcium
This was not directly examined in this thesis and is therefore only discussed briefly in 
this introductory chapter; it has been recently reviewed extensively by Kovacs &
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Kronenberg (1997). In summary calcium is actively transported across the placenta 
and this process involves both calcium-binding proteins located in the 
cytotrophoblastic cells and a Ca2+-ATPase dependent pump located in the membrane 
on the fetal side of the placenta. Maternal hormones do not seem to be involved in the 
placental transfer o f calcium and current thinking is that it is chiefly regulated by 
parathyroid hormone-related protein (PTHrP). PTHrP was first identified as the cause 
o f the hypercalcaemia o f malignancy in 1987 (Moseley, Kubota, Diefenbach-Jagger, 
Wettenhall, Kemp, Suva, Rodda, Ebeling, Hudson, Zajac & Martin). PTHrP as its 
name suggests has a strong resemblance to PTH and homology at its amino-terminal 
end means that it has similar actions on kidney and bone. However the mid-portion of 
the molecule has the additional role of acting as the main regulator of placental 
transport of calcium (Maclssac, Heath, Rodda, Moseley, Care, Martin & Caple, 1991). 
PTHrP is produced in many sites throughout the developing fetus including the fetal 
parathyroids and the placenta (Abbas, Pickard, Illingworth, Storer, Purdie, Moniz, 
Dixit, Caple, Ebeling & Rodda, 1990); it does not cross the placenta. PTHrP does not 
seem to be involved in neonatal calcium homeostasis, instead iPTH is the dominant 
hormone, as described below, in maintaining normocalcaemia.
Fetal and neonatal calcium physiology
Umbilical cord blood has been shown to contain higher levels o f total calcium, iCa2+, 
Mg, PO4 and albumin (Pitkin, Cruikshank, Schauberger, Reynolds, Williams & Hargis,
1980). The same study showed that fetal CT levels were higher than maternal levels 
confirming earlier work (Samaan, Anderson & Adam-Mayne, 1975) but the 
significance of this is unknown. Within 2 hours o f delivery fetal iCa2 has fallen 
significantly (p<0.01) and this continues to fall within the first day o f life. The neonate 
responds, as an adult would, by producing increasing amounts o f iPTH (Loughhead, 
Mimouni, Ross & Tsang, 1990). The role o f vitamin D in fetal calcium metabolism is 
uncertain; various animal experiments seem to indicate that it is not necessary for fetal 
calcium homeostasis or skeletal formation but nevertheless it is known that the fetus 
can produce both 1,25-DHCC and also its receptor suggesting that vitamin D must 
have an, as yet undetermined, physiological role in fetal life (Kovacs & Kronenberg, 
1997).
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1.2G Calcium and hypertension
The role played by extracellular iCa2+ in blood pressure homeostasis and, especially, in 
the pathophysiology of hypertensive disease has been increasingly appreciated in the 
last decade or so, although Ringer first noted a requirement for iCa2+ in maintaining 
cardiac muscle contraction in 1883, and Addison showed that oral calcium 
supplements lowered blood pressure in 1924. Recent research has looked at many 
aspects of calcium’s involvement in hypertension from its intracellular second 
messenger function through to epidemiological and dietary work linking calcium intake 
and level of blood pressure. Work has also been done to see if any of the calciotrophic 
hormones, such as PTH play a part in the aetiology o f hypertension.
The cellular basis of vasoconstriction
Contraction of vascular smooth muscle is initiated by depolarization of the cell 
membrane by an action potential. Unlike the situation in striated muscle, where the 
depolarization is caused by the influx o f sodium ions (Na ) alone, in smooth muscle 
both Na+ and iCa2+ contribute. These ions then diffuse throughout the cell and activate 
adenosine triphosphatase (ATPase) activity in the heads o f the myosin filaments. The 
energy released by dephosphorylation o f the ATP allows the myosin filaments to pull 
along the actin filaments thus causing overall shortening o f the muscle ie. 
vasoconstriction. Vascular relaxation occurs as a calcium pump gradually shifts the 
iCa2+ from intrcellular to extracellular pools (Guyton, 1986).
Therefore it can be seen that extracellular iCa2+ is essential to initiate smooth muscle 
contraction and it could be surmised that calcium deficiency might be associated with 
hypotension but this is probably only true in extreme deprivation states. However in 
vitro experiments with vascular strip preparations have shown that the relationship of 
extracellular calcium to the magnitude o f an induced contraction is non-linear; in fact it 
is parabolic (fig. 1.2ii). This reduction in vascular reactivity with increasing 
concentrations of extracellular calcium may be due to the membrane-stabilizing effect 
of iCa2+. Acute infusion of calcium in humans has not been shown to have an effect 
on blood pressure but long term oral dietary supplementation with calcium has been 






Figure 1.2ii The relationship between extracellular iCa2+ concentration and the 
change in vascular tissue tone
Dietary calcium and hypertension
On a larger scale, metabolic studies have looked at dietary intake, circulating levels and 
urinary excretion of calcium and have found many abnormalities in the hypertensive 
population. However the clinical data appears contradictory, probably reflecting the 
many subgroups of hypertension and their heterogeneous causes. Also most large 
studies assessed calcium intake only by dietary recall, which is an intrinsically 
inaccurate method, as it depends on individual memory. A further difficulty with 
studies involving thousands of individuals is that it is difficult to control for 
confounding factors.
Many studies suggest that a calcium deficient diet is associated with hypertension. 
Ackley, Barrett-Connor & Suare (1983) reported an inverse association between 
dietary calcium intake and blood pressure in a predominantly white Southern California 
community assessing dietary calcium both in terms of milk consumption and by total 
dairy product intake. Data from the American National Center for Health Statistics 
support this looking at a much larger population (10 372 individuals) of all races 
(McCarron, Morris, Henry & Stanton, 1984). They showed that calcium was “the 
nutrient for which reduced intake was the most consistent in hypertensive individuals”. 
The inverse relationship held whether hypertension was defined as: systolic blood 
pressure (SBP) > 160, SBP >140 or the top 10% of the population.
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Serum calcium and hypertension
Whilst the dietary association of reduced calcium intake and hypertension is strong 
there is less evidence to show a link between low serum levels of calcium, or iCa2+, and 
hypertension. McCarron (1982) found lower fasting serum levels of iCa2+ in untreated 
mildly hypertensive subjects compared to normal controls; hypertension was defined as 
a diastolic blood pressure (DBP) >95mmHG or a mean arterial pressure >105mmHG. 
Strazzullo, Nunziata, Cirillo, Giannattasio, Ferrara, Mattioli & Mancini, (1982) found a 
non-significant reduction in both total serum calcium and serum iCa2+ in untreated 
essential hypertensive patients compared to controls and also a highly significant 
(p<0.005) increase in the UCE in the hypertensive group.
Whilst these studies link dietary deficiency o f calcium and hypertension others have 
linked excess calcium to hypertension although not at a dietary level. In a large 
epidemiological study o f 9 321 men Kesteloot & Geboers (1982) found a significant 
positive correlation between total serum calcium and both SBP and DBP.
This link between raised extracellular levels of calcium and high blood pressure seems 
to make more sense physiologically. Referring back to the parabolic relationship
between extracellular iCa2+ concentration and the degree of vascular smooth muscle
2+
contraction it should be remembered that the physiological range of iCa 
concentration is on the left hand side of the curve whilst supraphysiological levels(to 
the right hand side) are needed to produce relaxation. However it is likely to be high 
levels of intracellular iCa2+ which are important in causing increased vasoconstriction 
in hypertension while serum concentrations o f iCa2+ are relatively unimportant; indeed 
they may even be reduced because more calcium is sequestered within cells than in 
normal individuals.
Spontaneously hypertensive rats, intracellular iCa2+ and hypertension 
In vivo and in vitro a great deal of work has been done on animal models of human 
hypertension; in particular spontaneously hypertensive rats. This rat work has been 
summarized in a review article by McCarron (1985): in these hypertensive rats serum 
iCa2+ levels are low, PTH levels are raised and UCE is increased; acute administration
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of calcium to spontaneously hypertensive rats has been shown to increase BP; at a 
cellular level isolated strips of femoral artery showed increased vasoconstriction when 
exposed to increasing concentrations of calcium in the perfusing solution compared 
with tissue from normotensive rats. Defects in the ability o f red blood cell membranes 
to bind calcium have been shown in hypertensive rats and it appears that the activity of 
the membrane-bound Ca-ATPase pump is reduced which means that the ability of cells 
to buffer intracellular calcium is reduced. The permeability of vascular membranes to 
calcium is raised in hypertensive rats. This combination of increased membrane 
permeability and reduced intracellular buffering of calcium means that intracellular 
concentrations of calcium are raised in rats (McCarron, 1985). Human erythrocytes 
and platelets from hypertensive individuals have been compared to normotensive 
controls and have also been found to contain higher levels o f iCa2+ (Robinson, 1984).
Overall therefore the data appears to be contradictory with excess calcium being 
associated with hypertension at a cellular level but decreased calcium intake on the 
whole body scale linked with raised blood pressure. This shows the drawback of crude 
dietary and population evidence which disregard the complexity of human calcium 
homeostasis which involves several hormones and organ systems as described. 
Nevertheless the dietary studies raise interesting questions which can only be resolved 
by much more detailed study o f calcium homeostasis in man.
1.2H Hyperparathyroidism and hypertension
A link between hyperparathyroidism and hypertension was first reported by Hellstrom, 
Birke & Edvall in 1957. They defined hypertension as 150/100mmHg and found that 
70% of patients with hyperparathyroidism were hypertensive at some stage o f the 
disease; however they concluded that this was mainly due to a higher incidence o f renal 
disease in the hyperparathyroid patients. However, Lafferty (1981) reported 100 
consecutive cases of hyperparathyroidism of whom 42% were hypertensive, twice the 
prevalence found in an age and sex-matched control group; of the hyperparathyroid 
patients with hypertension, only 4 (10%) had raised serum creatinine levels.
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In 1980 a possible mechanism for this was put forward by an American group who 
confirmed that serum PTH was higher in hypertensive individuals compared with 
controls and showed that for any given level of sodium excretion the hypertensive 
group had significantly higher calcium excretion levels. They hypothesized that “ the 
increased [parathyroid] gland activity appears, in part, to be an appropriate,
physiological response to a .....  renal calcium leak, associated with essential
hypertension” (McCarron, Pingree, Rubin, Gaucher, Molitch & Krutzik, 1980). 
Subsequent work by Strazzullo et al (1983) confirmed that renal calcium excretion was 
increased in 55 hypertensive individuals compared with 55 age- and sex-matched 
controls and also showed significantly raised levels o f iPTH which they felt was a 
secondary phenomenon caused by the renal wastage of calcium.
Work from Holland has also looked at iPTH and shown that this is increased in young 
(20-39 year old) primary hypertensive subjects. In this study hypertension was defined 
as > 140/90mmHg but not sufficient to warrant treatment (Grobbee, Hackeng, 
Birkenhager & Hofinan, 1988). The authors suggested that they might have identified 
a select group likely to develop significant hypertension in later years (analogous to the 
group of women who develop gestational hypertension) but in contrast to Strazzullo et 
al (1983) and Grobbee et al (1988) found no difference in urinary calcium excretion 
between their “hypertensive” and normotensive groups.
1.2J Calcium and hypertension in pregnancy
Following work on the normal and hypertensive populations interest has spread to the 
pregnant sub-population and the possible link between calcium and pregnancy-induced 
hypertension (PIH) or even pre-eclampsia (PE) and eclampsia.
In 1980 Belizan and Villar observed a very low incidence o f pre-eclampsia and 
eclampsia in Guatemala where the overall nutrient intake is poor but the basic diet is 
high in calcium. Similar observations came from Ethiopia where people have a high 
calcium intake (derived from a basic diet o f grain) and a low rate o f hypertensive 
complications of pregnancy. Belizan’s group followed up these observations with a
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small randomized controlled trial in which 36 pregnant women aged between 20 and 
35 were allocated to lg  calcium daily, 2g calcium daily or placebo from 15 weeks of 
pregnancy until delivery. SBP fell by a greater amount in both supplemented groups 
during the second trimester o f pregnancy with respect to the control group; by the 
third trimester values for the lg  calcium group approached control values but the 2g 
group remained lower. DBP fell during the second trimester in all three groups but the 
fall was greater in both supplemented groups who had similar values. By the third 
trimester the unsupplemented women had the highest DBPs. PTH levels were 
measured during this study and found to be slightly, but not significantly, lower in the 
2g group (Belizan, Villar, Zalazar, Rojas, Chan & Bryce, 1983a). A much larger trial 
from the same group studied 1194 nulliparous women who received either 2g of 
calcium or placebo from 20 weeks of pregnancy until delivery; the incidence of 
hypertensive complications o f pregnancy was significantly reduced in the supplemented 
group (Belizan, Villar, Gonzalez, Campodonico & Bergei, 1991). Other studies have 
confirmed these findings (Villar, Repke, Belizan & Pareja, 1987 and Lopez-Jaramillo, 
Narvaez, Weigel & Yepez, 1989).
In 1988, Belizan, Villar and Repke suggested a mechanism whereby a low calcium diet 
resulted in increased PTH secretion leading to a rise in intracellular ionized calcium 
with increased muscular reactivity in vascular smooth muscle and hence to an increase 
in blood pressure (Fig 1.2iii).
>lCa (diet) —> tPTH  —> tcytosolic iCa2+ —» tvascular reactivity —> TBP 
tC a  (diet) -»  I  PTH -> I  cytosolic iCa2+ -»  Avascular reactivity —> 4<BP
Fig 1.2iii Hypothetical steps of the effect of calcium intake on blood pressure 
mediated by PTH (after Belizan, Villar & Repke, 1988)
A different mechanism to explain the BP lowering effect of calcium was suggested by 
Lopez-Jaramillo et al (1989) who postulated that calcium intake may affect the 
synthesis of prostaglandin I2 (PGI2), which is a potent vasodilator, but they did not 
measure this in their study.
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In summary therefore most of the earlier published clinical trials on calcium 
supplementation and blood pressure during pregnancy agreed that calcium is 
associated with a lower incidence of hypertension. However these trials were 
conducted in regions where the normal dietary intake o f calcium is very low compared 
to developed countries. Early work also only looked at small numbers o f women - 36 
in Belizan’s original trial in 1983b, 52 in Villar’s trial o f 1987 and 106 (Lopez-Jaramillo 
et al, 1989). Therefore further larger trials were established. Four years after work on 
this thesis began the results of the largest o f these, that run by the National Institute of 
Child Health and Human Development in the USA, which recruited 4 589 nulliparous 
woman who were randomized to either 2g calcium or placebo daily from the second 
trimester until delivery, reported no beneficial effect of calcium supplementation on 
BP. These woman were already taking a Western diet containing adequate calcium 
(Levine, Hauth, Curet, Sibai, Catalano, Morris, DerSimonian, Esterlitz, Raymond, 
Bild, Clemens & Cutler, 1997). Two years later the Australian group reported their 
results which did suggest a beneficial effect o f calcium supplements in reducing the 
incidence o f PE, defined as one DBP reading o f > 1 lOmmHG or two DBP readings of 
> 90mmHg together with 2+ proteinuria or > 300mg proteinuria/day. Their results 
showed a relative risk of 0.44[95% Cl 0.21-0.90; p=0.02] for developing PE in the 
calcium group. However it should be noted that the initial power calculations for this 
trial suggested that 948 nulliparous women needed to be recruited but, due to a lack of 
funding, the study was stopped after only 456 women had been enrolled (Crowther, 
Hiller, Pridmore, Biyce, Duggan, Hague, & Robinson, 1999).
1.2K Calcium metabolism in insulin dependent diabetes mellitus
Since the early 1970s, when it was first suggested that osteoporotic fractures might 
occur more frequently in diabetic subjects, evidence has been accumulating for 
abnormal calcium metabolism in IDDM. McNair, Madsbad, Christiansen, Faber, 
Transbol & Binder (1978a) showed that bone mineral mass was reduced by about 
10% in IDDM individuals aged from 7-70 years. They also found that the initiation of 
osteopenia seemed to coincide with the onset of clinical IDDM and significantly 
reduced (p<0.001) bone mineral content was seen after two years o f disease duration.
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In the following year the same group reported high PO4 concentrations in IDDM 
subjects (McNair et al, 1979). Later it was found that IDDM subjects had reduced 
levels of serum iCa2+ compared with normal controls; this reduction in serum iCa2+ was 
most marked in IDDM children under 16 (Fogh-Anderson et al, 1983). However the 
data are not all in agreement with Witt, White, Santiago, Seino & Avioli, (1983) 
reporting normal levels of serum iCa2+ in IDDM children although these were not 
directly compared with control children. Several studies (summarized by McNair in 
1988) have also shown lower levels of serum Mg in IDDM probably caused by 
inhibited reabsorption o f Mg in the DCT where glucose is being preferentially 
reabsorbed (Lindeman et al, 1967) - see above.
There are several reasons why iCa2+ may be low in IDDM subjects. Levels of lactate, 
beta-hydroxybutyrate and acetoacetate are increased and thus more calcium will be 
bound to these anions; also levels of non-esterified fatty acids are raised (Hansen & 
Johansen, 1970) and this will increase the amount of calcium bound to albumin. The 
normal response to a lowered iCa2+ is an increase in iPTH secretion, however this 
appears to be impaired in IDDM. In 1983 Fogh-Anderson et al, and another group 
(Witt et al, 1983) reported low PTH (using a C-terminal immunoassay) despite low 
concentrations of iCa2+ in IDDM subjects. Subsequent work using assays for iPTH 
have confirmed this (Sagegese, Bertelloni, Baroncelli, Federico, Calisti & Fusaro, 
1988; Thalassinos et al, 1993). The latter group also showed an increase, although not 
to normal levels, in IDDM subjects in whom glycaemic control improved. It was 
mentioned above (section 1.2C) that Mg deficiency impairs PTH secretion and this 
may be the mechanism behind the low values o f iPTH found in IDDM subjects as Mg 
excretion has been found to be increased in both diabetic rats (Fort, Lifshitz, Wapnir & 
Wapnir, 1977) and humans (McNair et al, 1979).
Calcium excretion is also raised in IDDM subjects compared to normal controls 
(McNair et al, 1979; Witt et al, 1983). This renal wastage of calcium is likely to be 
caused by both an osmotic diuresis produced by hyperglycaemia and also the low levels 
of iPTH. Improving glycaemic control leads to both a reduction in urinary calcium 
excretion and a rise in iPTH levels (Thalassinos, Hadjiyanni, Tzanela, Alevizaki & 
Philokiprou, 1993).
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Intestinal absorption of calcium has been shown to be reduced in diabetic compared to 
normal rats (Schneider & Schedl, 1972). The authors suggested that the low levels of 
PTH in diabetic rats might result in decreased conversion of 25-HCC to the more 
active 1,25-DHCC and hence to impaired intestinal calcium uptake; certainly 
administration of 1,25-DHCC to rats improved calcium absorption (Schneider, Omdahl 
& Schedl, 1976). However studies on human diabetic subjects have not found 
decreased absorption of dietary calcium but rather Aryperabsorption (Witt et al, 1983).
Concentrations of vitamin D metabolites may be altered in IDDM although the 
literature is confusing. In 1982 Christiansen, Christensen, McNair, Nielsen, & 
Madsbad compared 26 male IDDM subjects with normal controls and found decreased 
25-HCC, very reduced 24,25-DHCC but virtually normal 1,25-DHCC in the IDDM 
group. Later Witt et al, 1983 also reported similar levels of 1,25-DHCC in young 
IDDM subjects compared with controls bur raised levels o f 24,25-DHCC; however 
studies on vitamin D and bone metabolism in children who are still actively growing 
cannot be directly extrapolated to the adult population. Further studies on adult, 
Caucasian IDDM subjects and controls found no differences in 25-HCC or 1,25- 
DHCC levels (Nyomba, Bouillon, Bidingija, Kandjingu & de Moor, 1986).
The differing levels of 1,25-DHCC found in diabetic, compared to normal, subjects 
may reflect differences in glycaemic control leading to renal damage and hence to 
reduced renal-1-hydroxylase activity. Certainly Nyomba et al (1986) reported low 
1,25-DHCC in poorly controlled IDDM Bantu subjects. Similarly low levels have been 
found in adolescent IDDM subjects with persistent microalbuminuria compared to 
those with no microalbuminuria (Verrotti, Basciani, Carle, Morgese & Chiarelli, 1999) 
and in NIDDM patients with early diabetic nephropathy (Inukai, Fujiwara, Tayama, 
Aso & Takemura, 1997).
Calcitonin concentrations are raised in IDDM (Schaerstrom, Hamfelt & Soderhjelm, 
1986; Blasiak, 1989). In the face of low iPTH this may help to maintain serum iCa2+ 
within normal limits but this is still speculative.
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1.2L Calcium metabolism in IDDM pregnancy
In general very little is known about this subject although calcium metabolism in the 
infants o f diabetic mothers has been quite extensively studied and indeed this was one 
o f the reasons for embarking on the prospective study described in this thesis.
An increased rate of neonatal tetany, associated with low serum concentrations of 
calcium, were first reported in the infants o f IDDM mothers by Craig in 1958, however 
half of these infants were delivered before 37 weeks gestation. In order to see if this 
neonatal hypocalcaemia was associated with maternal diabetes rather than prematurity 
Tsang, Kleinman, Sutherland & Light, (1972) looked at infants of diabetic mothers 
compared with control infants matched for gestational age and confirmed that the 
infants o f the diabetic mothers were significantly more hypocalcaemic. They suggested 
that relative maternal hyperparathyroidism in diabetic pregnancy led to fetal 
hypoparathyroidism and hence low serum calcium but they did not measure PTH in 
diabetic pregnancy. Using a C-terminal assay for PTH Cruikshank, Pitkin, Varner, 
Williams & Hargis (1983) reported reduced concentrations o f PTH in IDDM 
pregnancy and a later study looking at iPTH (Mimouni et al, 1989) found low-normal 
concentrations of iPTH in IDDM pregnancy compared to normal pregnancy. Although 
there is no evidence to support maternal hyperparathyroidism leading to neonatal 
hypoparathyroidism infants o f diabetic women do seem to be hypoparathyroid 
(Bergman, Kjellmer & Selstam, 1974; Tsang, Wen-Chen, Friedman, Gigger, Steichen, 
Koffler, Fenton, Brown, Pramanik, Keenan, Strub & Joyce, 1975; Noguchi, Eren & 
Tsang, 1980; Cruikshank et al, 1983).
Impaired maternal Mg metabolism in IDDM pregnancy has been suggested as the 
mechanism for neonatal hypoparathyroidism and hypocalcaemia and this hypothesis is 
better supported by experimental evidence. IDDM mothers are significantly 
hypomagnesaemic compared to normal pregnant women (Mimouni et al, 1989). 
Maternal hypomagnesaemia in pregnant diabetic women is correlated with low levels 
o f serum Mg in their infants (Tsang, Strub, Brown, Steichen, Hartman & Wen-Chen, 
1976) and as mentioned above (section 1.2C, p i4) low levels o f Mg are associated 
with impaired release of PTH.
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1.3 THE RENIN-ANGIOTENSIN SYSTEM
Since 1898 when Tigerstedt and Bergman first extracted the protein substance which 
they named “renin” from the renal cortex of rabbits and demonstrated that it had a 
pressor effect when injected intravascularly, a massive amount of observation and 
experimentation has been carried out on what is now known as “the renin-angiotensin 
system” (RAS). Renin has been shown to be an enzyme which in itself does not 
produce hypertension; instead it acts on the substrate angiotensinogen (Aogen) in the 
first reaction of a cascade which ultimately produces angiotensin II (Ang II), the most 
potent circulating vasoconstrictor hormone yet described, - see Fig 1.3ii. Renin and 
Ang II are now known to be distributed throughout the body and throughout 
vertebrate species (Robertson, 1993). Ang II has been shown to have other actions 
besides vasoconstriction; for example it regulates aldosterone production, is a mediator 
in the control o f thirst (Fitzsimons, 1993) and is involved in reproductive 
steroidogenesis (Lumbers, 1993, Inagami, 1993). Much recent work has also focused 
on its role as an angiogenic agent and as a general growth promoter in many other 
tissues (Huckle & Earp, 1994).
1.3A Components of the RAS
In non-pregnant mammals most renin is synthesized within the kidney, in the 
juxtaglomerular (JG) apparatus, which is located mainly within the afferent arteriole 
walls (fig.l.3i). Following the discovery of renin it became apparent that most 
circulating renin is in an inactive, prohormone, form known as ‘prorenin’ first 
described by Lumbers in 1971, and present at ten times the concentration of renin in 
plasma (Sealey, Atlas & Laragh 1980). Prorenin protein contains an amino-terminal 
peptide of 43 amino acids split off by a proteolytic enzyme to create fully active renin 
(Schalekamp & Derkx, 1993) (fig 1.3ii). The renin molecule is composed of two very 
similar domains separated by a deep cleft which contains the binding site for renin 
substrate or Aogen (Murakumi, 1984). This conversion of prorenin to renin can occur 
extrarenally as well as in the JG apparatus.
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Fig 1.31 A juxtaglomerular apparatus showing many renin-secreting cells 
(stained brown) extending in continuity down the afferent arteriole.












ANGIOTENSIN III & 
OTHER PEPTIDE 
FRAGMENTS
Fig 1.3ii A simplified overview of the components of the RAS
Aogen, is an oc2-globulin synthesized in and secreted from the liver into the plasma. It 
exists in several different forms, especially in pregnancy, all of which arise from a 
single precursor of molecular weight approximately 50,000. Renin splits off a 
decapeptide, Ang I, from Aogen and Ang I is subsequently cleaved by angiotensin 
converting enzyme (ACE) to produce Ang II, the major active component of the 
whole RAS (fig. 1.3iii). Ang II is then broken down by various angiotensinases to 
form the less active angiotensin III (Ang III) and other fragments (fig. 1.3ii).
H - Asp - Arg - Val - Tyr - lie - His - Pro - Phe -OH 
Fig. 1.3iii The structure of human Ang II
1.3B Measurement of renin and angiotensin
Plasma renin activity (PRA) is the ability of the endogenous active renin in a plasma 
sample, acting on endogenous Aogen to generate Ang I under physiological
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temperature and pH conditions. This enzymatic reaction remains the most commonly 
used method to quantify PRA although some groups now use a specific direct 
immunoassay (see below). The plasma renin concentration (PRC) is measured by 
reacting the renin in a sample with excess (heterologous) Aogen under the same 
conditions. Plasma Aogen is measured by its ability to generate Ang I from an excess 
o f homologous renin, again under the same physiological conditions.
The development of radioimmunoassays to measure components of the RAS has been 
difficult because of problems with antibody specificity. Some initial radioimmunoassays 
gave lower plasma renin substrate (PRS) values than enzyme methods, presumably 
because Aogen exists in several forms not all of which were being detected by the 
assay; other assays produced higher values and were thought to be measuring 
immunoreactive (but not biologically active) degradation products as well as pure 
Aogen. Since Aogen is a large molecule from which only the first ten amino acids are 
cleaved to form Ang I, antibodies need to be directed specifically at this decapeptide to 
avoid misleading results. Using monoclonal antibodies directed against this portion o f 
Aogen an enzyme-linked immunosorbent assay has now been developed.
As the PRA alters under different clinical conditions, for example it is high during 
treatment with ACE inhibitors because o f the lack of negative feedback o f Ang II on 
renin production, it is useful to measure levels of Ang II, the active end-product of the 
RAS. This is difficult because physiological concentrations of Ang II are usually in the 
low picomolar range and require very sensitive assays. Also there are precursor and 
breakdown peptides which can cross-react in radioimmunoassays. Modem assays now 
obtain specificity by isolating Ang II from other peptides by high performance liquid 
chromatography or ion-exchange chromatography, and sensitivity by using 
radioimmunoassay techniques. Sample collection is also important as Ang II can be 
generated in plasma after sampling if inhibitors of cleavage are not used and samples 
are neither analysed immediately nor frozen. Normal diurnal variation must also be 
allowed for as should subject position and time from the last meal (Nussberger & 
Brunner, 1993).
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Although PRA is widely measured in clinical practice in non-pregnant subjects it was 
not measured in this thesis because in pregnancy Aogen concentrations are rate- 
limiting (see below). Instead enzyme and substrate concentrations were measured 
separately to obtain a better idea of what was acting where within the cascade.
1.3C Control of renin release
The physiological stimulants to renin release reflect its crucial role in maintaining blood 
pressure and circulating volume. Five basic mechanisms have been described: 
intrarenal baroreceptors, the amount of sodium sensed by the macula densa segment of 
the distal convoluted tubule (DCT), the sympathetic nervous system and humorally 
released catecholamines, other hormonal factors (eg. Ang II, prostaglandins and 
steroids) and plasma electrolytes such as potassium and Ca (Keeton & Campbell, 
1981).
D Baroreceptors
The existence of a renal baroreceptor that either increased or decreased renin secretion 
in response to a decrease or increase in mean renal perfusion was first suggested by 
Tobian in 1959. Since then the concept has been extensively investigated and refined 
and, in summary, it is now thought that these baroreceptors are located in the afferent 
renal glomerular arteriole. Stimuli which lead to a decrease in the transmural pressure 
gradient of these receptors, eg. a fall in blood pressure secondary to haemorrhage, lead 
to increased renin secretion.
iil The macula densa
The macula densa region of the DCT is composed of a specialized group of columnar 
or cuboidal cells that are in close contact with the granular juxtaglomerular cells o f the 
glomerulus from which the tubule originates. The macula densa is usually found at the 
boundary of the ascending loop o f Henle and the DCT and electron microscopy o f this 
region has shown that the macula densa and the granular cells are only separated by a 
thin, incomplete basement membrane. Much experimental work has been done on the 
role of the macula densa in renin release and this is summarized by Keeton & Campbell
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(1981); in essence a decrease in sodium transport to the macula densa stimulates renin 
release in humans. In contrast, in the rat, chloride seems to be the ion involved in the 
regulation of renin release by the macula densa and this illustrates the difficulty of 
extrapolating from animal work to humans.
iii) The sympathetic nervous system
Activation of (3-adrenergic neurones of the sympathetic nervous system within the JG 
cells stimulates renin release. This can be demonstrated by the intrarenal injection of 
both adrenaline and noradrenalin, and by the inhibition o f renin release by prior 
administration of propranolol. Also the plasma renin activity (PRA) is often elevated 
in the hypertension associated with phaeochromocytoma (Hiner, Gruskin, Baluarte, 
Cote, Sapire & Levitsky, 1976). Physiologically the sympathetic activity generated in 
response to hypovolaemic shock will result in increased renin secretion which acts both 
to maintain blood pressure and, via aldosterone, to conserve sodium and hence 
increase circulating volume.
iv) Hormonal and humoral factors
Various hormones influence renin secretion. Most importantly there is a short-loop 
negative feedback by plasma Ang II itself, suppression by anti-diuretic hormone and 
stimulation by prostaglandins (PG) and prostacyclin.
The relationship between PGs and renin release was first studied in 1968 by Vander 
who reported inconsistent results o f infused PGEi and PGE2 on PRA in dogs. One 
reason for these inconsistencies was that data from several doses of the different 
prostaglandins were pooled. Later work found a consistent rise in PRA when PGEi 
was injected into dogs (Weming, Vetter, Weidemann, Schwiekert, Stiel & 
Siegenthaler, 1971). Further work in humans showed stimulation o f renin release by 
PGAi (Golub, Speckart, Zia & Horton, 1976). In the mid-1970s prostacylin was 
discovered and as this was soon shown to be more potent than PGs of the E and F 
series the focus o f research shifted to the new compound. There is now compelling 
evidence that prostacyclin has a direct stimulatory effect on renin release in humans,
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rather than an indirect effect via its vasodilatory and hypotensive actions (Patrono, 
Pugliese & Ciabbattoni, 1982).
Oestrogens also alter renin secretion. It has been observed that PRA is increased 
during the luteal phase o f the human menstrual cycle (Brown, Davies, Lever & 
Robertson 1964a) and during human pregnancy (Brown, Davies, Lever & Robertson 
1964b). As discussed below PRA is a measure which is dependent on both enzyme and 
substrate concentration; the rise in PRA during the luteal phase is almost entirely due 
to the stimulatory effect o f oestrogen on Aogen synthesis rather than on renin synthesis 
itself. Progesterone can also stimulate renin release but this is thought to be 
secondary to the induction o f a natruresis brought about by the similarity between the 
progesterone and aldosterone molecules^
In view of the above it would be expected that oral contraceptives would alter renin 
release. Early work in this field was performed by Skinner and colleagues (1969). 
They found a two-fold increase in PRA and PRS concentration together with a 
suppression of PRC in women taking combined oral contraceptives (COC). They 
concluded that COCs increased PRA by increasing blood PRS and they postulated that 
increased levels of Ang II produced a fall in PRC by negative feedback. Subsequent 
work has confirmed the rise in PRS produced by the COC but has not shown an 
increase in PRA (Derkx, Stuenkel, Schalekamp, Visser, Huisveld & Schalekamp, 
1986). These differences may be due to the lower oestrogen doses now used in oral 
contraceptives. Possibly also, inadvertent activation o f prorenin occured in earlier 
studies which used acid-pretreated plasma, as it was not until 1971 that it was realised 
that acid pre-treatment of samples activated a form of renin (ie. prorenin) not active at 
physiological pH (Lumbers, 1971).
v) Plasma electrolytes
Numerous electrolytes have been shown to alter renin release and these have been 
reviewed by Keeton & Campbell (1981). The decrease in renin secretion caused by an 
increased load of sodium at the macula densa has already been mentioned. Potassium 
also appears to decrease renin release while an increase in plasma magnesium 
stimulates renin release. Conversely falling magnesium levels reduce renin production.
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Calcium and parathyroid hormone
iCa2+ is known to be required by most secretory cells for stimulus-secretion coupling to 
occur (Rubin, 1970). It is also involved in the contraction of smooth muscle (see 
below). Since the granular JG cells are both secretory cells and modified smooth 
muscle cells one would expect calcium to be involved in the control of renin release. 
However the relationship is likely to be even more complicated since calcium can 
inhibit sodium reabsorption (Freedman, Moulton & Spencer, 1958), alter 
catecholamine release (Rubin, 1970) and affect blood pressure (see below).
Early experiments showed that the infusion of both calcium chloride and calcium 
gluconate into anaesthetized dogs reduced the rate of renin secretion (Kotchen, Maull, 
Luke, Rees & Flamenbaum, 1974; Watkins, Davis, Lohmeier & Freeman, 1976). This 
inhibition o f renin release was thought to occur via a direct action of iCa2+ on the JG 
cells, not via the renal nerves where increasing iCa2+ would cause an increase in 
noradrenaline secretion and hence an increase in renin secretion, and not by an action 
on the baroreceptors where a decrease in afferent arteriolar radius, in the face of a 
constant renal perfusion pressure, would also lead to increased renin secretion.
Numerous further experiments have increased the evidence in favour of calcium having 
an inhibitory effect on renin release, in contrast to the more typical findings in exocrine 
and endocrine cells, where the calcium concentration is usually positively correlated 
with the secretion rate. Following the above experiments which involved either whole 
animals or slices of renal cortex Baumbach & Leyssac (1977) looked at isolated 
preparations of rat glomeruli. They found that decreasing the extracellular 
concentration o f iCa2+ increasd renin secretion, while increasing the intracellular 
concentration of iCa2+ using a calcium ionophore which facilitated iCa2+ influx into the 
cells inhibited renin release. They also showed that the calcium antagonist lanthanum 
decreased renin release. Others found that chelating extracellular iCa2+ with 
ethylenediamintetraacetic acid (EDTA) which subsequently produced a fall in 
intracellular iCa2+, increased renin release (Park & Malvin, 1978). Much more recently 
Porter, Conlin, Scott, Brown & El-Hajj Fuleihan (1999) showed that physiological 
increases in serum iCa2+ in humans were associated with an increase in PRA. The 
mechanism(s) by which raised intracellular iCa2+ concentrations inhibit renin release
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remains hypothetical and two are outlined in a review by Sk<|)tt & Jensen (1993). One 
possibility is that iCa2+ may activate chloride channels allowing chloride to flow out of 
cells [followed by potassium], thus the osmotic pressure o f  the cell falls and water is 
lost by the JG cell and its renin-containing organelles which therefore are less able to 
secrete renin; another hypothesis is that the secretory granules and the cell membrane 
are separated by a network of myofilaments which contract as the intracellular 
concentration of iCa2+is raised, this decreases contact between them and so secretion 
cannot occur.
Chronic calcium loading has been shown not to affect PRA, or renal renin content in 
rats (Kotchen et al, 1974; Kotchen, Galla & Luke, 1977). In 1975 Brinton reported 
elevated PRA in four out o f seven hypertensive patients with primary 
hyperparathyroidism but this was not the case with normotensive patients with primary 
hyperparathyroidism or secondary hyperparathyroidism or with hypercalcaemia of 
other cause. These authors concluded that PTH per se had no affect on renin 
secretion. Later work in dogs (Smith, Mouw & Vander, 1979) showed that the 
infusion of relatively large doses of bovine PTH did lead to an increase in PRA which 
fell rapidly once the infusion was stopped. The same authors also stimulated the 
production of endogenous PTH, in dogs, by infusing citrate into the carotid artery and 
again found an increase in PRA in some, but not all, animals. It was noted that the 
non-responders had the largest increases in sodium excretion suggesting that PTH may 
exert two opposing effects on renin secretion; indirectly by inhibiting proximal sodium 
reabsorption it may increase the macula densa sodium load and thereby inhibit renin 
secretion, while it also directly stimulates renin release.
In 1992 Grant, Mandel, Brown, Williams & Seely showed that infusion o f the 1-34 
amino-terminal fragment of PTH increased PRA by over two-fold. The following year 
a French group (Saussine, Judes, Massfelder, Musso, Simeoni, Hannedouche & 
Helwig, 1993) provided evidence for a direct stimulatory effect o f PTH(l-34) on renin 
secretion in isolated rat kidneys. They then went on to look at the effects of 
extracellular iCa2+ alone and PTH and extracellular iCa2+ combined on renin release in 
isolated preparations of rabbit glomeruli. They found that a low iCa2+ medium
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increased basal renin secretion whilst high concentrations of extracellular iCa2+ 
inhibited renin secretion. However PTH was only able to increase renin production in 
the presence of extracellular iCa2+. They concluded that PTH was acting by inhibiting 
calcium influx to the glomerular cells, thus reducing intracellular iCa2+ and stimulating 
renin release as described above.
1.3D The pharmacokinetics of renin production
The reaction of renin on Aogen to produce Ang I is dependent on both the 
concentration of enzyme (renin) and substrate (Aogen) in the plasma and obeys 
Michaelis-Menton first order kinetics. In men and non-pregnant women the 
concentration of Aogen is around the Km for the reaction meaning that Ang I is 
generated at about half the maximal velocity possible. In pregnancy Aogen 
concentrations rise with gestation, peaking at term (Skinner, Lumbers & Symonds 
1972, Baker, Broughton Pipkin & Symonds 1990). The production o f angiotensin 
during pregnancy is known to be substrate dependent (Skinner et al, 1972), therefore 
the rise in Aogen alone is enough to increase the rate of Ang II production. Ang II 
levels rise significantly by the second trimester of human pregnancy compared with 
non-pregnant women (Baker et al, 1990). In the human fetus Aogen levels are less 
that those o f maternal levels although slightly higher than in non-pregnant adults 
(Tetlow & Broughton Pipkin, 1983). It seems that in the fetus, like the pregnant 
mother, it is the Aogen, rather than the renin, concentration which is rate-limiting in 
the reaction (Skinner et al, 1972).
Once, all ACE activity was thought to occur in the lung but now it is known that ACE 
is synthesised by the vascular endothelial cells of most tissues (Miyazaki, Okunishi, 
Nishimura & Toda, 1984). For example, intrarenal Ang II is synthesised by ACE 
produced in the endothelium of the proximal tubular cells (Chai, Allen & Adam, 1986). 
The high vascularization o f the lung probably explains why the bulk o f conversion of 
Ang I to Ang II takes place there. The placenta is also highly vascularized and
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therefore another important site of conversion; at term ACE activity in the placenta is 
about 13% of the adult lung value (Sim & Seng, 1984).
Ang II has a very short halflife being broken down by various angiotensinase enzymes 
to peptide fragments. For example angiotensinase A, found in the brain, kidney and 
vascular endothelium splits off the aspartate from position 1 creating the heptapeptide 
Ang III a less potent vasoconstrictor than Ang II (Harding & Felix, 1987). Ang III is 
hydrolysed even more rapidly than Ang II so its duration of action is much shorter. An 
endopeptidase (angiotensinase C) creates a heptapeptide angiotensin-(1-7), once 
thought to be inactive but now been known to bind to receptors in the central nervous 
system, (Ferrario, Barnes, Block, Brosnihan, Diz, Khosla & Santos, 1990) (section 
1.3F, p44).
1.3E Angiotensin receptors
Ang II acts on two receptors - the ATI and AT2 receptors. The ATI receptors 
mediate most of the “classical” actions of Ang II such as vasoconstriction. Ang II 
binds to the transmembrane ATI receptor which contains a guanine nucleotide 
regulatory protein (G-protein) which is coupled to phospholipase C. Binding of the 
Ang II activates the phospholipase cascade releasing second messengers such as 
inositol (1,4,5) triphosphate which then releases iCa2+ from the endoplasmic reticulum. 
This causes a rise in intracellular free iCa2+ which acts as a further messenger; in 
vascular smooth muscle; the increased iCa2+ concentration will also lead directly to 
vasoconstriction by initiating the actin-myosin interaction (fig. 1.3iv).
Within the kidney ATI receptors (Edwards, Stack, Weidley, Aiyar, Kennan, Hill & 
Weinstock 1992; and Sechi, Grady, Griffin, Kalinyak & Schambelan 1992) are situated 
on the afferent and efferent glomerular arterioles but stimulation of them preferentially 
causes efferent vasoconstriction. If renal blood flow is reduced by generalized 
hypotension this efferent vasoconstriction will help to maintain the glomerular filtration 
pressure. ATI receptors are inhibited by losartan, valsartan, ibresartan and 
candesartan and these antagonists are now licensed for clinical use in the treatment of 














Fig. 1.3iv The place of AT receptors and their inhibitors within the RAS
AT2 receptors are not yet fully characterized; they are found in the reproductive tract, 
some cerebral vessels and the kidney and may be concerned with growth (see below). 
AT2 receptors do not seem to be coupled to the mobilization of intracellular Ca2+ as 
ATI receptors are (Chappell, Jacobsen & Tallant,1995). Within the kidney Ang II 
acting on AT2 receptors stimulates sodium and fluid reabsorption by a direct effect on 
the renal tubules which tends to restore circulating volume (Goldfarb, 1994).
1.3F Extrarenal actions of the RAS
i) Aldosterone secretion
The first non-vasoconstrictor effect of the RAS to be described was the control of 
aldosterone secretion. Initially pituitary adrenocorticotrophic (ACTH) hormone was
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thought to regulate this, but in 1961 Davis and colleagues reported that nephrectomy 
abolished the aldosterone response to acute haemorrhage in hypophysectomized dogs, 
and that giving synthetic Ang II markedly increased aldosterone secretion; Ang III has 
a similar effect in animals but not in man. It is also known clinically that in 
hypoadrenal patients whose disease has an adrenal origin fludrocortisone is needed in 
approximately 90% whereas in those with hypopituitary hypoadrenalism it is needed in 
only 10%.
Aldosterone increases sodium absorption from urine, sweat, saliva and the 
gastrointestinal secretions. The urinary reabsorption of sodium is followed by water 
reabsorption in the distal collecting tubule (DCT) and collecting duct. At the same 
time that sodium is reabsorbed potassium and hydrogen ions are secreted so the 
extracellular fluid (ECF) volume is increased while acid-base balance is maintained. 
Thus renin acts to maintain blood pressure in the short term by causing rapid 
vasoconstriction and in the longer term by increasing circulating volume via 
aldosterone (Espiner & Nicholls,1993) and also by stimulating drinking (see below).
iil The RAS within the brain
The first central action o f Ang II was discovered by Bickerton and Buckley in 1961 
when they showed that Ang II injected centrally, into the carotid artery, could raise 
blood pressure in vascularly isolated dogs’ heads connected to the body by the nervous 
system only. This pressor effect is mediated by the sympathetic nervous system and 
can be reduced by a-adrenergic blockers.
The next central action o f the RAS to be demonstrated was its involvement in the 
control of thirst and sodium appetite. High levels of Ang II-responsive neurones have 
been found in the subfornical organ and in the vascular organ o f the lamina terminalis 
which control drinking and salt intake. Essentially raising the intracerebral levels of 
Ang II leads to increased drinking and salt intake; this o f course will act to restore 
circulating fluid volume after fluid loss so once more Ang II is seen to be maintaining 
blood pressure (Fitzsimons, 1993).
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Recent evidence suggests that Ang II is not the only component of the RAS which is 
physiologically active in the brain. Ferrario et al (1990) have shown that a prolyl- 
endopeptidase together with other endopeptidases act centrally to produce 
angiotensin-(l-7) directly from Ang I without involving ACE. They next demonstrated 
that angiotensin-(l-7) was as potent as Ang II in stimulating release of vasopressin 
from the posterior pituitary gland but that it lacked direct pressor and dipsogenic 
effects.
in) Ang II in the ovary and testis
Renin and Ang II have been shown to be produced locally within both the ovary and 
testis where they have a paracrine role. Follicular aspirates from stimulated ovarian 
follicles were shown to contain fourteen times as much renin-like activity as plasma 
(Fernandez, Tarlatz, Rzasa, Caride, Laufer, Negro-Vilar, DeChemey & Naftolin
1985). Subsequently follicular renin concentration (FRC) was shown to be similar to 
PRC in unstimulated cycles; FRC was unaffected by clomiphene citrate but increased 
when gonadotrophins were used for ovarian hyperstimulation. Follicular renin 
substrate (FRS) was only slightly higher than PRS and barely increased with 
hyperstimulation. The authors concluded from this that gonadotrophins themselves 
stimulate renin production and that within the ovary it is FRS which is the rate-limiting 
factor in the generation of Ang I (Brameld, Broughton Pipkin & Symonds, 1990). 
Growth and maturation of the ovarian follicle requires a high blood flow and Ang II 
probably plays an intraovarian angiogenic role - see below. It also appears to stimulate 
granulosa cell aromatase activity which leads to oestradiol production. Its 
vasoconstrictor activities may also be involved in non-dominant follicular atresia 
(Lumbers, 1993).
In the testis Ang II is one of the mediators of seminiferous tubule contraction and it 
also regulates fluid and anion secretion into the epididymal fluid, both o f which 
activities contribute to the transport o f sperm. Whether renin or Ang II are involved in 
male steroidogenesis is not definitely known, but it is possible Ang II is a moderate 
inhibitor of testosterone production (Inagami, 1993).
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1.3G Angiotensin II as a regulator of cell growth and proliferation
In 1977 it was reported that Ang II could promote the proliferation of adrenocortical 
cells in culture (Gil, 111 & Simonian, 1977) and then the same effect was noted with 
fibroblasts (Schelling, Ganten, Speck & Fischer, 1979). Mention has been made above 
of the widespread occurrence o f ACE activity, once thought to be limited to the lung, 
and it appears that these locally-regulated pathways for Ang II production, which are 
o f course independent o f the systemic physiological factors regulating vasomotor tone, 
are involved in growth regulation.
This action of Ang II seems to be mediated via AT 1 receptors. Binding to these by 
Ang II activates tyrosine kinases, a response which is dependent on iCa2+. This iCa2+- 
dependent, Ang II-stimulated tyrosine phosphorylation leads to the activation of 
several peptides known to be involved in cell growth such as platelet derived growth 
factor, basic fibroblast growth factor and transforming growth factor pi.
In addition to stimulating the production of these factors Ang II also appears to 
influence the expression o f many growth-related genes such as c-fos, c-jun, c-myc, 
JunB, Egr-1 and cMGl, known to be active in adrenal tissue, hepatocytes, mesangial 
cells, heart, intestinal epithelial cells and the brain (Huckle & Earp, 1994). Whether 
these growth-promoting effects of Ang II are important physiologically, in the non­
pregnant subject, is not yet established. They do seem to have a pathogenic role. For 
example the left ventricular hypertrophy which occurs as an adaptive process in 
chronic hypertension is Ang II mediated and this can be reversed (Asmar, Pannier, 
Santoni, Laurent, London, Levy & Safar 1988; Gilbert 1992) or prevented, (Massie 
1992, Kloner & Przyklenk, 1993) by the use o f ACE inhibitors, an effect important 
clinically. This effect of ACE inhibitors occurs at lower concentrations than those 
needed to produce significant hypotension (Owens 1985; Gohlke, Stoll, Lamberty, 
Mattfeld, Mall, van Even, Martorana & Unger, 1992). Another pathological condition 
in which Ang II is implicated as a growth factor is in mesangial proliferation in several 
of the glomerulopathies (Gavras & Gavras, 1993) where ACE inhibitors are used 
therapeutically.
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1.3H The RAS in insulin dependent diabetes
Circulating Aogen concentrations are normal in both well-controlled (Day, Luetscher 
& Gonzales, 1975; Feldt-Rasmussen, Mathisen, Deckert, Giese, Christensen, Bent- 
Hansen & Nielsen, 1987) and unstable (Feriss, O’Hare, Kelleher, Sullivan, Cole, Ross 
& O’Sullivan, 1985) IDDM. However renin production and secretion by the JG cells 
o f the kidney is abnormal in IDDM. It appears that even in the early stages of IDDM, 
before there is clinical evidence o f nephropathy, more prorenin is secreted whilst levels 
o f active renin are low (Day et al, 1975; Luetscher, Kraemer, Wilson, Schwartz & 
Bryer-Ash, 1985). It is now possible to monitor developing nephropathy using a 
sensitive assay which is able to detect albumin in the urine at lower concentrations than 
those detected by albustix, confusingly this is described as microalbuminuria. As 
nephropathy develops, assessed by measuring microalbuminuria, the levels o f prorenin 
found in both IDDM and NIDDM increase (Luetscher et al, 1988). This may be 
caused by chronic glycosylation, and therefore inactivation, of prorenin-processing 
enzymes. For example in 1981 Coradello, Poliak, Pagano, Leban & Lubec showed 
that cathepsin B, a kidney protease that is known to convert prorenin to renin, became 
inactive after incubation with high concentrations o f glucose. Another possibility is 
that the neuroendocrine processes involved in renin production and secretion are 
affected by IDDM. In 1979 Tuck, Sambhi & Levin demonstrated decreased 
sympathetic activity and impaired P-receptor mediated responsiveness o f renin release 
in IDDM patients with peripheral neuropathy. Ultimately as IDDM progresses and JG 
cells are destroyed by hyalinosis of the renal arterioles there will be less cells available 
to produce renin.
Since levels o f active renin are low one would expect circulating levels o f Ang I, Ang 
II and aldosterone to be low in IDDM and this appears to be the case (Tuck et al, 
1979; Weidmann, Beretta-Piccoli & Trost, 1985; Feldt-Rasmussen et al, 1987).
Serum ACE activity has been variously reported to be increased (Lieberman & Sastre, 
1980; Feldt-Rasmussen et al, 1987), normal (Giampietro, Lenzi, Sampietro, Miccoli & 
Navalesi, 1986) or low in diabetic subjects. Discrepant findings may reflect differences
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between patient groups studied, control groups or in methodology. Alternatively it 
may be that any rise in ACE activity in IDDM is intermittent and so not always 
detectable. However since ACE is normally present in excess the significance o f a 
further rise is unknown.
Different stages of IDDM also have different impacts on the RAS. For example in 
diabetic ketoacidosis renin, Ang II and aldosterone usually rise acutely whilst ACE 
activity falls. This activation of the RAS is probably due to the combined effects of 
sodium, fluid and potassium depletion and raised adrenergic activity. As the 
ketoacidosis is treated the RAS activity returns to normal (Christlieb, Assal, 
Katsilambros, Williams, Kosak & Susuki, 1975). As mentioned above as IDDM 
progresses and complications such as nephropathy develop the RAS is affected 
increasingly with raised levels of prorenin but reduced active renin.
Hypertension occurs twice as frequently in diabetic patients as in non-diabetics 
(Christlieb, Warram, Krolewski, Busick, Ganda, Asmal, Soeldner & Bradley, 1981) 
and it has a significant additive effect on the development and progression of both the 
macrovascular (atherosclerosis and left ventricular hypertrophy) and microvascular 
(nephropathy and retinopathy) complications of the disease. All of these complications 
are a consequence of overgrowth of vascular endothelium and/or smooth muscle and it 
has been suggested that this overgrowth is Ang II mediated through cytokines and 
growth factor expression as discussed previously. Certainly ACE inhibitors have been 
demonstrated to slow the progress o f diabetic glomerulosclerosis and atherosclerosis 
(Hsueh & Anderson, 1993), although these data should be interpreted with caution as 
it is not entirely clear whether this beneficial effect is produced by inhibiting cell 
proliferation or the BP lowering effect o f ACE inhibitors. Certainly the UK 
prospective diabetes survey (UKPDS) in non-pregnant type II diabetes mellitus did not 
find differences between atenolol and captopril in slowing the development of 
nephropathy. However these results need to be interpreted with caution as the study 
was not adequately powered to show such diflfrerences (UKPDS, 1998). As yet ACE 
inhibitors have not been shown to affect the progress of retinopathy which is mainly 
influenced by glycaemic control rather than BP control. Again over the period o f the 
UKPDS patients treated with atenolol and captopril showed an equal deterioration in
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retinopathy measured by retinal photography but again this needs to be regarded with 
caution as mentioned above (UKPDS, 1998).
It seems paradoxical that Ang II may be responsible for this vascular endothelial 
hypertrophy and renal pathology in IDDM whilst overall levels o f both it and Ang I are 
low in diabetic subjects (see above). In an attempt to reconcile this apparent 
contradiction, it has been suggested that diabetic patients may have an increased 
sensitivity to Ang II. In 1984 Drury, Smith & Ferriss demonstrated an increased 
vasopressor responsiveness to Ang II in type I diabetic patients with no vascular 
complications and Weidmann et al, (1985) showed that the dose o f infused Ang II 
required to increase diastolic pressure by 20mmHg was less in diabetic subjects 
compared with normal subjects and particularly low in those with diabetes and 
hypertension. In general, where circulating concentrations o f an agonist are low, 
receptor density for that agonist is increased; this is probably the mechanism for the 
increased pressor responsiveness to Ang II in IDDM.
The use of ACE inhibitors in diabetic nephropathy
In 1985 Taguma and colleagues reported the results of a study which followed on 
from the chance observation that proteinuria in one of their long-term haemodialysis 
patients was reduced after he was given captopril to treat hypertension. They were 
able to show that proteinuria in 10 diabetic subjects was reduced from 10.6±2.2g/24hr 
to 6.1±1.4g/24hr (p<0.01) following treatment with captopril. This reduction was 
apparent after 2 weeks of treatment and stabilized within four weeks (Taguma, 
Kitamoto, Futaki, Ueda, Monma, Ishizaki, Takahashi, Sekino & Sasaki, 1985). 
Subsequent work from Sweden showed that over two years captopril slowed the rate 
of decline in glomerular filtration rate in diabetic subjects with nephropathy (Bjorck, 
Nyberg, Mulec, Granerus, Herlitz & Aurell, 1986).
It was mentioned above that recent results from the UKPDS suggest that this ACE- 
mediated reduction in development o f diabetic nephropathy is merely a side-effect of 
the BP lowering effect of ACE inhibitors. However in a regression analysis of 100 
clinical studies evaluating the effect of various classes of antihypertensive agents on
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blood pressure lowering and proteinuria in diabetic nephropathy ACE inhibitors were 
shown to lower protein excretion more than would be expected if the effect were 
merely due to the degree of fall of blood pressure which they produce (Keane, 
Anderson, Aurell, deZeeuw, Naims & Povar, 1989). One possible mechanism is that 
overgrowth of the vascular endothelium which leads to glomerulosclerosis, as 
discussed above, is reduced. Another likely aetiological factor is that intrarenal Ang II 
causes an increase in the hydraulic pressure across the glomerular capillary membranes, 
in other words creating “intrarenal hypertension” and that this is reduced by ACE 
inhibitors; certainly this appears to be the mechanism of angiotensin II-induced 
proteinuria in rats (Bohrer, Deen, Robertson & Brenner, 1977). However conclusions 
drawn from meta-analysis o f multiple studies (Keane et al, 1989) must be regarded 
with caution and have not received universal agreement.
By analogy with ACE inhibitors, Ang II receptor antagonists may have similar 
beneficial effects within the kidney. In a small study of patients with non-diabetic 
proteinuria and hypertension losartan and enalapril reduced proteinuria equally 
(Gansevoort RT, de Zeeuw D & de Jong PE, 1994). This study was underpowered 
and further work needs to be done in this area.
1.3J The renin-angiotensin system in pregnancy
The RAS is one of the first hormone systems to recognise pregnancy. In fact plasma 
concentrations of renin, Aogen, Ang II and aldosterone all change during the menstrual 
cycle (Brown et al, 1964a; Kaulhausen, Leyendecker, Benker & Breuer, 1978) and if 
pregnancy occurs the raised concentrations found in the luteal phase persist, and 
indeed increase further.
Cross-sectional and longitudinal studies have looked at PRC, PRS and Ang II 
concentrations during pregnancy. PRC is significantly increased in the first trimester 
compared to non-pregnant women and continues to rise throughout pregnancy 
(Skinner et al, 1972, Baker et al, 1990) although there may be a small fall at term 
(Oats, Broughton Pipkin, Symonds & Craven, 1981). PRC falls rapidly after delivery
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(Broughton Pipkin, Oats & Symonds, 1978) and is virtually back to non-pregnant 
levels by 6 weeks postnatally (Baker et al, 1990).
The precise mechanism for the hyperreninaemia o f pregnancy is not fully understood. 
It is likely to be progesterone driven as progesterone is know to be a marked 
natriuretic. This loss o f sodium then acts as a stimulus to renin and ultimately 
aldosterone release and this acts to conserve sodium. Circulating levels of PGE2 and 
prostacyclin are also elevated during pregnancy and both these, as has already been 
discussed, increase renin production.
PRS or Aogen rises by about four-fold during pregnancy, with the rise becoming 
significant by the second trimester (Skinner et al, 1972; Weir, Brown, Fraser, Lever, 
Logan, Mcllwaine, Morton & Robertson, 1975; Baker et al, 1990). This increase is 
thought to be oestrogen-driven and similar changes occur in women taking oral 
contraceptives (Derkx et al, 1986). It was mentioned above that Aogen exists in 
several different forms of different molecular weight. In non-pregnant women the high 
molecular weight form (HMW-Aogen) makes up less than 5% of the total Aogen. 
During pregnancy this rises steadily to about 20% by term, the rise becoming 
statistically significant by the end o f the first trimester (Tetlow & Broughton Pipkin
1986). These HMW-Aogen molecules found in pregnancy are likely to be mainly 
polymers, on the basis o f their molecular weights found on gel chromatography 
Whether or not these HMW-Aogens are physiologically active has not yet been 
determined.
The increase in both plasma renin and Aogen in normal pregnancy is accompanied by a 
rise (in the order o f 100%), in Ang II (Weir et al, 1975; Baker et al, 1990) which 
varies markedly from individual to individual. This rise becomes statistically significant 
by the second trimester, continues to rise to a maximum in the third trimester, begins 
to fall within 24 hours of delivery and is virtually back to non-pregnant levels by six 
weeks postpartum (Baker et al, 1990).
In order to prevent a rise in blood pressure in response to these increased levels during 
pregnancy the maternal vascular system must become less sensitive to the RAS. In
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1967 Talledo showed that the vascular response to infused Ang II was significantly 
reduced in normal pregnancy (Talledo, Rhodes & Livingston, 1967). He then went on 
to demonstrate increased sensitivity to infused Ang II in pre-eclamptic patients 
compared to normal pregnant controls (Talledo, Chesley & Zuspan 1968). In 1973 
Gant and colleagues reported a prospective study in which they found that primigravid 
women who subsequently developed hypertension showed an increased sensitivity to 
Ang II as early as 18 to 22 weeks gestation. Although this was a large series of 192 
patients many were Afro-American teenagers and the overall incidence of pregnancy 
induced hypertension in the study was exceptionally high at 37.5%.
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Following these observations several studies have tried to determine whether reduced 
sensitivity to infused Ang II can be used to predict the subsequent development o f PE. 
The first o f these studies to be published was that o f  Morris and colleagues (1978) who 
looked at 26 primigravid patients, testing them weekly from 29 to 32 weeks gestation. 
They found unacceptably high false-positive and false-negative rates and concluded 
“that assessment of the risk of pregnancy induced hypertension (PIH) with the use of 
the diastolic pressor response to infused A-II is unreliable” (Morris, O’Grady, 
Hamilton & Davidson, 1978). Later studies found the test to be more sensitive but still 
not very specific with false positive rates o f 55% (Oney & Kaulhausen, 1982) and up 
to 42.1% in an Asian population (Nakamura, Ito, Matsui, Yoshimura, Kawasaki & 
Maeyama, 1986). In 1990 Dekker reported a comparison between the supine pressor 
test and Ang II infusion at 28 weeks gestation as predictors of the development o f PIH 
in 90 normotensive, nulliparous women. He found that Ang II infusion had a 
specificity of about 90% and a sensitivity o f 92%; the supine pressor test had a similar 
specificity but a low sensitivity o f only 25% (Dekker, Makovitz & Wallenburg, 1990).
All o f these studies point to the involvement o f the RAS in the pathogenesis o f PE and 
PIH but they are likely to be of limited clinical use because of both the invasiveness of 
the test and the amount of manpower involved in performing it. Therefore there has 
been interest in developing a less invasive method of determining an individual’s 
response to Ang II. Platelets are a relatively accessible model of smooth muscle cells; 
they share many structural and biochemical characteristics and similarities between 
aspects of platelet behaviour and changes in vascular tone have been described
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(Cameron & Ardlie, 1982; Cowley, Stainer, Cockbill & Heptinstall, 1984). A cross- 
sectional study performed by Baker and colleagues and reported in 1991 found 
significantly higher platelet Ang II binding in pregnant women who developed PIH 
compared to women who remained normotensive. Women who also developed 
proteinuria had even higher (but not significantly so) platelet Ang II binding. Later the 
same group compared platelet Ang II binding with Ang II infusion in 34 primigravid 
women, 10 o f whom developed PIH. They found that “the use of platelet Ang II 
binding alone in predicting the outcome o f the pregnancies, as assessed using 
discriminant analysis, was more sucessful than when any o f the infusion parameters 
were used, with 77% of patients being correctly classified” (Baker, Broughton Pipkin 
& Symonds,1992).
It should be remembered that although there has been great interest in reduced 
sensitivity to Ang II in pregnancy and loss o f this reduced sensitivity in pregnancies 
which are subsequently complicated by PE the actual mechanism of the reduced 
sensitivity is unknown. It has been postulated by several groups that it is caused by the 
elevated levels o f PGs found in pregnancy. Following on from this authors have 
suggested that the comparative increase in sensitivity to ang II in pregnancies which 
are destined to become pre-eclamptic may be caused by lower levels of vasodilating 
PGs in these pregnancies and perhaps also higher levels of the vaso-consticting PGs. 
Work in this field has been hampered by the extremely short half-life of the PGs and by 
the lack of a suitable animal model for human pregnancy. These theories have been 
ably summarized by Friedmann, 1988. Following on from these theories o f PG 
imbalance in pre-eclamptic pregnancy, trials o f low doses of cyclo-oxygenase inhibitors 
(eg. aspirin), which reduce thromboxane production whilst prostacyclin production is 
relatively spared, were designed to see if PE could be prevented. Although the results 
o f early small trials were encouraging the multi-centre collaborative low dose aspirin 
study in pregnancy failed to support the routine use of prophylactic or therapeutic 
aspirin (CLASP collaborative group, 1994).
The RAS in the uterus and placenta
Although the components of the RAS were being located in the uteroplacental unit 
from as early as 1968 (Symonds, Stanley & Skinner, 1968), their significance was not
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originally understood. It now appears that the RAS is crucially important in the 
process of implantation and placentation (Myatt, 1992). Ang II increases vascular 
permeability which may facilitate endometrial infiltration by fetal trophoblast; it also 
stimulates angiogenesis. The regulation of vascular resistance and blood flow in the 
placenta is complex. Although Ang II is a vasoconstrictor it is now known to 
stimulate the synthesis o f prostaglandins E and I (vasodilators) in the uteroplacental 
unit (Glance, Elder & Myatt, 1985). In low doses Ang II infusion into monkeys has 
been shown, directly, to increase uterine blood flow and the same effect has been 
measured indirectly in humans using Doppler velocity ratios (Loquet, Broughton 
Pipkin, Symonds & Rubin, 1990). In support of this captopril is known to reduce 
uterine blood flow.
It has been suggested that Ang II is also involved in the regulation of fluid and 
electrolyte transport across the fetal membranes, as in the renal tubules, but this has 
not been conclusively shown to occur in human pregnancy.
The uteroplacental RAS may be important in uterine contraction during labour. Ang II 
is known to cause uterine smooth muscle to contract in vitro and it also increases 
intracellular iCa2+ in human myometrial smooth muscle cells, which in turn causes 
phosphorylation o f myosin light chains and hence contraction. This uterine contraction 
response to Ang II increases as pregnancy progresses possibly due to loss of 
progesterone dominance with later gestation. It may be that oxytocin and Ang II act 
synergistically on the uterus around the time of labour - certainly intracerebral Ang II is 
known to stimulate pituitary oxytocin release (Broughton Pipkin, 1993).
The fetal RAS
The fetal RAS is not the subject o f this thesis. In brief, fetal PRS, assayed in cord 
blood taken from babies delivered following labour at 35 or more weeks of gestation, 
is higher than in non-pregnant adults but lower than maternal PRS; this does not apply 
if the babies have been delivered by elective Caesarean section (Tetlow, 1983). Fetal 
PRC is higher than maternal levels. No correlation has been demonstrated between 
maternal and umbilical PRS or PRC suggesting that the maternal and fetal RAS are 
independent, (Tetlow & Broughton Pipkin, 1983). The use o f angiotensin converting
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enzyme inhibitors is totally contraindicated in pregnancy even though they are efficient 
hypotensive agents. This is because of severe adverse effects on the developing fetal 
renal system causing oligohydramnios, stillbirth and neonatal renal failure (Broughton 
Pipkin, 1989); this suggests that before birth the RAS plays an important role in fetal 
cardiovascular and volume homeostasis.
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AIMS OF THESIS
Work on this thesis began in 1992 when there was great hope that calcium 
supplementation given to normal pregnant women might reduce the incidence o f pre­
eclampsia which caused so much maternal and neonatal mortality and morbidity both 
nationally and on a global scale. Although one small, single-handed project could not 
hope to solve such a complex problem it was felt that by concentrating on a sub­
group, known to be at increased risk of pre-eclampsia, namely pregnant women with 
IDDM, useful information could be obtained. As calcium homeostatic mechanisms 
are known to be linked to the renin-angiotensin system, also implicated in the aetiolgy 
of pre-eclampsia, and both o f these systems are known to be disordered in non­
pregnant IDDM it was decided to look at components o f both systems. Thus the 
overall aim was to investigate the hypothesis that pregnant IDDM women have 
abnormalities in both calcium metabolism and the renin-angiotensin system which 
might predispose them to the development of pre-eclampsia. To this end several 
related smaller studies were planned:
1. To conduct a prospective, randomized, double blind, placebo controlled trial on 
the effect of a daily 1.5g oral calcium supplement, given from mid-second 
trimester until delivery, on the BP of normal and IDDM pregnant women.
2. To determine and compare fasting concentrations of:





urinary excretion of the electrolytes, creatinine and albumin 
in normal and IDDM pregnant women at 21 and 31 weeks gestation and in the same 
women when no longer pregnant, looking for both a pregnancy and a disease effect. 
Also to see if these parameters were affected by the long term calcium supplements 
being taken by half the women at 31 weeks gestation.
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3. To study the short term (4 hours) effect of a lg  oral calcium load, given to normal 
and IDDM pregnant women at 21 and 31 weeks gestation and to the same women 
after the end of their pregnancies, on the variables listed above.
4. To look at the diets o f the normal and IDDM women during and after pregnancy 
to see if the calcium intake of the two groups was different.
5. It was also hoped to examine concentrations of 25-DHCC and 1,25-DHCC but 
this had to be abandoned after promised fimds were withdrawn. 1,25-DHCC was 
measured in a few women before funding was withdrawn but the numbers were 




The study was carried out at The Royal United Hospital, Bath. The biochemical 
analyses were performed in the on-site laboratories but hormone analyses were carried 
out in specialist laboratories as detailed below.
ETHICAL APPROVAL
Local ethical committee approval was sought and obtained for the research protocol 
and consent form, which was signed by the participating women, as described below.
OUTLINE OF STUDY PROTOCOL
This was a prospective, randomized, double blind, placebo controlled study. A broad 
outline is given below with each aspect of the protocol then being dealt with in greater 
detail:
First/early second trimester - recruitment of women
- weight, height and BP measurement
20-22 weeks gestation
24 hour urine collection for Ca, Mg, P 0 4, albumin, creatinine and electrolytes 
5 hour session in laboratory
Recording of weight and BP.
Baseline fasting blood for elctrolytes, ionized calcium and hormones as 
described below.
1 hour fasting urine collected and analysed as above
Standard breakfast and lg  oral calcium load followed by hourly blood and urine 
sampling for analysis as above
Randomization to either 1.5g calcium or placebo daily for the remainder o f the 
pregnancy.
BP recording at fortnightly intervals from this time until delivery.
30-32 weeks gestation - exact repetition of above.
Post-partum, once breast feeding discontinued- exact repetition of above.
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RECRUITMENT
Two groups o f twenty pregnant women were recruited: the first consisting o f normal 
controls and the second of women with IDDM, the onset o f which pre-dated the index 
pregnancy. All the women were told verbally about the study and asked if they would 
be interested in participating. If  they expressed an interest they were given an 
information sheet which reiterated the aims of the study and described what would be 
required of the volunteer. The women were advised to take this home and to discuss it 
with their partners before coming to a final decision. Following this they signed a 
consent form which followed guidelines issued by the Bath District Health Authority 
Research Ethics Committee (see Appendix 1).
Exclusion criteria
Women with a history of renal calculi, essential hypertension, parathyroid disease, or 
surgery to either the thyroid or parathyroid glands were excluded.
The general practitioners o f the participating women were informed o f their patient’s 
inclusion in the trial by letter.
Most o f the subjects were recruited during the first trimester of pregnancy with a 
minority entering early in the second trimester (see results). All of the latter group had 
booked their pregnancy with a midwife before 10 weeks gestation and for these 
women the booking weight, height and blood pressure recorded by that midwife were 
used. The remaining majority o f women attended the laboratory during the first 
trimester where they were weighed, their height was recorded and their blood pressure 
measured.
BLOOD PRESSURE MEASUREMENTS
Throughout the study blood pressure measurements were obtained using a standard 
mercury syphygmomanometer. Cuff size was determined by upper arm circumference; 
a standard cuff (bladder size 12 x 22cm) was adequate in almost all cases but for some 
(arm circumference >33cm) a larger cuff was used (bladder size 14 x 31cm). All 
subjects were at rest for at least 10 minutes before any recordings were made. Any 
tight clothing was removed from the non-dominant arm so that there was no
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constriction and the cuff could be applied easily. The first readings were obtained with 
the subjects sitting comfortably in the upright position. The brachial artery was located 
in front o f the elbow and a stethoscope placed directly over it without undue pressure. 
The cuff was then pumped up rapidly to approximately 30mmHg above the point at 
which Korotkoff sounds disappeared. Air was released slowly so that the mercury fell 
steadily at a rate of 2 - 3mm/s. The systolic blood pressure was taken as the point 
where the first clear tapping sound was heard. The top of the mercury meniscus was 
read to the nearest 2mmHg. During pregnancy the diastolic blood pressure was taken 
as the point where the sounds first become muffled (Korotkoff phase IV) as during 
pregnancy the auscultated Korotkoff sounds may persist to zero due to peripheral 
vasodilation making the Korotkoff V point (disappearance of Korotkoff sounds) 
meaningless. If  it was present the Korotkoff V point was also recorded. For non­
pregnant measurements phase V was used throughout as this corresponds most closely 
to the true diastolic blood pressure as measured by intra-arterial catheter. Three 
recordings were taken, the first was discarded and the next two averaged.
Blood pressure was recorded on one occasion during the first trimester between 10 
and 12 weeks gestation. It was next recorded at 20 - 22 weeks just before the subject 
began either the calcium supplements or placebo and from then on was taken at two 
weekly intervals until delivery. Approximately 85% of the readings were performed by 
the investigator to eliminate inter-observer error. On occasions when this was not 
possible the readings were taken by a midwife who had been trained to follow the 
protocol described above.
ORAL CALCIUM LOADS
These were carried out twice antenatally, as described above, and once postnatally, 
usually after the subject had stopped breast feeding. As some subjects continued to 
breast feed for prolonged periods, one for > 2 years, it was not always possible to wait 
until subjects had completely discontinued feeding; in these cases the postnatal oral 
calcium load was performed once the frequency o f breast feeds had fallen to only one 
per day. The same protocol was followed for all 3 experiments.
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On the day before the study the subjects began a 24 urine collection using a plain 
bottle. The 24 hour urine samples were later analysed for calcium, magnesium, 
phosphate, creatinine and microalbumin - see below. Subjects arrived at the laboratory 
between 08.00 and 09.00hr having had nothing to eat or drink since the evening before 
Smoking was also not allowed from midnight the night before but as none of the 
volunteers smoked this was not an issue. The diabetic subjects delayed their normal 
morning insulin injection until arrival.
On arrival the subjects were asked to empty their bladders and were given 200ml of tap 
water to drink. Then they were weighed and their height was measured. They then 
rested in a comfortable chair whilst a 21g cannula (Venflon) was inserted into a 
suitable vein and 30ml of blood was withdrawn. The cannula was flushed with 5ml of 
heparinized saline (Hepsal) and secured in position. One hour later they emptied their 
bladder again using a commode situated in a room adjacent to the laboratory whilst 
their breakfast was prepared. All the subjects ate a standard breakfast:
2 Weetabix 
200ml full fat milk









In addition a lg  calcium load was given as 2 “Cacit” tablets dissolved in 200ml of tap 
water. These are orange-flavoured effervescent tablets containing 1.25g calcium 
carbonate which each dissolve to provide 500mg of elemental calcium as calcium 
citrate. Tap water in the Bath area contains 2.5mg of calcium per 200ml.
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The volunteers spent the next 4 hours seated in the laboratory. At hourly intervals they 
emptied their bladders, drank 200ml of water and had 30ml o f blood withdrawn. 
During this time blood pressure measurements were taken as described above. The 
subjects were also taken through a dietary questionnaire (Ryan, Kellow, Jphns, Black, 
Sorenson, Fogelman, 1994) with food portion models to determine their dietary 
calcium intake (Appendix II). After 4 hours the intravenous cannula was removed and 
the subjects were given a sandwich lunch after which they were free to go.
PREPARATION AND ANALYSIS OF SAMPLES
The 30ml of blood taken was divided into prepared tubes: 12ml into 2 plain glass tubes 
which was allowed to clot at room temperature, 12ml into chilled lithium heparin glass 
tubes, 5ml into a chilled bottle, prepared on site, containing lOOpl disodium EDTA, 
and 1ml into a plain vacutainer - this was also allowed to clot at room temperature. 
Slightly more than 30ml o f blood was removed on the first occasion while the 
volunteer was still fasting and approximately 3 ml were placed in a plain, clotted 
vacutainer for later measurement o f fructosamine The chilled tubes were transferred 
immediately to a centrifuge and spun at 4°C for 10 minutes at 2,500rpm. The plasma 
obtained was decanted into pre-labelled small plastic tubes and stored at -20°C within 
20 minutes. The clotted samples were spun similarly at room temperature and aliquots 
o f serum were also stored at -20°C.
The volumes of urine passed hourly were measured using a cylinder graded in 2ml 
divisions and aliquots of approximately 10ml were placed in plastic tubes and stored at 
-20°C.
The 24 hour urine sample and the vacutainer blood samples were taken to the 
laboratories of the Royal United Hospital on the day of the study. Fructosamine was 
measured on the DAX 48 analyser. Essentially the test is based on the ability o f 
ketoamines to reduce nitroblue tetrazolium in alkaline medium to form the dye 
formazan. The rate of production of formazan is directly proportional to the 
fructosamine concentration and is measured photometrically at 548nm. The interassay 
CV varied from 5.67% to 5.98%. Fructosamine, rather than Haemoglobin Ale, was
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measured as this gives an insight into glycaemic control over a shorter, and hence, 
more recent, time period of 2-3 weeks.
Ionized calcium
Ionized calcium was measured on a 1ml clotted blood sample taken into a plain clotted 
vacutainer, thus excluding air from the sample as exposure to carbon dioxide lowers 
the pH of the serum sample which raises the ionized calcium value. In addition the 
serum was analysed as rapidly as possible after transfer to the laboratory. An AVL 
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Fig.2.1 Diagram of measuring system for ionized calcium
As shown in Fig. 2.1, an ion (calcium) selective membrane separates the sample whose 
electrolyte concentration is unknown from an electrode solution whose electrolyte 
concentration is known. The membrane is constructed so that it undergoes a specific 
reaction with the electrolyte in the sample and acts as an ion exchanger. Therefore a 
potential difference is set up across the membrane. The concentration of the inner 
solution in the electrode is known and this determines the potential on that side of the 
membrane. On the sample side of the membrane the concentration is unknown but by 
measuring the potential difference across the membrane with a voltmeter the unknown
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ionized calcium concentration can be calculated using the Nemst equation. The 
interassay CV at 0.8mmol/l Ca2 is 2.5%, improving to 1.3% at 1.5mmol/l.
Measurements of serum and urine electrolytes and glucose
Glucose was measured using the DAX 48 analyser. Glucose is first phosphorylated 
and then converted to 6-phosphogluconate-8-lactone by D-glucose-6-phosphate 
dehydrogenase. The latter reaction concurrently reduces NAD to NADH and this 
results in an increased light absorbance at 340nm which is directly proportional to the 
glucose concentration. The interassay CV is 2.9%.
Urine calcium, albumin and creatinine were analysed on the Roche Cobas Bio 
centrifugal analyser. Urine sodium, potassium, urea, phosphate and magnesium and 
serum sodium, potassium, urea, creatinine, chloride, urate, phosphate, albumin, 
magnesium and calcium were analysed on the Johnson & Johnson Ektachem Kodak 
750 system. The urine control material was Biorad Lypocheck levels 1 and 2 and the 
serum control material was Ektachem performance verifier 1 and 2. The interassay 
CVs were:
Performance verifiers (PERV) 1 and 2 (blood)












Biorad Lypocheck level 1 (urine)
Sodium Potassium Urea Phosphate Magnesium
CV(%) 3.6 4.1 3.9 4.9 1.3
Biorad Lypocheck levels 1 and 2 (urine)
Calcium Creatinine Microalbumin
Level 1 CV(%) 3.4 2.1 3.9
Level 2 CV(%) 2.6 2.9 3.3
The assay for urine calcium is a colourimetric method which uses o-cresolphthalein and 
8-OH quinolone to eliminate interference from magnesium ions. The reagents are 
supplied by Biorad.
Serum intact parathyroid hormone
Frozen serum samples were transferred to the Biochemistry Department of the 
University Hospital of Wales, Cardiff where iPTH was measured using the Ciba 
Coming “Magic Lite” assay. 200pl of serum, which contains iPTH together with an 
excess of biologically inert carboxy-terminal fragments, is mixed with antibody labelled 
with a chemiluminescent acridinium ester which is specific for the amino-terminal 
sequence of PTH. This binds to the iPTH but not the C-terminal fragments. After an 
overnight reaction a C-terminal specific monoclonal antibody linked to magnetic 
particles is added in large excess. This binds both C-terminal fragments and iPTH. 
The particles are separated on a magnet and washed free of any unbound material. The 
amount of luminescence associated with the solid phase depends on the amount of 
hormone “sandwiched” between C-terminal solid phase antibody and acridinium 
labelled N-terminal antibody and is used to provide a direct measure of the intact 
hormone concentration by comparison with known standard concentrations of 
synthetic human 1 -84 PTH. The limit of detection of the assay is 0.8pmol/l.
Plasma renin substrate and plasma renin concentration
Frozen samples of plasma prepared by mixing blood with disodium-EDTA were taken
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to the Department of Obstetrics & Gynaecology at the Queen’s Medical Centre, 
Nottingham for assay. PRC was measured by reacting the renin in samples with 
excess (heterologous) Aogen under standard conditions. PRS was measured by its 
ability to generate Ang I from an excess of homologous renin under the same 
physiological conditions. The inter- and intra-assay CVs for PRS were 12.7% and 
6.3% respectively and 10.7% and 5.6% for PRC.
RANDOMIZATION TO ORAL CALCIUM SUPPLEMENTATION OR 
PLACEBO
After completing their first oral calcium load the subjects were randomly allocated to 
receive either 1.5mg of elemental calcium in the form of 3 “Calcichew” tablets daily 
(Shire Pharmaceuticals) or 3 placebo tablets in the form of white lactose tablets 
supplied by the Pharmacy at Royal United Hospital, Bath. Computerized 
randomization was carried out separately for the normal and IDDM women to ensure 
that 10 of each group received calcium and 10 o f each group received placebo. Details 
of the group to which each woman had been assigned were held by pharmacy and only 
released at the end of the trial. The women themselves were not aware of which they 
were taking. The pharmacy also kept a record of the number of tablets dispensed to 
each volunteer. After delivery the women returned their unused tablets to the 
pharmacy; thus it was possible to calculate how many tablets they had taken and hence 
their compliance.
STATISTICAL METHODS
Results are expressed as means ± standard error of the mean (SEM) or medians with 
interquartile ranges (IQR) as appropriate. In some cases the standard deviation (SD) is 
also quoted to allow comparisons with the work of others. The statistical package for 
social scientists version 7.5 for Windows was used to analyse data. In general, 
normally distributed data were compared using the Student’s T test (paired or unpaired 
as appropriate) provided that Fisher’s test was not significant. If  Fisher’s test was 
significant or if the data were not normally distributed then non-parametric tests were 
used. Analalysis of variance (ANOVA) with post hoc T test by Scheffe at p< 0.01, or 
Kruskal Wallis analysis of variance with post hoc Mann Whitney U test, for non- 
parametric data, was used to calculate time-related or pregnancy-related changes in
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variables. In keeping with convention p<0.05 was regarded as significant and p<0.01 
highly significant. On occasion, as mentioned in the text, data which were not 
normally distributed were logio transformed to create a normal distribution before 
further analysis was performed.
Wherever scatter graphs are used to illustrate correlations between two variables the 
equation for the “line of best fit,” calculated by linear regression is quoted in the form 
of y = a + bx where “a” is the intercept on the y axis and “b” is the slope of the line; 
both “a” and “b” are given with their appropriate SEM. Differences in the slopes and 
intercepts o f regression lines were calculated longhand by T-test. Again in keeping 
with convention p<0.05 was regarded as significant, with p<0.01 being highly 
significant.
Labelling of figures
Normal women are shown in red and IDDM women in green. "Gestation" has been 
used to describe the different times at which the oral calcium loads were performed 
including the post-pregnancy study and "time" is used to denote the time from 
ingesting the breakfast and calcium tablets. Where the data are compared by gestation 
within one group of women 2nd trimester data are shown in turquoise , 3rd trimester 
data in pink and the not pregnant data in brown. The phrase "not pregnant" is used in 
preference to "post-partum" as the women were deliberately not studied until a time 




3.1A Demographic characteristics of subjects
20 normal pregnant and 20 insulin-dependent pregnant diabetic women were recruited 
in total. Basic demographic data on the subjects are shown in table 3.1. All were 
Caucasian.





3 II N) O n = 20
M aternal age (yrs) 29.9 (0.9) 30.3(1.1) ns
Prim iparous:M ultiparous 9:11 14:6
Smokers 0 0
BMI in 1st trimester (kg/m2) 23.3 (0.7) 24.1 (0.7) ns
1st trim ester systolic blood pressure (mmHg) 112(2) 113(2) ns
1st trim ester diastolic blood pressure(mmHg) 73 (2) 72 (2) ns
Occupations of volunteers
Control women were mainly drawn from hospital staff with 6 doctors, 9 nurses or 
midwives, 2 receptionists, 1 secretary, 1 laboratory technician and one other who 
worked in administration at the Ministry of Defence. The IDDM group were more 
mixed with 5 bank or building society clerks, 4 housewives, 3 shop assistants, 2 civil 
service workers, 1 doctor, 1 nurse, 1 health care assistant, 1 teacher, 1 personal 
assistant and 1 in marketing. Diabetic details for this group are shown in table 3.2.
69
3.1B Details of diabetic control and complications




















D1 26 10 56 218 0.3 None
D2 36 23 22 N/A 0.2 None
D3 39 33 56 356 1.4 Treated
D4 37 9 68 232 0.9 Minimal
D5 29 2 18 327 0.8 None
D6 31 11 36 232 1.1 None
D7 26 1 44 273 0.5 None
D8 31 10 60 7.5%* 0.7 Minimal
D9 22 12 16 267 0.9 None
DIO 25 18 86 264 0.6 None
D ll 26 11 40 247 0.8 None
D12 37 28 24 293 3.9 None
D13 30 22 36 296 1.3 None
D14 30 25 100 305 0.7 Treated
D15 37 10 66 253 0.5 None
D16 31 6 64 281 0.7 None
D17 24 3 48 329 0.5 None
D18 29 19 35 281 0.6 None
D19 33 5 46 5.1%* 0.6 None
D20 27 26 38 222 0.7 Minimal
*These patients were booked in a neighbouring district general hospital and were 
recruited to increase the number of IDDM women in the study. Haemoglobin Ale was 
used in this hospital, rather than fructosamine, as an indicator of diabetic control.
The normal ranges are those used outside of pregnancy.
Urinary infection was excluded in all the women at booking.
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3.1C Obstetric and perinatal outcome
One normal woman delivered at 30 weeks. The infant went to the Neonatal Intensive 
Care Unit (NICU) and was discharged well. The others delivered at term (Table 3.3).

























N1 42 NVD F 4.02 119 6 9 -
N2 38 El LSCS F 3.69 118 9 9 -
N3 40 NVD M 3.57 94 9 10 -
N4 39 NVD M 3.94 111 9 9 -
N5 38 El LSCS M 3.56 114 10 10 -
N6 41 NVD F 3.50 97 6 9 -
N7 39 NVD M 3.57 102 9 10 -
N8 41 NVD F 4.15 117 9 10 -
N9 40 Forceps F 3.40 101 9 10 -
N10 40 NVD F 3.43 96 9 10 -
N il 37 El LSCS M 3.8 118 9 10 -
N12 39 NVD M 3.8 116 10 10 -
N13 38 El LSCS F 2.89 90 9 10 -
N14 41 NVD F 3.56 97 9 10 -
N15 41 NVD F 3.54 94 7 7 -
N16 30 Forceps M 1.68 92(C) Intubat
ed
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N17 38 El LSCS M 3.72 110 9 10 -
N18 40 Em LSCS M 4.57 122 8 10 -
N19 38 El LSCS M 3.00 91 9 10 -
N20 38 NVD M 3.36 98 9 10 -
NVD = normal vaginal delivery; C = centile; El LSCS = elective Caesarean section;
Em LSCS = emergency Caesarean section
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Individualized birth weight ratios have been given in preference to centiles because 
these reflect the mother’s height, weight and parity and so are a more logical outcome 
measure of pregnancy than birth weight alone (Wilcox, Johnson, Maynard, Smith & 
Chilvers, 1993). These are not available for babies at less than 37 weeks or 259 days’ 
gestation and for these babies the centiles have been given and indicated by (C).
The elective LSCS rate for this group o f women was 30%, approximately double the 
Caesarean section rate for the hospital. 5 of the 6 elective operations were repeat 
procedures where the woman chose not to have a trial o f labour. Many of the normal 
volunteers were doctors and midwives and this group o f women are probably more 
reluctant than the general population to undergo labour in the presence o f a uterine 
scar. They are also less likely to be talked out of a desire for an elective operative 
delivery by the obstetrician looking after them. The final elective Caesarean section 
was for a transverse lie.
Details of the deliveries o f the IDDM women are summarized in table 3.4. The usual 
policy for delivery of IDDM women in Bath was to induce labour at 38 weeks. If the 
woman had had a previous Caesarean section (4 of the volunteers) then an elective 
repeat Caesarean section was performed rather than allowing a trial o f labour. The 
other elective sections were performed on the two primigravid patients who developed 
PE, for 2 cases of pre-labour fetal distress (D7 and D8) and at the request of the 
mother (D15). 5 of the emergency LSCS were performed for failure to progress after 
induction of labour and the last (D20) was for fetal distress.
In Bath infants of IDDM mothers were routinely admitted to NICU to monitor their 
blood sugars and this accounts for the 12 NICU admissions of 1-2 days’duration. 
Longer stays were on account of prematurity - (D3 and D5), while the baby’s heart 
condition was investigated (D13), because of birth trauma (D16) and infant D7, who 
was delivered because o f an abnormal pre-labour cardiotocograph and was bom in a 
poor condition needing intensive resuscitation and ventilation.
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Dl 38 NVD M 2.44 76 9 10 2+
D2 40* Em LSCS F 3.93 112 9 10 1
D3 34 (P) El LSCS M 2.06 5(C) 9 10 21
D4 38 El LSCS M 3.23 85 9 10 2
D5 34 (P) El LSCS F 3.23 99(C) 7 9 5
D6 38* Forceps M 3.60 110 9 10 1
D7 37 El LSCS M 2.92 100 Intubated 19
D8 35 El LSCS F 3.00 90(C) 9 10 -
D9 39* NVD M 3.63 109 9 9 1
DIO 37 (P) El LSCS M 3.12 98 9 10 r
D ll 38* Em LSCS M 3.78 114 8 10 2
D12 38 El LSCS M 3.76 118 8 9 1
D13 37* Em LSCS M 4.10 134 9 10 9+++
D14 37 El LSCS M 4.12 122 8 10 -
D15 38 El LSCS F 3.75 116 9 10 1
D16 38* Forceps F 3.95 130 4 9 8++++
D17 38* Em LSCS M 4.59 140 9 10 1
D18 36 Em LSCS M 3.16 72(C) 9 10 2
D19 38 NVD M 3.58 107 9 10 -
D20 38* Em LSCS M 3.51 112 9 9 1
C = centile
* = induction of labour 
NVD = normal vaginal delivery;
El LSCS = elective Caesarean section; Em LSCS = emergency Caesarean section 
congenital hypospadias ++ undescended testes ++ ventricular septal defect 
delivery complicated by shoulder dystocia - the baby’s clavicle was fractured
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Women marked by a (P) developed pre-eclampsia (PE), defined as a sustained BP o f 
greater then 140/90mmHg in association with >2+ o f proteinuria. One o f these three 
women had been randomized to calcium supplementation. The individual case details 
are summarized below and the results o f these women are presented separately.
D3
A 39 year old woman, who had had IDDM for 33 years, was in her second pregnancy. 
Her first pregnancy had also been complicated by PE. In the index pregnancy her 
booking BP was 110/70mmHg. She was admitted at 33 weeks with 3+ proteinuria on 
dipstix testing. Initially her BP was not severely elevated but within a week it rose to 
170/95. As the local NICU was lull she was transferred to a neighbouring hospital and 
was delivered of a healthy 2.06kg male infant by elective repeat Caesarean section. 
Following delivery her BP settled spontaneously to 100/70mmHg and her proteinuria 
diminished. Notably however when studied 62 weeks after the delivery her 24hr 
microalbumin result was 65.8mg/l compared to 10mg/l at 20 weeks gestation. This 
raises the possibility o f underlying diabetic nephropathy which may also have been 
present when the diagnosis of PE was made. This woman was allocated placebo.
D5
This 29 year old primigravida had had IDDM for 2 years. She had no underlying renal 
disease and booked with a BP o f 95/65. She was admitted at 32 weeks gestation with 
a BP of 160/100mmHg and 2+ proteinuria on dipstix testing. She was monitored 
closely but at 34 weeks gestation her condition deteriorated and she required 
intravenous hydralazine to control her BP. She was delivered o f a female infant 
weighing 2.64kg by elective Caesarean section. Following delivery her BP and 
proteinuria rapidly resolved, confirming a diagnosis o f PE. She was unwilling to give 
blood for a postnatal study but her 24hour microalbuminuria was 5.2mg/l similar to her 
value of 4.4mg/l at 20 weeks gestation. Her non-pregnant BP was 115/75mmHg.
This women was allocated to calcium supplements.
DIO
This 25 year primigravida had had IDDM for 18 years. She also had no underlying 
nephropathy and booked with a BP o f 100/60mmHg. Her pregnancy was uneventful
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until 37 weeks when her BP was measured in the antenatal clinic and found to be 
155/100mmHg. She had 3+ proteinuria on dipstix testing. She was admitted and 
delivered a male infant weighing 3.12kg by elective Caesarean section. Subsequently 
her BP returned to 100/70mmHg and a 24 hour urine collection showed only 26.2 mg/1 
microalbuminuria. Again PE was felt to be the likely cause of the hypertension in 
pregnancy. This woman was allocated to placebo.
The results of the women who developed PE are presented separately.
Randomization to calcium supplementation or placebo
This occurred immediately after the women had undergone the 21 week calcium load 
study. Therefore results for the 31 week study were first analysed in four groups: 
normal women receiving calcium supplementation; normal women on placebo; IDDM 
women receiving calcium supplementation; IDDM women on placebo. For nearly all 
analytes there was no difference between the supplemented and placebo groups but 
whenever this occurred it is mentioned in the appropriate section of the results 
chapter. The four subgroups were then re-analysed simply as “normal” or “IDDM” 
increasing the sample size available for comparison between 21 and 31 weeks’ 
gestation.
3.3D Compliance with prescribed intervention
The number o f tablets taken by each individual were determined by subtracting the 
number returned from the number dispensed by pharmacy. The number that should 
have been taken was calculated by multiplying the numbers of days between the start 
o f randomization and delivery for each individual patient. Two normal women, on 
active tablets complained o f nausea and only took 21% and 54%. Median compliance 
in the remaining normal women was 93% (range 82%-100%). None o f the IDDM 
women complained of any side-effects from the tablets. Their compliance was 
91%(76%-100%). This was statistically indistinguishable from the normal women.
Although compliance was poor in two o f the normal women on active calcium
supplements analysis o f  the results was performed on an “intention to treat” basis.
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3.1E Dietary calcium studies
This was assessed by means of a food questionnaire (appendix II) administered by the 
investigator using appropriate food portion models. Results are shown in table 3.5 and 
table 3.6 for the women who developed PE.
Table 3.5 Daily calcium intake assessed by questionnaire before calcium 











Ca (mg/day) 1316(80) 1574(158) 
{310.8} {569.1}
ns 1146(66) 1316(139) 
{254.3} {502.6}
ns
Although calcium intake was higher in pregnancy in both groups this was of borderline 
statistical significance with p values of 0.05 and 0.06 for normal and IDDM women 
respectively.
Table 3.6 Daily dietary calcium of the 3 diabetic women who developed PE





Timing of calcium load studies
The study protocol aimed to study all the women firstly at 20-22 weeks gestation, then 
at 30-32 weeks (one normal volunteer failed to make this appointment because of the 
death of her mother) and finally postnatally once they had stopped breast feeding. The
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last was particularly difficult to achieve as by this stage many of the volunteers had 
returned to work and were also busy with a new baby making it hard for them to find 
time to attend hospital for an entire morning. Gestation details for the calcium load 
studies are shown in table 3.7.
Table 3.7 Gestation when calcium load studies performed. Median (range)










median 21 21 ns 31 31 ns 40 29 ns
range 20-23 20-23 30-35 30-35 6-75 16-54
The women with PE were studied at the following times:
• D3 - 22, 30 and 62 weeks
• D5 - 22, 31 and 84 weeks
• DIO - 21, 34 and 44 weeks
Menstrual details for the after pregnancy study are shown in table 3.8.





Follicular phase 2 4








These numbers are too small to allow statistical comparisons to be made.
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3.IF  Blood pressure results
Control group
Results for the normal women are shown in table 3.9 and for the IDDM women in 
table 3.10. Although the single first trimester reading was taken at a variety of times 
between 9 and 12 weeks’ gestation they have been grouped together as “12 weeks”. 
The women were not allocated to calcium or placebo until 20 weeks’ gestation. 
However they are shown as subdivided for the first trimester and the not pregnant 
results; these subgroups were then compared and there was no statistical difference 
between the baseline blood pressures (BP) of the women allocated to placebo or 
calcium supplements. As only 3 normal women had BP readings at 40 weeks these 
are not shown.
Following randomization the women had their BP measurements taken fortnightly. 
At no gestation was there any difference between either the systolic BP (SBP) or the 
diastolic BP (DBP) of the women receiving placebo compared with the women 
receiving calcium supplements. This lack of effect of calcium supplementation on 
either SBP or DBP in normal women is shown graphically in fig. 3.1 and fig. 3.2.
Table 3.9 BP readings in the normal women. Mean ± SEM
Gestation SBP SBP DBP DBP
Placebo Ca Placebo Ca
Not preg 108.4(5.3) 108.6(2.7) 68.0(3.1) 71.6(2.7)
12 112.2(3.9) 113.7(2.1) 72.8(3.4) 70.5(1.8)
20 112.3(4.9) 106.6(5.6) 65.7(8.4) 63.4(3.7)
22 110.3(4.1) 111.6(2.6) 70.1(3.1) 67.1(2.9)
24 109.9(3.1) 110.3(2.2) 66.1(2.7) 60.9(1.8)
26 110.1(1.7) 114.6(2.2) 66.3(3.3) 68.1(2.6)
28 110.9(1.7) 112.3(2.4) 65.8(2.3) 64.4(2.3)
30 111.1(2.2) 113.0(4.3) 66.5(2.3) 65.9(2.8)
32 111.9(3.9) 112.8(4.6) 67.9(2.3) 70.4(3.9)
34 120.8(3.3) 112.2(5.6) 75.2(4.2) 68.7(3.6)
36 118.5(2.3) 110.5(5.2) 74.1(3.1) 69.3(3.2)
























Fig. 3.1 SBP (mean ± SEM) in normal women, with or without calcium 
















28 32 36NP 20 24
12 22 26 30 34 38
Gestation (wks)
Fig. 3.2 DBP (mean ± SEM) in normal women, with or without calcium 
supplementation from 20 weeks, plotted against gestation
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The data show no relationship between SBP and gestation either as a whole or as 
placebo/Ca subgroups. However, overall, there was a significant effect o f gestation 
on the DBP readings (ANOVA; p<0.01).
IDDM group
Table 3.10 BP readings in IDDM women. Upper results include the women who
ts. Mean ± SEM
le women with PE 
were delivered by 38 weeks; n=17 for the lower results.
developed PE whilst these are excluded from the lower resu
Gestation SBP SBP DBP DBP

























































































38 119.8(5.3) 114 78.3(4.3) 76
n=20 for the upper results until 34 & 36 weeks when n=18, all t
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Visual inspection of the data suggested that there was no significant difference 
between the BP readings whether the women who developed PE were included or 
excluded and this was confirmed by t-test. This shows that the women who went on 
to develop PE were no different to those who did not develop PE in terms o f basal BP 
before the clinical onset of the disease. Once the women were admitted with a 
diagnosis of PE no further BP measurements were taken for this thesis.
BP in the IDDM women did not correlate with duration o f diabetes, reflecting the fact 
that women with significant diabetic vascular disease were not recruited to this trial.
Effect of calcium supplementation
Although differences between placebo and supplemented groups were not significant 
at individual gestational dates, these were significantly different overall being lower 
with calcium supplementation than placebo both for SBP (ANOVA; p<0.001) and 
DBP (ANOVA; p<0.05) as illustrated in figs 3.3 and 3.4.
However when both these figures are examined more closely it is immediately 
apparent that at 20 weeks when the women were randomized to either calcium or 
placebo, by chance, the women in the group allocated to calcium had lower SBP and 
DBP than those who received placebo . To correct for this bias data were recalculated 
as percentage changes from the 20 week data point and individual t-tests were then 
performed at each subsequent gestational age. This analysis showed no significant 
effect o f calcium supplementation on either SBP or DBP (fig.3.5 and fig.3.6). 
Similarly data for normal women recalculated from 20 weeks also showed that 
calcium supplementation had no effect on percentage change of either SBP or DBP -  
not illustrated.
Unlike the normal women ANOVA for the IDDM women showed no effect of 
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32NP 20 24 28 36
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Gestation (wks)
Fig. 3.3 SBP (mean ± SEM) in IDDM women, with or without calcium 
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Fig. 3.4 DBP (mean ± SEM) in IDDM women, with or without calcium 





















20 24 28 32 36
Gestation (wks)
Fig. 3.5 Percentage change in SBP (mean ± SEM) from the SBP at 20 weeks 








20 24 28 32 36
G estation (wks)
Fig. 3.6 Percentage change in DBP (mean ± SEM) from the SBP at 20 weeks 
gestation in the IDDM women with or w ithout calcium supplementation plotted 
against gestation
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Differences between the normal and IDDM women
The normal women appeared to have lower BP in general. Simple factorial analysis 
looking at the effect of gestation on SBP and DBP with diabetic status as the co- 
variate did show a significant effect with SBP being lower in the normal women -  
p=0.01, and DBP also being lower in the normal group -  p<0.001.
As mentioned above pregnancy had a significant effect on the DBP in the normal 
women (ANOVA; p<0.01) with values falling after 12 weeks and then rising from 34 
weeks until delivery. There was no such difference in the IDDM women. These data 
for the women on placebo are illustrated in fig. 3.7 while data for the women on 
calcium supplementation are shown in fig.3 8. It can be seen that there is no “mid- 

























Fig. 3.8 DBP (mean ± SEM) in normal and IDDM women on calcium 
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3.2 BASELINE BIOCHEMISTRY RESULTS
In general throughout the results chapters normal women are compared with IDDM women 
first, looking at the three gestations separately, then changes induced by pregnancy are 
described in both groups and finally differences in the way pregnancy affects the subgroups 
are presented. Results for the women who developed pre-eclampsia (PE) are given 
separately at the end of each sub-section.
3.2A Fasting serum results
1. Normal and diabetic women compared at all three time periods
 ^I
iCa , albumin and electrolytes were compared between controls and the IDDM group at 21 
weeks (table 3.11)







Sodium mmol/1 136.7 (0.7) 137.3 (0.5) ns
Potassium mmol/1 3.9 (0.1) 4.0 (0.1) ns
Creatinine pmol/1 54.7 (2.0) 57.5 (2.0) ns
Ionized calcium mmol/1 1.16(0.01) 1.18(0.01) ns
Magnesium mmol/1 0.72 (0.02) 0.70 (0.02) ns
Phosphate mmol/1 1.18(0.02) 1.19(0.06) ns
Urate mmol/1 0 . 2 2  (0 .0 1 ) 0 . 2 0  (0 .0 1 ) ns
Albumin g/1 37.0 (0.5) 36.8 (0.5) ns
Results for the 31 week study after randomization to either calcium (1.5g daily) or placebo 
have been subdivided into four groups: normal and IDDM women on placebo and normal 
and IDDM women on calcium. These are illustrated graphically in fig.3.9. At 21 weeks 
there were no significant differences in calcium and electrolyte concentrations between the 
women who were randomized to calcium or placebo. At 31 weeks women receiving 
calcium had higher serum creatinine levels than women on placebo and lower Mg levels.
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Serum creatinine (micromol/l) Serum ionized calcium (mmol/l)
□  Normal
□  Diabetic ■  Normal 
□  Diabetic


























■  Normal 
□  Diabetic
Fig. 3.9 Fasting concentrations of iCa2+, albumin and electrolytes at 31 weeks. Women 
on placebo are in the left hand columns, those on calcium on the right. Mean + SEM.
* p<0.05 for normal volunteers on placebo compared to calcium supplements
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When the women were studied outside pregnanty lower values of serum Mg, PO4, urate and 
albumin were found in the IDDM group compared with the normal women. (Table 3.12).







Sodium mmol/l 142.4 (0.5) 140.0(1.5) ns
Potassium mmol/l 4.3 (0.1) 4.3 (0.1) ns
Creatinine pmol/l 62.4 (2.0) 63.7 (2.0) ns
Ionized calcium mmol/l 1.18(0.01) 1 . 2 0  (0 .0 1 ) ns
Magnesium mmol/l 0.79 (0.02) 0 . 6 6  (0 .0 2 ) < 0 . 0 1
Phosphate mmol/l 1.30 (0.04) 1.15(0.04) <0.05
Urate mmol/l 0.27 (0.01) 0 . 2 1  (0 .0 1 ) <0 . 0 1
Albumin g/1 46.2 (0.8) 43.0(1.4) <0.05
2. The effect of pregnancy on normal women
There was a very highly significant effect of pregnancy (p<0.001) on serum sodium, 
potassium and creatinine which was not affected by calcium supplementation (ANOVA). 
Post-hoc analysis by Scheffe showed that these three variables all fell significantly by 21 
weeks gestation with no further fall between 21 and 31 weeks. Serum ionized calcium was 
unaffected by either normal pregnancy or by calcium supplementation (fig. 3.10).
Serum P0 4 in the normal women was significantly lower (p<0.01) at 21 weeks gestation 
compared with not pregnant values and from 2 1  to 31 weeks there was a further slight but not 
significant rise (fig. 3.11).
Serum Mg levels were also lower at 21 weeks compared to not pregnant values (p<0.05). At 
31 weeks serum Mg levels were affected by calcium supplementation; at 31 weeks Mg was 
lower in the supplemented group at 0.63(0.02)mmol/L compared with 0.68(0.02)mmol/L in 
those on placebo (p<0.05) (fig. 3.9). As mentioned above there was no difference between 
mean serum Mg levels at 21 weeks for these two groups.
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Pregnancy, as expected, also had a highly significant (p<0.01) effect on serum urate 
(ANOVA). Post-hoc analysis showed that this was caused by a fall from not pregnant serum 
urate concentrations to those found at 21 weeks gestation. Values for 21 and 31 weeks were 
not significantly different although they were slightly higher at 31 weeks, 0.24(0.0 l)mmol/L 
compared with 0.22(0.01 )mmol/L.
3. The effect of pregnancy on IDDM women
There was no significant fall in serum sodium, PO4 or urate in IDDM pregnancy and values 
for the second and third trimesters were the same. Serum potassium and creatinine were both 
lower in the second trimester compared with the post-partum data but they did not fall further 
with advancing gestation. Serum Mg was not significantly different between the second 
trimester and post-partum but it did fall between the second and third trimesters from
0.70(0.02)mmol/L to 0.60(0.02)mmol/L (p<0.01). Calcium supplementation status had no 
effect on serum magnesium levels which were identical at 0.60(0.02)mmol/L in the two 
subgroups (fig.3.12). Serum iCa2+ remained the same at all three gestations, regardless of 
supplementation status (fig. 3.10).
4. Comparison of the effect of pregnancy on normal and IDDM women
Pregnancy in normal women was associated with a fall in serum albumin and all the 
electrolytes measured except for iCa2+. In contrast in IDDM pregnancy there was no fall in 
serum sodium. Serum potassium and creatinine were less at 21 weeks than post-partum 
(p<0.01 and p<0.05 respectively) but did not fall between the second and third trimesters. 
iCa2+ behaved similarly in both groups o f women remaining stable at all gestations (fig. 3.10).
Serum PO4 and Mg were lower (p<0.05 and p<0.01) in diabetic women outside pregnancy 
compared to the control group. As both fell significantly with pregnancy in the normal 
women, but not in the diabetic women, at 21 weeks gestation there was no difference in 
either fasting PO4 or Mg (figs.3.11 & 3.12). PO4 appeared to rise slightly between the 
second and third trimesters in the normal women but this difference was not significant.
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There was no difference between the normal and diabetic groups in third trimester fasting 
PO4 either when the women were looked at in the subgroups o f placebo / supplemented 
(fig. 3.11) or when these groups were combined (not shown).
In both groups of women Mg levels fell between the second and third trimesters when the 
supplemented and placebo groups were considered together. However when the women 
were subdivided it became clear that, as mentioned above, calcium supplementation resulted 
in lower serum Mg levels in the normal women; this difference was not apparent in the 
IDDM women (fig. 3.12).
Serum urate behaved in a similar way in that it was lower in the IDDM women outside 
pregnancy but at 21 weeks there had been a fall in the normal women and not the diabetic 
women so second trimester values were the same in the two groups (fig. 3.9). There was a 
non-significant rise between 21 and 31 weeks in the normal women; in contrast serum urate 









Not pregnant 21 weeks 31 weeks (P) 31 weeks
(Ca)





Not pregnant 21 weeks 31 weeks (P) 31 weeks
(Ca)
Fig.3.11 Fasting serum phosphate -  mean ± SEM . P(placebo);Ca(supplemented) 
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31 weeks (P) 31 weeks (Ca)Not pregnant 21 weeks
■ Normal 
□ IDDM
Fig.3.12 Fasting serum magnesium -  mean ± SEM. P(placebo);Ca(supplemented) 
*p<0.01 comparing non-pregnant normal and IDDM women
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5. Diabetic women who developed PE
D5 was unwilling to give blood when not pregnant so serum electrolyte and albumin results 
outside of pregnancy are only available for D3 and DIO. It can be seen (Table 3.13) that 
during pregnancy the women who subsequently developed PE tended to have higher basal 
fasting levels of sodium, potassium, creatinine, Mg and P 04; iCa 2+ results appeared similar. 
D3 had an unusually high albumin result at 21 weeks but this had returned to the normal 
range by 31 weeks. DIO had raised urate levels at both 21 and 31 weeks despite not 
developing clinically apparent PE until 37 weeks.








Sodium mmol/l 139 139 138 N/A 138 138 135 138 141
Potassium mmol/l 4.5 4.4 4.4 N/A 4.6 4.5 4.3 4.1 4.5
Creatinine pmol/I 67 95 79 N/A 79 64 62 80 89
Ionized calcium 
mmol/l
1.15 1.17 1.17 N/A 1.19 1 . 2 1 1 . 2 0 1 . 2 1 1.16
Mg mmol/l 0.67 1 . 0 0 0.69 N/A 0.9 0.7 0.58 0.80 0.84
Phosphate mmol/l 1.29 2.33 1.07 N/A 1.45 1.17 1 . 2 1 1.25 1 . 1 2
Urate mmol/l 0.13 0.16 0 . 2 0 N/A 0.18 0 . 2 2 0.23 0.33 0.59
Albumin g/I 42 46 33 N/A 38 32 44 36 31
FASTING PLASMA GLUCOSE RESULTS
Predictably these were always significantly higher in the IDDM women (Table 3.14)
Table 3.14 Fasting plasma glucose concentration (mmoI/L). Mean (SEM)
2 1  weeks 31 weeks Not pregnant
Normal 3.8(0.1) 3.7(0.1) 4.2(0.1)
IDDM 6 .6 (0 .8 )* 5.8(0.7)* 10.7(1.1)*
*p<0.01 comparing normals with IDDM
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In the normal women pregnancy had a significant (p<0.05) effect on fasting plasma glucose 
concentration; in the IDDM women it had an even greater effect with p<0.001 (ANOVA 
for both). Post hoc testing by Scheflfe showed no difference between the 21 and 31 week 
data but with both being significantly different (p<0.01) from the non-pregnant data. The 
dramatic reduction in fasting plasma glucose in the IDDM women indicates how motivated 
these women were to achieve tight diabetic control throughout their pregnancy.
PARITY
Parity did not affect fasting levels of serum sodium, potassium, creatinine, iCa, Mg, PO4, 
urate or albumin, or fasting plasma glucose in either the normal or the IDDM women but it 




Creatinine clearances were calculated from both the 24 hour urine collections and for 
the basal fasting hour of the experiment, and when these were compared they were not 
statistically significantly different from each other. One of the IDDM patients (D7), 
despite repeated instructions failed to collect all urine passed in 24 hours on two 
occasions. These two collections were therefore known not to be accurate and were 
excluded from analysis. One hour values in this patient were 117.1ml/min and 
113.9ml/min respectively. Table 3.15 summarizes the creatinine clearance results 
calculated form the 24 hour urine collections. Creatinine clearances for the IDDM 
women have been calculated both including and excluding results for the women who 
went on to develop PE. It can be seen from table 3.16 that the individual creatinine 
clearances in D3 and DIO were lower than the average values for the IDDM women.
At 21 weeks the creatinine clearances of the women who went on to receive calcium 
and placebo were compared and were statistically the same. At 31 weeks both normal 
and IDDM women on calcium supplements had similar creatinine clearance results 
compared with the women on placebo (Table 3.15).
Table 3.15 Creatinine clearance calculated from 24hr urine collections (ml/min). 
Mean ± SEM.







Normal 135.6(5.7)* 146.6(7.4)! 148.6(13.4) 144.7(7.3) 111.3(14.7)
IDDM + PE 112.1(5.5) 117.5(8.1) 125.1(13.3) 108.2(7.4) 102.8(7.7)
IDDM -  PE 118.0(4.9) 121.7(8.8) 123.7(14.0) 108.1(8.4) 109.7(7.4)
*p<0.05 comparing normal with IDDM including and excluding PE
!p<0.05 comparing normal with IDDM including PE
Pregnancy had a significant effect on creatinine clearance in the normal women with 
significant increases from the not pregnant values to 2 1  weeks and a further rise by 31 
weeks. Creatinine clearances also increased during pregnancy in the IDDM women 
although in this case the significant rise occurred between the not pregnant values and 
the 21 week data with no further rise with increasing gestation (Wilcoxon signed 
ranks). This pattern was seen whether or not the women who subsequently developed 
PE were included or excluded from the analysis although the rise from non-pregnant
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to 21 week values was more significant if the women who developed PE were 
excluded (p=0.008 vs p=0.03). From table 3.16 it can be seen that pregnancy had a 
minimal effect on the creatinine clearances of the women who went on to develop PE.
Table 3.16 Creatinine clearance (ml/min) for women who developed PE
2 1  weeks 31 weeks Not pregnant
D3 91.6 116.3 103.3
D5 113.9 108.1 109.7
DIO 99.5 89.6 97.7
3.2C 24 hour urinary calcium, Mg and P 0 4 excretion
Table 3.17 shows the urinary excretion per 24 hours of calcium, Mg and P04. 
Surprisingly whether or not the women were taking calcium supplements did not 
affect the 24 hour excretion of any of these ions. Therefore when the 31 week data 
were analysed further they were treated as a unit rather than being subdivided.
Table 3.17 24 hour urinary excretion rates (mmol). Median (IQR).



























There was no difference in 24 hour calcium excretion between the normal and the 
IDDM women at any of the three times when the women were studied. Gestation had
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a significant effect (Kruskall Wallis ANOVA) on 24 hour urinary calcium excretion 
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Fig. 3.13 24 hour urinary calcium excretion rates in normal and IDDM women 
during and after pregnancy. Values shown are medians, interquartile range and 
absolute range.
Table 3.18 shows urinary calcium excretion rates in the women who developed PE. 
DIO was significantly hypocalciuric both during and after her pregnancy.
Table 3.18 24hr urinary excretion of calcium in women who developed PE (mmol)
2 1  weeks 31 weeks Not pregnant
D3 7.6 7.9 8.7
D5 16.2 12.4 7.3
DIO 2.4 0 . 6 0 . 6
24 hour excretion of Mg was the same in normal and IDDM women at all three times. 
Analysis of the data by Kruskall Wallis ANOVA showed no effect of gestation in
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Fig. 3.14 24 hour urinary Mg excretion rates in normal and IDDM women 
during and after pregnancy. Values shown are medians, interquartile range and 
absolute range.
Data for the women who became pre-eclamptic are shown below in Table 3.19. 
These were not different from the remainder of the IDDM women’s results.
Table 3.19 24hr urinary excretion of Mg in women who developed PE (mmol)
2 1  weeks 31 weeks Not pregnant
D3 4.7 7.7 5.9
D5 7.8 6.4 3.6
DIO 4.9 3.5 5.7
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24 hour excretion of phosphate was also the same in the two groups of women and 


















Not pregnant 2nd trimester 3rd trimester
G estation
Fig. 3.15 24 hour urinary P 0 4 excretion rates in normal and IDDM women 
during and after pregnancy. Values shown are medians, interquartile range and 
absolute range.
Data for the women who became pre-eclamptic are shown below in table 3.20. As 
with calcium (Table 3.18), but not Mg (Table 3.19), DIO had low urine excretion 
rates.
Table 3.20 24 hr urinary excretion of PC►4 in women who developed PE (mmol)
2 1  weeks 31 weeks Not pregnant
D3 22.4 29.2 24.6
D5 47.6 35.4 15.9
D10 16.3 12.3 1 1 . 2
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3.2D Baseline fasting fractional excretion (FE) of specific cations
FE rates which take account of individual renal function (see below) were also 
determined and analysed since the normal and IDDM groups had different baseline 
renal function. These were calculated using data from the first hour of the experiment 
ie. the hour before the patients ate their breakfast and the calcium load. The formula 
used was:
Fractional excretion X(%) = [Urinary X mmol/L] x [Plasma creatinine mmol/L] x 100
[Urinary creatinine mmol/L] x [Plasma X mmol/L]
where X = ion
There were no significant differences between FE rates of sodium, potassium, 
calcium, Mg or PO4 when the women were subdivided into those receiving placebo 
and calcium (p values ranged from 0.3 to 0.9), therefore the data from 31 weeks were 
grouped together to obtain two larger groups rather than four smaller groups.
In normal women pregnancy did not have a significant effect on FE of sodium, 
potassium, Ca, Mg or PO4 (ANOVA) - Table 3.21 and Fig.3.16. When FE rates 
between 21 and 31 weeks were compared only the FE of PO4 was different being 
higher at 2 1  weeks (p=0 .0 1 ).
Table 3.21 Fractional excretion rates in normal women (%). Mean ± SEM.






FE sodium 0.66(0.07) 0.55(0.06) 0.59(0.07)
FE potassium 13.55(1.00) 10.40(1.24) 13.55(1.43)
FE Ca 1.34(0.19) 2.02(0.41) 1.09(0.27)
FE Mg 2.19(0.38) 2.26(0.41) 1.92(0.36)
FE phosphate 8.83(0.83) 6.22(0.5)* 8.08(1.65)
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Fig. 3.16 Fractional excretion (FE) rates of varying cations and P 0 4 at different 
gestations in normal volunteers.
In the IDDM women the FE of sodium increased in pregnancy comparing both 21 and 
31 weeks with the non-pregnant value (p<0.05 for both), (Table 3.22 and fig.3.17). 
FE sodium was unchanged between 21 and 31 weeks. ANOVA confirmed a 
significant effect of gestation (p<0.05). FE of potassium, Mg and P0 4 were unaltered 
by pregnancy. The FE of calcium was higher at 21 weeks than outside pregnancy 
(p<0.05); this difference was not apparent at 31 weeks which was indistinguishable 
from 21 weeks and non-pregnant (Table 3.22 and fig. 3.17).
Table 3.22 Fractional excretion rates in IDDM women (%)






FE sodium 0.89(0.09)* 0.78(0.07)* 0.54(0.08)
FE potassium 13.59(1.49) 11.25(1.26) 10.72(1.64)
FE Ca 1.77(0.28)! 1.54(0.29) 0.96(0.13)
FE Mg 2.60(0.35) 2.32(0.32) 2.93(0.50)
FE phosphate 12.30(1.00) 11.47(1.33) 11.24(1.63)
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Fig. 3.17 Fractional excretion (FE) of varying cations and P 0 4 at different 
gestations in IDDM volunteers.
FE rates in normal and IDDM women compared
When the normal and IDDM women were compared FE of potassium and calcium 
were not affected by disease status (2 way ANOVA). Differences in FEMg between 
the normal and IDDM women just failed to reach significance outside pregnancy 
(p=0.07) but were the same at 21 and 31 weeks. Outside pregnancy FE of sodium and 
PO4 were also the same in the two groups. However within pregnancy FE of sodium 
and P0 4 were higher in the diabetic women. At 21 weeks the higher FE of sodium in 
the IDDM group was almost significant at p=0.05; by 31 weeks this difference was 
apparent (p=0.01). At 21 weeks FE of P 0 4 was higher in the IDDM women (p<0.05), 
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Fig 3.18 Fractional excretion of phosphate in normal and IDDM women, mean ± 
SEM.
FE rates of the IDDM women who developed PE are shown in Table 3.23. The FE of 
potassium at 21 weeks was high in D5 and DIO and the FE of calcium and Mg were 
high in D3 and D5 at all gestations.
Table 3.23 Fractional excretion rates (%) in women who developed PE
D3 D5 D10
2 1  wk 31wk NP 2 1  wk 31wk 2 1 wk 31wk NP
FE sodium 0.95 0.65 0.35 0.73 0.61 1.44 0.43 0.74
FE potassium 11.95 8.89 4.36 25.76 10.14 26.42 4.12 8.59
FE Ca 5.90 2.60 3.18 4.12 4.34 0 . 6 6 0.34 0 . 2 2
FE Mg 5.43 4.28 4.48 5.09 3.68 0.63 2.87 3.87
FE phosphate 14.20 14.69 13.61 22.28 16.54 8 . 8 8 8.96 1 2 . 8 6
PARITY
Parity had no significant effect on creatinine clearance in either group of women. It 
also did not effect baseline FE rates of sodium, potassium, calcium, Mg or PO4 in 
either the normal or the IDDM women.
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3.3 CALCIUM LOAD EXPERIMENTS
3.3A Serum electrolytes
i. Sodium and potassium
Fasting values of serum sodium in the normal and IDDM women have been presented in 
section 3.2A. Serum sodium remained the same for the four hours following the 
standard breakfast and calcium load at all gestations in both groups of women. (Table 
3.24). Calcium supplement status had no effect on the serum sodium response to the 
calcium load in either group of women. In general the IDDM volunteers tended to have 
lower levels of serum sodium than the normal women and this reached statistical 
significance as indicated in Table 3.24. Small numbers, particularly in the sub-groups at 
31 weeks, may account for the failure to reach significance at other points.
Table 3.24 Serum sodium (mmol/1) in normal and IDDM volunteers. Mean ±
SEM.
























































*p<0.05 comparing normal and IDDM
Pregnancy, as shown in section 3.2A, was associated with a significant (p<0.01) fall in 
serum potassium in both groups of women. Like serum sodium, potassium
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concentrations were unaffected by the breakfast and calcium load (ANOVA performed 
on data for each gestation), see Table 3.25. calcium supplement status had no effect on 
the response of serum potassium to the meal at 32 weeks gestation.
Table 3.25 Serum potassium (mmol/1) in normal and IDDM volunteers. Mean ±
SEM
























































!p<0.01 comparing normal with IDDM and normal with the fasting result in the normal 
women
When the data were analysed comparing individual hours there was a significant fall 
(p<0 .0 1 ) between the fasting and 1 hour results in the normal women at 2 1  weeks; this 
was the only time and the only sub-group of women when such a difference was 
apparent and may be the result of a type I error associated with performing multiple 
comparisons. The low 1 hour result in the normal women at 21 weeks is likely to be the 




Serum iCa2 rose very significantly (p<0.01 one-way ANOVA) in both normal and 
IDDM women at all three time periods studied following the oral calcium load as shown 
in Table 3.26 and fig. 3.19. Post-hoc testing showed a significant difference between 
fasting and 4 hr values outside pregnancy in both groups of women while at 21 and 31 
weeks there was a significant increase by 2hr in the normal women and by 3 hours in the 
IDDM women. Serum iCa2+ was continuing to rise when the studies ended 4 hours 
after the calcium load at all three gestations.
Table 3.26 Serum iCa2+ (mmol/1) in normal and IDDM volunteers. Mean ± SEM.
























































When the 31 week data were subdivided according to whether the women were 
receiving calcium supplements or placebo there was no difference in fasting serum iCa 
between the two subgroups of normal women. There was also no statistical difference 
between the fasting values for the two subgroups of IDDM women although on visual 
inspection of the data it appeared that those women on placebo had lower fasting levels 


































Fasting 1 hr 2 hr 3 hr 4 hr
Time (hr)
Fig. 3.19 Serum iCa2+ concentrations in normal and IDDM women following oral 
calcium loading at (upper graph) 21 weeks gestation, (lower graph) 31 weeks 



















Fig. 3.19 (cont) Serum iCa2+ concentrations in non-pregnant normal and IDDM 
women following oral calcium loading. Mean ± SEM.
Fig. 3.20 shows the increase in serum iCa2+ with time comparing the women on placebo 
with those on supplements; when the slopes of the graphs were compared (t-test) there 
was no difference between the rate of rise of serum iCa2+ with time between those in 
the supplemented subgroup compared with those on placebo in either the normal or the 
IDDM women.
As mentioned in the Methods section the equations for the scatter graphs illustrating 
correlations are given in the form of 
y = a + bx
where “y” is the variable on the y-axis; “a” is the intercept on the y-axis; “b” is the 












2 3 4 5■1 0
Time (hr)
Ca iCa2+ = 1.18(0.02) + 0.06(0.01 )[time] 




















r O .64; p<0.01
Time (hr)
Ca iCa2+ = 1.19(0.02) + 0.05(0.01)[time]
Placebo iCa2+ = 1.15(0.01) + 0.05(0.01)[time]
Fig. 3.20 The relationship between serum iCa2+ and time following the oral 
calcium load in normal (upper graph) and IDDM (lower graph) women 
subdivided according to the calcium supplement status of the women
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iii Serum magnesiun
Serum Mg levels (Table 3.27) were not affected by the oral calcium load. The repeated 
samples after the standard meal confirmed that the IDDM women had lower serum Mg 
levels than the control group outside pregnancy (p<0.01). This difference was not 
apparent during pregnancy presumably because of the slight fall (p<0.05) in serum Mg 
which had occurred in the control women by the second trimester and which persisted 
into the third trimester.
Table 3.27 Serum magnesium (mmol/1) in normal and IDDM volunteers. Mean ±
SEM.
























































p<0.05 and !p<0.01 comparing normal and IDDM women
S p<0.05 comparing supplemented and placebo groups of normal women
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iv Serum  phosphate
In the normal women serum P04, unlike serum Mg, was affected by the oral calcium 
load. In normal women in the second trimester serum phosphate fell 1 hour after the 
calcium load and levels remained low at hour 2. Following this they rose again and by 4 
hours were indistinguishable from fasting values. These changes were very significant 
(ANOVA, p<0.001). Post-hoc testing by Scheffe confirmed that the differences 
occurred between the 1 and 2 hour values and the 4 hour value. At 31 weeks there 
were no differences in fasting serum P04 levels in normal women regardless of whether 
they were on calcium supplements or not; after the oral calcium load both groups 
followed the 21 week gestation pattern with an initial fall and a return to baseline by 4 
hours. Again this was significant (ANOVA, p<0.001). These changes are shown 
graphically in fig. 3.21. A similar pattern occurred in the non-pregnant woman but just 














— ♦—- Non pregnant
- - *  - 21 weeks
— - 31 weeks (P)
— * - -31 weeks (Ca)
Fig. 3.21 Mean serum phosphate in normal women subdivided by gestation and 
by the calcium supplement status of the women
The IDDM women behaved similarly to the normal women, in that their serum P 04 fell 
initially and then rose back to basal levels in response to oral calcium loading in both 
trimesters of pregnancy. However these changes were not significant in the IDDM 
women unlike the normal women (ANOVA). Again the supplement status of the 
women had no effect on their serum P04 response. It was mentioned above (section
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3.2A) that fasting serum P04 was significantly (p<0.05) lower in non-pregnant IDDM 
women than controls. Despite starting from a lower baseline the non-pregnant IDDM 
women appeared to show initial suppression after oral calcium, followed by a rise in 
serum P04 back to baseline values. However the difference between the fasting and 1 
hour values just failed to reach significance p=0.05 and similarly to the non-pregnant 








— * - Non pregnant
- - •  - 21 weeks
--- A—-  31 weeks (P)
--- ■ - -  31 weeks (Ca)
Fig. 3.22 Mean serum phosphate in IDDM women subdivided by gestation and 
by the calcium supplement status of the women
v Serum urate and albumin
Concentrations of these substances were not affected by oral calcium loading in either 
group of women on any of the three occasions studied. Data not shown.
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3.3B Correlations between serum ionized calcium, phosphate and magnesium
Serum iCa2+ showed a positive correlation with serum P04 in normal women at 21 
weeks gestation (p<0.001) and in the non-pregnant state (r=0.24; p<0.05); there was no 
correlation at 31 weeks (p=0.7). In the IDDM women no correlation was apparent at 
21 weeks but at 31 weeks there was a positive correlation (p=0.016) and again this was 
apparent in the non-pregnant diabetic women (r=0.39; p<0.01) (fig.3.23). When the y- 





















1 . 1 1.2 1.3 1.4
Serum  ionized calcium (mmol/L)
Normal [P04] = 0.18(0.52) + 0.89(0.43)[iCa2+]
IDDM [P04] = -0.44(0.46) + 1.24(0.37)[iCa2*]
Fig. 3.23 Correlation between the concentration of serum PO4 and serum iCa2* in 
non-pregnant normal and IDDM women
In normal women there was no correlation between serum iCa2+ and serum Mg at any 
gestation (fig.3.24). However in the IDDM women (fig. 3.24) there was a significant 
positive correlation both at 21 weeks (r=0.28, p<0.01) and outside pregnancy (r=0.33, 
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Fig. 3.24 Correlations between serum Mg and serum iCa2+ in normal (upper 
graph) and IDDM (lower graph) women at varying gestations.
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In the normal women there was no correlation between serum Mg and serum P 04 at 
any gestation. In the IDDM women there was a positive correlation between these two 
















.3 .4 .5 .6 .7 .8 .9 1.D
Serum  m agnesium  (mmol/L)
Normal[P04]=l .00(0.12)+0.20(0.16)[Mg]
IDDM[P04 ]=0.69(0.14)+0.60(0.20)[Mg]
Fig. 3.25 Correlation between serum concentrations of Mg and P 0 4 in normal and 
IDDM women at 21 weeks gestation
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3.3C Plasma glucose and calcium homeostasis
Plasma glucose concentrations are shown in table 3.28.
Table 3.28 Plasma glucose concentration (mmol/L). Mean ± SEM.
Time from meal 21 weeks 31 weeks Not pregnant
Fasting Normal 3.8(0.1) 3.7(0.1) 4.2(0.1)
IDDM 6.6(0.8) 5.8(0.7) 10.7(1.1)
1 hour Normal 4.2(0.3) 5.0(0.3) 3.8(0.3)
IDDM 10.6(0.9) 8.6(0.7) 12.7(1.2)
2 hour Normal 4.0(0.2) 4.5(0.2) 4.2(0.2)
IDDM 10.2(1.0) 9.6(0.7) 13.0(1.3)
3 hour Normal 3.9(0.1) 4.0(0.2) 4.4(0.2)
IDDM 8.2(1.1) 7.5(0.6) 10.5(1.5)
4 hour Normal 4.0(0.1) 3.9(0.1) 4.7(0.1)
IDDM 6.6(0.8) 5.0(0.4) 8.2(1.4)
In the normal women the meal did not significantly affect plasma glucose concentration 
either at 21 weeks’ gestation or outside pregnancy (ANOVA). At 31 weeks there was 
a significant effect (p<0.001)) with the 1 hour value being significantly higher than the 
fasting and 4 hour values.
In the IDDM women the standard breakfast had a significant effect on plasma glucose 
concentration during pregnancy (p<0.01 for both gestations) but was not significant 
outside pregnancy (p=0.68) -  ANOVA for all.
Simple factorial ANOVA showed that gestation, time after breakfast and diabetic status 
all had highly significant effects on plasma glucose concentration (pO.OOl for all).
The response of plasma glucose to the standard breakfast at 21 weeks’ gestation is 









Fig. 3.26 Plasma glucose concentration following the standard breakfast at 21 
weeks’gestation in normal and IDDM women. Mean ± SEM.
Correlations between plasma glucose and serum iCa2+. Mg and PQ4
Plasma glucose did not correlate with serum iCa2+ concentration in either group of
women at any gestation.
In the normal women there was no correlation between plasma glucose and either serum 
Mg or serum phosphate concentrations (figs. 3.27 & 3.28). In the IDDM women at 21 
weeks serum glucose was significantly negatively correlated with serum Mg (r= -0.29; 
p<0.01) and serum phosphate (r=-0.60, p<0.001). At 31 weeks’ gestation the negative 
correlation was still apparent for Mg (r=-0.24,p<0.05) and P04 (r=-.0.41,p<0.001). In 
the non-pregnant IDDM women plasma glucose did not correlate with serum P04 
(r=0.09, NS) but did have a significant negative correlation (r=-0.40, p<0.01) with 
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3rd trimester [Mg] = 0.64(0.02)-0.02(0.01)[glu]
Fig. 3.27 Correlations between plasma glucose and serum Mg in normal (upper 
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0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0
P lasm a glucose (mmol/L)
Non-pregnant [P04] = 1.1 l(0.14)+0.09(0.03)[glu] 
2nd trimester [P04] = 1.08(0.07)+0.05(0.02)[glu] 
3,d trimester [P04] = 1.24(0.09)-0.04(0.02)[glu]
2.0
Gestation




0.0 10.0 20.0 30.0
P lasm a g lucose (mmol/L)
Non-pregnant [P04] = 1.04(0.06)+0.01(0.01)[glu]
2nd trimester [P04] = 1.38(0.05)-0.09(0.01)[glu]
3rd trimester [P04] = 1.25(0.04)-0.05(0.01)[glu]
Fig. 3.28 Correlations between plasma glucose and serum phosphate in normal 
(upper graph) and IDDM (lower graph) women at different gestations
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3.3D Urinary excretion of creatinine and electrolytes
i Creatinine clearance
Table 3.29 shows creatinine clearance results in both groups of women immediately 
before and after the standard breakfast and oral Ca load. The fasting values in these 
tables have been calculated from the hourly aliquots of urine collected in the 
laboratory on the morning of the calcium load experiment and differ slightly from the 
creatinine clearances calculated from the 24 hour urine collections made by the 
volunteers (Table 3.15). However when comparing the effect of the meal it is more 
appropriate to use these hourly creatinine clearance results as they were collected 
under identical conditions to the subsequent samples.
Table 3.29 Creatinine clearance (ml/min) in normal and IDDM volunteers. 
Mean ± SEM.









































Oral calcium loading and the standard breakfast had no effect on creatinine clearance 
in either group of women at any of the three time periods (ANOVA).
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ii Sodium and potassium excretion
FE sodium rates for both the normal and IDDM women before and after the standard 
meal are shown in Table 3.30. As mentioned in section 3.2D, calcium supplement 
status had no elfect on FE sodium on the morning of the experiment, therefore the 31 
week data are presented and analysed as a unit.
Table 3.30 FE sodium (%) in normal and IDDM volunteers before and following 
the breakfast and calcium load. Mean ± SEM.









































*p<0.05 comparing normal and IDDM
In general the FE sodium increased after the standard breakfast and calcium load in 
both groups of women (fig. 3.29 & fig. 3.30). ANOVA was performed to analyse 
whether time from the breakfast and oral calcium had a significant effect on FE 
sodium. In the non-pregnant women this was highly significant for both the normal 
and IDDM women (p<0.001) for both. A similar significant effect of time was seen 
at 21 weeks (p<0.001 in the normal women and p<0.01 in the IDDM group; 
ANOVA). However at 31 weeks although visual inspection of the data (fig. 3.30) 
does show an increase in FE sodium after the meal in the normal group this was not 
statistically significant (p=0.09). FE sodium of the IDDM women at 31 weeks was 
also not affected by the meal (p=0.68).
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When the FE sodium response to the standard meal was compared between the 
normal and IDDM women using multiple regression analysis disease status had no 














Fasting 1 hr 2 hr 3 hr 4 hr
Time (hr)
Fig. 3.29 The FE sodium (mean i  SEM) response to the standard meal and oral 



















Fig. 3.30 The FE sodium (mean ± SEM) response to the standard meal and oral 
calcium load in normal and IDDM women at 21 weeks (upper graph) and 31 
weeks (lower graph)
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When figs 3.29 and 3.30 are compared it can be seen that the FE sodium response to 
the meal was reduced from the non-pregnant state to 21 weeks and then reduced again 
by 31 weeks. This pattern was more marked in the IDDM women.
FENa rates for the women who developed PE are shown below in table 3.31. They 
responded to the meal with a similar pattern of increasing FENa.
Table 3.31 FENa (%) in diabetic women who developed PE
D3 D5 D10
21wk 31wk NP 21 wk 31wk 21 wk 31wk NP
Fasting 0.95 0.65 0.35 0.73 0.61 1.44 0.43 0.74
1 hour 1.06 - 0.33 0.47 0.63 1.36 0.51 1.03
2 hour 1.01 0.92 0.47 1.30 0.66 1.20 0.46 1.06
3 hour 1.46 0.75 0.59 1.37 0.78 1.95 0.85 1.90
4 hour 1.42 0.78 0.55 0.44 0.58 2.27 1.24 1.24
The FE potassium rates at the different time periods are summarized in table 3.32.
Table 3.32 FE potassium (%) in normal and IDDM volunteers before and 
following the breakfast and calcium load. Mean ± SEM.________________









































p<0.01 comparing normal and IDDM
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Outside pregnancy the FE potassium response to the meal and oral calcium load was 
the same in the normal and IDDM women (fig.3.31). ANOVA was performed and 
confirmed a significant effect of time from the meal on FE potassium (p<0.01 for the 
normal women and p<0.05 for the IDDM women). In the normal women the 2hr data 
were significantly different to both the fasting and 4hr results whereas for the IDDM 
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Fig.3.31 The FE potassium (mean/SEM) response to the standard meal and oral 
calcium in normal and IDDM women outside pregnancy
During normal pregnancy ANOVA did suggest that time after the meal had a 
significant effect on the FE potassium (p<0.001 for both 21 and 31 weeks). Post hoc 
analysis showed that the only results to be significantly different were the 4hr values. 
In IDDM pregnancy FE potassium did not show a significant response to the meal and 
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Fig. 3.32 The FE potassium (mean ± SEM) response to the standard meal and 
oral calcium load in normal and IDDM women at 21 weeks (upper graph) and 31 
weeks (lower graph)
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The FEK rates in the women who subsequently developed PE are shown in table 3.33. 
D3 had lower FEK rates at all times but the other two women did not exhibit any 
consistent pattern when compared with the rest of the IDDM women.
Table 3.33 FEK (%) in diabetic women who developed PE
D3 D5 D10
21wk 31wk NP 21 wk 31wk 21wk 31wk NP
Fasting 11.95 8.89 4.36 25.76 10.41 26.42 4.12 8.59
1 hour 13.29 - - 35.21 14.36 23.72 6.82 10.81
2 hour 14.73 10.91 7.53 20.72 12.47 16.52 6.84 8.25
3 hour 16.85 12.62 10.32 27.45 16.70 25.26 8.05 10.94
4 hour 20.39 12.23 12.57 33.58 18.60 22.36 9.76 11.28
Correlations between the FE sodium and FE potassium
Outside pregnancy there was a significant positive correlation between the FE of these 
two cations in both the normal (r=0.27; p<0.05) and IDDM women (r=0.39; p<0.01) -  
see fig. 3.33. During pregnancy the situation was confused. At 21 weeks there was 
no correlation in the normal women (r=0.16; p=0.12) but there was in the IDDM 
women (r=0.56; p<0.001); at 31 weeks there was a positive correlation in the normal 
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Fig. 3.33 Correlation between FE sodium and potassium in non-pregnant normal 
and IDDM women
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iii Urinary calcium excretion
As mentioned in section 3.2C calcium supplement status had no effect on the 
excretion of calcium on the morning of the experiment, therefore the 31 week data are 
presented and analysed as a unit Table 3.34. There was no significant difference 
between UCE in the normal and IDDM women at any time or gestation.
Table 3.34 Urinary calcium excretion rates (mcmol/min) -  median (IQR).









































In normal volunteers the urinary calcium excretion rate per minute (UCEPM) 
increased significantly after the oral calcium load at all three times when the women 
were studied. As UCEPM was not normally distributed values were converted into 
logio values and ANOVA could then be performed with post hoc testing by Scheffe at 
0.01. At all three gestations ANOVA showed a highly significant (p<0.001) effect of 
time after the calcium load on UCEPM. Post hoc testing showed that significant 
differences occurred between the fasting and lhr values, and the hour 2,3 and 4 
results. No further rise was apparent in logioUCEPM after hour 3 and values were 
maintained at this high plateau in the 4th hour (table 3.34 and figs. 3.34 & 3.35).
In the IDDM women UCEPM followed a similar pattern to the normal women 
(figs.3.34 & 3.35).
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Simple factorial ANOVA looking at the combined effects of diabetic status, gestation 
and time after the oral calcium load on logioUCEPM showed that diabetic status was a 
significant factor (p=0.01) but that time and gestation were more significant (p<0.001 
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Fig. 3.34 UCEPM before and after the standard breakfast and oral calcium load 
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Fig. 3.35 UCEPM before and after the standard breakfast and oral calcium load 
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Not pregnant logio(UCEPM) = 0.15(0.07)+0.21(0.03)time 
2nd trimester logio(UCEPM) = 0 32(0.07)+0.19(0.03)time 
3rd trimester logio(UCEPM) = 0.50(0.06)+0.14(0.03)time
Gestation
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Time (hr)
Not pregnant logio(UCEPM) = 0.35(0.09)+0.15(0.04)time 
2nd trimester log10(UCEPM) = 0.65(0.06)+0.13(0.02)time 
3rd trimester log10(UCEPM) = 0.42(0.08)+0.21(0.03)time
Fig. 3.36 Correlation between UCEPM and time from the oral calcium load in 











Fractional excretion of calcium rates (FECa) were calculated using the concentration 
of serum iCa2+ rather than the total serum calcium concentration. The FECa on the 
morning of the experiment was not affected by whether the women were receiving 
calcium supplements or placebo (p=0.7 in normal women and p= 0.8 in IDDM 
women). Therefore the 31 week data were grouped together to simplify analysis 
(table 3.35)
Table 3.35 FECa (%) in both normal and IDDM women. Mean ± SEM.









































In the normal women at all three gestations ANOVA showed a highly significant 
effect of time after the calcium load on the FECa (p<0.001). The same was true for 
the IDDM women. Diabetic status had no effect on the FECa response to the calcium 
load at any gestation (fig 3.37). ANOVA was also performed on both groups of 
women to see if gestation affected the response to oral calcium but it had no effect 
(fig. 3.37).
The correlations between the concentrations of serum iCa2+and the FECa were 
significant in both groups of women at all three study times (fig 3.38). There were 
also significant correlations between serum iCa and logio UCEPM (not illustrated). 
The rate of increase in FECa with increasing serum iCa2+ was not affected by disease 
status but did alter significantly (p<0.001 comparing each gestation with the other 
two) with gestational age. The greatest increase occurred in the 2nd trimester and the 
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Not pregnant FECa = 1.12(0.33)+0.92(0.14)time 
2nd trimester FECa = 1.74(0.47)+1.36(0.19)time 
3rd trimester FECa = 1.38(0.46)+1.30(0.19)time
Fig. 3.37 Correlation between FECa and time from the oral calcium load in 
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IDDM  FECa = -14.46(4.70) + 
14.20(3.81) iCa2+
Fig. 3.38 Correlations between FECa and serum iCa2+ at 21 weeks (upper 
graph), 31 weeks (middle graph) and outside pregnancy (lower graph).
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Fractional excretion of calcium rates for the women who developed PE are shown in 
table 3.36. When this is compared with table 3.35 it can be seen that D3 and D5 had 
raised fasting levels of FECa whilst DIO had levels on the low side. Also D3 largely 
failed to increase her FECa at any gestation.
Table 3.36 FECa (%) in diabetic women who developed PE
D3 D5 D10
21wk 31wk NP 21 wk 31wk 21wk 31wk NP
Fasting 5.90 2.60 3.18 4.12 4.34 0.66 0.34 0.22
1 hour 4.02 2.92 2.52 7.61 3.47 0.56 0.12 0.26
2 hour 4.37 4.20 3.91 16.94 11.32 1.04 0.12 0.36
3 hour 7.11 3.30 3.98 19.15 11.80 2.93 0.31 1.68
4 hour 4.61 3.83 3.69 12.15 11.80 4.01 0.59 1.62
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iv Urinary phosphate excretion
The fractional excretion of phosphate (FEPO4) rates in both groups of women are 
shown below in table 3.37. Again this was unaffected by whether the women were 
receiving calcium supplements or not.
Table 3.37 FEPO4 (%) in both normal and IDDM women. Mean ± SEM.
Time from meal 21 weeks 31 weeks Not pregnant
Fasting Normal 8.8(0.8)* 6.2(0.5)! 8.1(1.7)
IDDM 12.3(1.0) 11.5(1.3) 11.2(1.6)
1 hour Normal 10.3(0.8)! 7.9(0.8)! 7.1(2.3)
IDDM 15.0(1.2) 12.6(1.3) 9.7(1.8)
2 hour Normal 6.5(0.5)! 6.8(0.9)* 6.2(1.5)
IDDM 11.1(1.0) 10.6(1.1) 8.7(1.5)
3 hour Normal 4.4(0.6)! 4.2(0.7)! 5.5(2.1)
IDDM 8.0(1.0) 8.4(0.9) 5.9(1.4)
4 hour Normal 7.3(1.8) 3.9(0.6)! 4.8(1.2)
IDDM 9.0(1.8) 8.1(1.6) 4.4(1.4)
*p<0.05 comparing normal and IDDM 
!p<0.01 comparing norml and IDDM
In the normal women at 21 weeks’ gestation time after oral calcium loading had a 
significant effect on FEPO4, (ANOVA, p<0.001). Post hoc testing showed that the 
significant difference was between the peak which occurred at lhr and at the 3 hr 
nadir. ANOVA also showed a similar highly significant (p<0.001) effect of time on 
FEPO4 at 31 weeks’ gestation. In the non-pregnant normal women the meal and oral 
calcium load led to a gradual fall in FEPO4 over the next 4hrs, which was not 
significant (ANOVA, p=0.8).
In the IDDM women ANOVA showed a significant effect of time after the meal on 
FEPO4 at 21 weeks’ gestation (p<0.01) and outside pregnancy (p<0.01). This just 
failed to reach statistical significance at 31 weeks (p=0.058).
It was mentioned above that FEPO4 was significantly higher in the IDDM women 
than in the normal women during pregnancy. This difference was maintained
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throughout the calcium load experiments during pregnancy, except for the final hour 
of the 21 week experiment when there was no difference between the normal and 
IDDM women’s results (Table 3.37). Outside pregnancy there was no significant 
difference between the two groups of women. Simple factorial ANOVA of the effect 
o f time after the meal and calcium load on FEPO4 with diabetic status as the co- 
variate showed that disease status was highly significant (p<0.001). Fig. 3.39 
highlights the differences between the two groups of women.
In the normal pregnant women there was a significant (p<0.05) negative correlation 
between FECa and FEPO4 rates at 21 weeks but this was not the case for the IDDM 
women. At 31 weeks again there was a significant (p<0.05) negative correlation 
between the FE rates o f these ions in the normal women but the correlation in the 
IDDM women just failed to reach statistical significance (p=0.07). There was no 
correlation outside pregnancy in either group of women (fig. 3.40).
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Fig. 3.39 FEP04 after the oral Ca load at 21 weeks (upper graph), 31 weeks 
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Non-pregnant FEP04 = 7.59(1.33) -  0.45(0.34)FECa 
2nd trimester FEPO4 = 8.67(0.75) -  0.29(0.14)FECa 
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Non-pregnant FEPO4 = 13.08(2.63)- 1.32(0.74)FECa 
2nd trimester FEP04 = 10.83(1.08) + 1.51(0.20)FECa 
3rd trimester FEPO4 = 11.59(0.93) -  0.34(0.19)FECa
Fig. 3.40 Correlations between FECa and FEPO4 in normal (upper graph) and
IDDM (lower graph) women at different gestations
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FEPO4 rates for the women who developed PE are shown below in table 3.38. It was 
not possible to see a characteristic pattern in FEPO4 for this group. D3 and D5 tended 
to have higher FEPO4 rates but even this did not apply at all times. DIO was fairly 
close to the average results for the other IDDM women at all three times.
Table 3.38 FEPO4 (%) in diabetic women who developed PE
D3 D5 DIO
21wk 31wk NP 21 wk 31wk 21wk 31wk NP
Fasting 14.2 14.6 13.6 22.3 16.5 8.9 9.0 12.9
1 hour 26.1 - 12.4 27.1 15.8 11.2 10.8 9.0
2 hour 18.9 14.4 6.4 49.7 14.9 13.9 13.2 4.85
3 hour 31.5 9.0 2.5 32.0 8.8 12.4 3.5 2.0
4 hour - 8.8 1.1 2.44 5.37 9.6 11.1 1.4
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v Urinary magnesium excretion
Fractional excretion rates of magnesium (FEMg) are shown in table 3.39.
Table 3.39 FEMg (%) in both normal and IDDM women. Mean ± SEM.









































It was mentioned above that there was no difference in basal FEMg between the 
normal and IDDM women at any gestation. The breakfast and calcium load had a 
very significant effect (ANOVA, p<0.001) on the FEMg which increased in both the 
normal and IDDM women at all three occasions study gestations. Post hoc analysis 
showed that FEMg had increased significantly by hour 3 and that hour 4 remained at 
the same high level. Diabetic status had borderline influence on the response to the 
meal at 21 weeks gestation (simple factorial ANOVA, p=0.04) but not at either 31 
weeks or after pregnancy. FEMg response to the meal is shown in fig. 3.41. For 
clarity only the 21 week data is shown as the response was similar at the other times.
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Fig. 3.41 FEMg after the oral Ca load at 21 weeks in normal and IDDM women. 
Mean ± SEM.
FEMg values for the women who developed PE are shown below (table 3.40). D5 
and D10 tended to behave in a similar way to the other IDDM women while D3 had a 
totally different pattern with virtually no increase in FEMg following the calcium 
load. This is very similar to her lack of increase in FECa (table 3.36). Also D3 and 
D5 had high basal levels of FEMg compared to the other IDDM women, again this is 
similar to their high basal levels of FECa.
Table 3.40 FEMg (%) in diabetic women who developed PE
D3 D5 D10
21wk 31wk NP 21 wk 31wk 21wk 31wk NP
Fasting 5.43 4.28 4.48 5.09 3.68 0.63 2.87 3.87
1 hour 4.72 - 2.75 5.87 7.35 1.28 2.25 3.74
2 hour 3.75 4.53 3.07 11.40 8.09 0.99 2.71 4.03
3 hour 5.09 4.03 2.40 15.20 5.52 7.58 6.31 7.13
4 hour - 4.18 2.96 10.81 8.61 9.73 8.57 7.52
n i 1 !
I
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3.4 HORMONE RESULTS
3.4A The effect of calcium loading on serum iPTH
1. Fasting values
In the normal women pregnancy had no significant effect on fasting levels of serum 
iPTH and neither did calcium supplementation (fig 3.42). It can be seen that the 
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Fig. 3.42 Fasting serum iPTH in the normal women. Values shown are median 
(IQR) ( absolute range).
In the IDDM women pregnancy had a significant effect on iPTH with values being 
lower at 21 weeks when compared to not pregnant (p<0.05, Wilcoxon signed ranks). 
Calcium supplementation had no effect on fasting iPTH in the IDDM women at 31 
weeks. Between 21 and 31 weeks there was a slight rise in fasting iPTH in the diabetic 
women but this was not statistically significant (fig. 3.43).
Compared to normal controls IDDM women tended to have lower iPTH at all 
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Fig. 3.44 Fasting iPTH in normal and IDDM women. Values shown are median 
(IQR) ( absolute range).
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2. Following oral calcium loading
The oral calcium load produced an immediate suppression of iPTH in both groups of 
women at all three time periods and regardless of whether or not they were on calcium 
supplements. This suppression was maintained throughout all 4 hours of the 
experiment. ANOVA was performed on normally distributed logio[iPTH] confirming a 
very significant effect of the oral calcium loading (p<0.01). Post-hoc testing confirmed 
what visual inspection of the data suggested, namely that the difference occurred 
between the fasting and 1 hour values in all groups and at all times except for the non 
pregnant diabetic women in which suppression occurred more slowly, only becoming 
apparent at 2 hours.
Values of iPTH at all times and gestations are shown in table 3.41. The response of 
serum iPTH to oral calcium loading is shown graphically in fig. 3.45 -  only the 21 
week data is shown for clarity as the other time periods were similar.
Table 3.41 Serum iPTH(pmol/l) in normal and IDDM women. Median (IQR)























































*p<0.05 comparing normal and IDDIV
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Fig. 3.45 Effect of a standard breakfast and oral calcium loading on serum iPTH 
at 21 weeks gestation. Values shown are median (IQR) ( absolute range).
The correlation of logi0[iPTH] with time for both groups of women is shown in fig. 
3.46. When the slopes of these graphs were compared by a modified t-test there were 
all statistically similar showing that neither disease status nor gestation affected the 
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r-^0.42; p«=0.01
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r^0.37; p^0.01
T Not pregnant 
r=0.32; p<0.01
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2nd trimester log,o[iPTH] = 0.30(0.04) -  0.17(0.02)time 
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Not pregnant log,0[iPTH] = 0.29(0.06) -  0.23(0.02)time 
2nd trimester log,0[iPTH] = 0.20(0.04) -  0.19(0.02)time 
3rd trimester log,0[iPTH] = 0.23(0.04) -  0.12(0.02)time
Fig. 3.46 Correlations between logl0[iPTH] and the time from the oral Ca load
in normal (upper graph) and IDDM (lower graph) women at different gestations
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Results of serum concentrations of iPTH for the IDDM women who developed PE are 
shown below in table 3.42. In general they followed a similar pattern to above in that 
there was an immediate suppression of iPTH following the standard breakfast and oral 
calcium loading which had not returned to baseline at the conclusion of the 
experiments. It can be seen that DIO had exceptionally high values of iPTH in the 3rd 
trimester.
Table 3.42 Serum iPTH (pmol/L) in diabetic women who developed PE
D3 D5 D10
21wk 31wk NP 21 wk 31wk 21wk 31wk NP
Fasting 2.3 3.2 3.2 1.1 0.9 2.0 7.6 2.7
1 hour 1.9 1.6 1.7 <0.8 1.2 2.0 N/A 1.7
2 hour 1.7 1.8 1.0 <0.8 <0.8 1.2 3.5 1.8
3 hour 1.1 1.9 1.1 <0.8 1.0 <0.8 3.0 <0.8
4 hour 1.5 2.2 1.3 <0.8 <0.8 1.0 2.4 <0.8
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3.4B Correlations between serum iPTH and other variables
Logio[iPTH] showed significant (p<0.01) negative correlations at 21 weeks, 31 weeks 
and outside pregnancy with serum iCa2+ in the normal women and at 31 weeks and 
after pregnancy in the IDDM women (p<0.01). At 21 weeks in the IDDM women the 
correlation just failed to be significant (p=0.06) (fig. 3.47).
Outside pregnancy there were significant negative correlations between logio[iPTH] 
and the concentration of serum P 0 4 (p=0.002) in both normal and IDDM groups (fig. 
3.48) but no correlation during pregnancy.
In the normal women there was no correlation between logio[iPTH] and serum 
magnesium concentration on any of the three occasions when the women were studied. 
However the IDDM women exhibited a significant correlation between these two 
factors at 21 weeks’ gestation (r = -0.35; p<0.01) and outside o f pregnancy (r= -0.29; 
p<0.05). There was no correlation at 31 weeks’ gestation (r=0.06; p=0.6) (fig. 3.49). 
As significant correlations also occurred between serum iCa2+ and serum Mg in the 
IDDM women at 21 weeks and outside pregnancy, but not at 31 weeks nor in the 
normal women (fig. 3.24), partial correlation analysis was used to control for a 
possible confounding effect of serum iCa2+. Using this there was still a significant 
negative correlation (p<0.01) between serum iPTH and serum Mg in the IDDM 
women at 21 weeks but not outside pregnancy.
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Serum  ionized calcium (mmol/L)
Not pregnant logl0[iPTH] = 2.24(0.67) -  1.73(0.54)iCa2+
2nd trimester log,„[iPTH] = 0.93(0.46) -  0.72(0.38)Ca2+
3rd trimester logl0[iPTH] = 2.36(0.45) -  1.86(0.37)iCa2+
Fig. 3.47 Correlations between logl0[iPTH| and serum iCa2+ in normal (upper
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Not pregnant [P04] = 1.11(0.02) -  0.26(0.08)log,o[iPTH]
2nd trimester [P04] = 1.11(0.02) -  0.17(0.1 l)log,„[iPTH]
3rd trimester [P04] = 1.12(0.02) -  0.12(0.07)loglo[iPTH]
Fig. 3.48 Correlations between logi0[iPTH] and serum P 0 4 in normal (upper
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Not pregnant [Mg] = 0.67(0.01) -  0.20(0.03) log,0[iPTH]
2nd trimester [Mg] = 0.71(0.01) -0.19(0.06) logl0[iPTH]
3rd trimester [Mg] = 0.61(0.01)-0.04(0.03) logl0[iPTH]
Fig. 3.49 Correlations between logi0[iPTH] and serum Mg in normal (upper
graph) and IDDM (lower graph) women at different gestations
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Correlations between iPTH and urinary excretion rates
In the normal women there was a highly significant negative correlation between 
logio[iPTH] concentration and the FECa: r=-0.22, p<0.05 at 21 weeks; r=-0.32, 
p<0.01 at 31 weeks; r=-0.24, p<0.05 outside pregnancy (fig.3.50). In the pregnant 
IDDM women the same highly significant correlations occurred at 21 weeks (r=-0.33, 
p<0.01) and 31 weeks (r=-0.37, p<0.01) but not outside pregnancy (r=-0.19, NS) 
(fig.3.50).
There was no correlation between logio[iPTH] and the FEPO4 at any gestation in either 
group o f women.
Logio[iPTH] and the FEMg were significantly negatively correlated in the normal 
women at 21 weeks (r=-0.31, p<0.01) and at 31 weeks
(r=-0.31, p<0.01) but not outside pregnancy (r=-0.15, NS) (fig.3.51). There were also 
significant negative correlations between these two variables in the IDDM women at 
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.8 .8 1.0-.2 0.0 .2 .4*4
Log (intact parathyroid hormone)
Not pregnant FECa = 3.95(0.45) -  2.49(1.24) logi0[iPTH] 
2nd trimester FECa = 4.56(0.42) -  3.17(1.43) log,0[iPTH] 
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.8 .8 1.00.0 .2 .4-.4 -.2
Log (intact parathyroid hormone)
Not pregnant FECa = 3.11(0.27) -  1.37(0.89) logl0[iPTH]
2nd trimester FECa = 4.77(0.34) -  4.91(1.57) log,0[iPTH]
3rd trimester FECa = 4.54(0.35) -  4.80(1.31) log,0[iPTH)
Fig. 3.50 Correlations between logi0[iPTH] and FECa in normal (upper graph)
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Log (intact parathyroid hormone)
Not pregnant FEMg = 4.07(0.35) -  1.15(1.00) logi0[iPTH] 
2nd trimester FEMg = 5.36(0.34) -  3.54(1.13) logio[iPTH] 
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Not pregnant FEMg = 6.56(0.34) -  5.24(1.12) logi0[iPTH]
2nd trimester FEMg = 5.66(0.34) -  4.49(1.55)) log10[iPTH]
3rd trimester FEMg = 4.70 (0.35) -  1.37(1.31) log10[iPTH]
Fig. 3.51 Correlations between logiofiPTH] and FEMg in normal (upper graph)
and IDDM (lower graph) women at different gestations
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I.25-DHCC CONCENTRATIONS
The original plan was to measure this in all the subjects but promised funding was 
withdrawn. However before this became apparent the laboratory did analyse a few 
fasting samples as shown in table 3.43. The same women were not analysed at the 
different gestations so comparisons between gestations could not be made. None of 
the IDDM women who developed PE had 1,25-DHCC measured.
Table 3.43 Fasting concentrations of 1,25-DHCC (pg/ml) in normal and IDDM 
women at 21 and 31 weeks gestation. Median (IQR).
Normal women IDDM women
21 weeks 31 weeks 
n=4 n=7
21 weeks 31 weeks 
n=7 n=7
1,25-DHCC 75.9(31.8-132.2) 84.7(75.8-128.0) 74.2(44.1-85.2) 75.7(58.6-87.5)
Although these figures show an 11% reduction in third trimester concentrations of
1,25-DHCC in the IDDM women when compared to the normal group this was not 
statistically significant.
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3.4C Effects of acute calcium loading on PRC and PRS
1. Fasting values
In the normal women PRC rose significantly (p<0.05) with pregnancy, this rise was 
apparent by 21 weeks and there was no further significant rise between the 21 week 
data and the 31 week data (fig.3.52). When the 31 week data was subdivided into 
those receiving calcium or placebo it appeared that PRC was higher in the 
supplemented group but this was not statistically significant (table 3.44 and fig.3.54). 
PRS also increased significantly during pregnancy; the 21 week data were very 
significantly (p<0.001) higher than the data for outside pregnancy and there was also 
a rise (p<0.05) from 21 to 31 weeks gestation (fig.3.53). Calcium supplementation 
had no effect on PRS values (table 3.44 & fig.3.54).
Table 3.44 Fasting values of PRC (ng/ml/hr) and PRS (mcgAngl/ml) in normal
and IDDM women at different gestations. Median (IQR)

























*p<0.05 comparing normal and IDDM
In the IDDM women there was a non-significant rise in PRC in pregnancy (table 3.44 
& fig.3.52). PRS was significantly higher at 21 weeks when compared with the non­
pregnant data (p<0.001) but there was no rise from 21 to 31 weeks (table 3.44 & 
fig.3.53). Calcium supplementation had no effect on PRC or PRS (fig.3.54).
Compared to normal women IDDM women had lower values of PRC in pregnancy at 
all gestations studied (p<0.05). PRS values were the same in both groups of women 
during and outside of pregnancy but the pattern of the pregnancy-induced rise was 




















Not pregnant 2nd trimester
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3rd trimester
Fig. 3.52 Fasting PRC in normal and IDDM women by varying gestations of 












Not pregnant 2nd trimester 3rd trimester
Gestation
Fig. 3.53 Fasting PRS in normal and IDDM women by varying gestations of 
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Fig. 3.54 The effect of calcium supplementation on PRC and PRS in normal and 
IDDM women in the third trim ester of pregnancy. Values shown are median 
(IQR) (absolute range).
Effect of parity
Analysis of the second trimester data showed an effect of parity with the multiparous 
IDDM women having lower PRC than the normal multiparous women (p=0.014). 
This difference was not apparent in the primigravidae (p=0.2). By the third trimester 
all the IDDM women showed lower PRC than the normal women regardless of parity 
(table 3.45 & fig. 3.55). PRS was unaffected by parity (table 3.46).
Table 3.45 Effect of parity on PRC (ng/ml/hr) in normal and IDDM women
Second trim ester Third trim ester
Normal IDDM Normal IDDM
Primigravidae 6.0(3.8-9.6) 3.3(2.4-6.3) 8.3(5.7-17.6) 4.2(2.9-6.0)*
M ultiparous 7.2(4.2-9.0) 2.2(1.1-3.5)* 5.4(2.6-10.0) 2.1(2.1-4.4)*
*p<0.05 comparing normal and IDDM
Table 3.46 Effect of parity on PRS (mcgAngl/ml) in normal and IDDM women
Second trim ester Third trim ester
Normal IDDM Normal IDDM
Primigravidae 1.48(1.06-2.67) 2.28(1.97-2.67) 1.87(1.50-3.13) 2.75(2.16-3.04)
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Fig.3.55 The effect of parity on PRC in normal and IDDM pregnancy in the 
second and third trimesters. Values shown are median (IQR) (absolute range).
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PRC and PRS following the standard meal and oral Ca challenge
Although there appeared to be a rise in PRC in the normal women within one hour of 
the standard meal and oral calcium (table 3.48; fig. 3.56) this was not statistically 
significant. PRC in the IDDM women was also not affected by the standard meal 
(table 3.47; fig. 3.56). PRS in both the normal and the IDDM women was unaffected 
by the standard meal and oral calcium at any of the three periods studied (table 3.48; 
fig. 3.61).
Table 3.47 PRC (ng/ml/hr) and PRS (mcgAngl/ml) in normal and IDDM 
following
a standard meal and calcium load at varying gestations. Median (IQR).
21 weeks 31 weeks Not pregnant
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Fig.3.56 PRC in normal □ (upper graph) and IDDM (lower graph) women 




















2 n d  L i i m o l e i  
□  3rd trimester
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I 1 Not pregnant
13rd trimester
Time (hr)
Fig.3.57 PRS in normal □ (upper graph) and IDDM (lower graph) women 
before and after the standard meal and oral Ca load at the three study 
gestations.
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PRC and PRS results for the IDDM women who developed PE are shown in table 3.48. 
Of particular note are the high values found in D5 at 31 weeks gestation, approximately 
one week prior to her admission with clinically apparent PE.
Table 3.48 PRC(ng/ml/hr) & PRS(mcgAngI/ml) in IDDM women who developed
PE
D3 D5 D10
21wk 31wk NP 21 wk 31wk 21wk 31wk NP
Fasting PRC 2.1 0 0 0 12.6 4.8 0 0
PRS 2.34 2.28 0.65 3.62 5.43 1.67 1.75 1.08
1 hour PRC 0 0 0 2.4 9.6 4.8 0 2.1
PRS 2.93 1.95 0.81 2.84 4.78 1.55 1.43 0.67
2 hour PRC 2.1 0 0 - 9.0 6.6 0 2.1
PRS 2.77 1.93 0.89 - 3.62 1.66 1.53 1.37
3 hour PRC 0 0 0 2.7 13.2 8.1 0 2.7
PRS 1.81 2.30 0.88 4.29 5.26 1.69 1.18 1.30
4 hour PRC 2.4 0 0 - 10.5 4.8 0 2.7
PRS 3.27 1.76 1.21 - 4.45 1.83 1.03 1.28
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3.4D Correlations between the RAS and other variables
Glucose
There was no significant correlation between plasma glucose and PRC in either group 
of women outside pregnancy (r = -0.14,NS for normal women; r = 0.07,NS for IDDM 
women). At 21 weeks there was also no correlation (r = 0.02,NS for normal women; 
r = -0.11,NS for IDDM women). At 31 weeks there was a very significant positive 
correlation between PRC and plasma glucose in the normal women (r=0.4; p<0.01) 
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4.0 12.0 10.00.0 8.0
P lasm a glucose (mmol/L)
Normal[PRC] = 1.94(1.87) + 1.42(0.43) [glu]
IDDM [PRC] = 4.29(0.85) + 0.05(0.12)[glu]
Fig. 3.58 Correlation between plasma glucose and PRC in the third trim ester
PRS did not correlate with glucose during pregnancy in either group of women. In 
the non-pregnant subjects there was a significant positive correlation between these 
variables (r=0.57;p<0.01) in the normal women but a negative correlation (r=-0.47; 







































■ 2nd trim ester 
r=-0.19; p = NS
T Not pregnant 
r=  0.37; p = 0.002o.o
8.06.0 7.03.0 4.0 5.02.0
P lasm a glucose (mmol/L)
Not pregnant PRS = -3.09(0.75) + 0.96(0.17)glucose 
2nd trimester PRS = 2.85(0.43) -  0.21(0.10)glucose 
3rd trimester PRS = 2.60(0.39)- 0.16(0.01 )glucose
10.0 20.0 
P lasm a g lucose (mmol/L)
Gestation
■ 3rd trim ester
r =  -0 .0 0 3 ; p = NS
■ 2nd trim ester 
r=-0.02; p= NS
T Not pregnant 
r =  -0.47; p <0.001
30.0
Not pregnant PRS = 1.73(0.21) -  0.20(0.02)glucose 
2nd trimester PRS = 2.41(0.20) -  0.05(0.02)glucose 
3rd trimester PRS = 2.65(0.28) -  0.01(0.04)glucose
Fig. 3.59 Correlations between plasma glucose and PRS in normal (upper
graph) and IDDM (lower graph) women at different gestations
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Sodium and potassium
Plasma sodium and potassium did not correlate with either PRC or PRS in either the 
normal or the IDDM subjects at any gestation.
Ionised calcium
There was a significant (p=0.01) negative correlation between serum iCa2+ and PRC 
in the non-pregnant normal women (r = -0.29) but this association did not persist into 
pregnancy (r=-0.14;NS) at 21 weeks, (r= -0.19;NS) at 31 weeks. There was no 
similar correlation in the non-pregnant IDDM women (r= -0.11;NS) (fig.3.60). There 
were also no significant correlations between PRC and serum iCa in the pregnant 
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r = -0.11 ;p=NS
■  Normal
r = -0.29 ;p=0.010.0
Serum  ionized calcium (mmol/L)
NormalfPRC] = 29.69(9.36)-21.58(7.74)[iCa2+] 
IDDM[PRC] = 8.95(7.01)-5.30(5.70)[iCa2+]
Fig. 3.60 Correlation between serum i( a : and PRC in the non-pregnant women
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Magnesium
There were also significant correlations between serum Mg and PRC but these were 
not consistent (fig. 3.61). In the normal women at 21 weeks there was a negative 
correlation (r=-0.37;p<0.001) but at 31 weeks no correlation (r=-0.10;NS). Outside 
pregnancy there was a positive correlation which just failed to reach significance 
(r=0.22;p=0.07). In the IDDM women there was no association outside pregnancy 
(r=-0.09;NS) or at 21 weeks (r=0.13;NS) but at 31 weeks there was a significant 
negative correlation (r= -0.26; p<0.05). Serum Mg was not correlated with PRS.
Intact PTH
There was a significant negative correlation (r= -0.3;p=0.007) between PRC and iPTH 
in the IDDM subjects at 21 weeks gestation but not at any other gestation and there 
was no correlation between PRC and iPTH in the normal subjects at any gestation. 
PRS did not correlate with iPTH outside pregnancy but during pregnancy there was a 
significant negative correlation between the two hormones: for the normal women at 
21 weeks r= 0.25; p<0.05 and at 31 weeks r= -0.28; p<0.01; for the IDDM women at 
21 weeks r= -0.24; p<0.05. At 31 weeks in the IDDM group there was no correlation 
(fig. 3.62).
When the intercepts on the y axis of fig. 3.62 were compared by t-test there was a 
significant (p<0.001) difference between the pregnant, both 2nd and 3rd trimesters, and 
the non-pregnant data for both groups o f women. Diabetic status did not significantly 
affect the values o f the intercepts. In the normal women although the slopes of the 2nd 
and 3rd trimester graphs looked different to the non-pregnant slope this was not 
confirmed by t-test. The slopes of the IDDM graph were not compared as only one of 
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2nd trimester PRC = - 17.27(2.68)- 14.38(3.40)Mg 
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.3 .5 .6 .7 .8 .9 1.0.4
Serum  m agnesium  (mmol/L)
Not pregnant PRC = -0.20(3.68) + 3.78(5.49)Mg 
2nd trimester PRC = 1.94(1.52) + 2.54(2.17)Mg 
3rd trimester PRC = 12.37(3.23) -  12.62(5.28)Mg
Fig. 3.61 Correlations between serum magnesium and PRC in normal (upper
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•  2nd trim ester 
r = -0.25; p = 0.01
T Not pregnant 
r=  0.10; p = NS
2.0 4.0 6.0
Serum  intact PTH (pmol/L)
Not pregnant [PRS] = 1.06(0.27) -  0.01(0.10)[iPTH] 
2nd trimester [PRS] = 2.38(0.15) -  0.22(0.08)[iPTH] 




























f e w - ’ ■ ■ .
▼
Gestation
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r - 0.10; p=  N8
2nd trim ester 
r=  -0.24; p = 0.03
Not pregnant 
r=  0.10; p = NS
0.0 2.0 4.0 6.0
Serum  intact PTH (pmol/L)
8.0
Not pregnant [PRS] = 0.97(0.16) -  0.03(0.08)[iPTH]
2nd trimester [PRS] = 2.48(0.17) -  0.19(0.11 )[iPTH]
3rd trimester [PRS] = 2.64(0.20) -  0.02(0.1 l)[iPTH]
Fig. 3.62 Correlations between PRS and serum iPTH in normal (upper graph)
and IDDM (lower graph) women at different gestations
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Fractional excretion of sodium and potassium
In the normal women there was a significant, negative correlation (r= -0.35;p<0.01) 
between PRC and FENa; this was also apparent at 31 weeks gestation (r= -0.32; 
p<0.01) but was lost at 21 weeks gestation (r= -0.96;NS). In the IDDM women there 
was no correlation between these two variables at any gestation (fig. 3.63). PRS did 
not correlate with FENa.
FEK in the normal women did not correlate with either PRC or PRS at any gestation. 
In the pregnant IDDM women there was a positive correlation between PRC and FEK 
(r=0.27;p<0.05 at 21 weeks and r=0.41;p<0.001 at 31 weeks). This correlation was 
not apparent in the non-pregnant IDDM women.
PRS correlated negatively with the FEK in the non-pregnant IDDM women (r= -0.32; 
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r*  -0.32; p =  0.003
■ 2nd trim ester 
r= -0 .1 0 ;p  = N9- A
T Not pregnant 
r = -0.35; p =  0.0040.0
0.0 5.0 10.0 15.0 20.0
P lasm a renin concentration (ng/ml/hr)
Not pregnant FENa = 1.06(0.07) -  0.04(0.01)[PRC] 
2nd trimester FENa = 1.02(0.09) -  0.01 (0.01)[PRC] 
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r=  0.21; p = NS
Not pregnant 
r=  0.01; p = NSo.o
0.0 5.0 10.0 15.0 20.0
P lasm a renin concentration (ng/ml/hr)
Not pregnant FENa = 0.95(0.09) = 0.01(0.02)[PRC]
2nd trimester FENa = 0.89(0.11) = 0.62(0.03)[PRC]
3rd trimester FENa = 0.79(0.05) -  0.01(0.01)[PRC]
Fig. 3.63 Correlation between PRC and FENa in normal (upper graph) and
IDDM (lower graph) women at different gestations
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DISCUSSION
This study has found interesting differences between normal and IDDM pregnancy 
both in terms of the renal handling o f specific substances and the intact parathyroid 
hormone response to oral calcium loading. Some of these differences confirm 
previous work whilst others are new findings. They will be discussed below and an 
attempt will be made to explain them.
The findings about the RAS in IDDM pregnancy confirm differences between these 
and normal pregnancies found by earlier workers; to our knowledge the RAS has not 
been studied prospectively in the same IDDM women during and after pregnancy. 
The finding of very high PRC and PRS just prior to the onset of PE in one diabetic 
woman has raised the possibility that altered RAS activity in IDDM pregnancy may 
partially account for the increased incidence of PE in these pregnancies. Possible 
differences in the RAS of primigravid and multigravid IDDM women were also found 
which have not previously been reported.
There were numerous flaws in this study some of which could have been prevented by 
better planning; however many were as a result o f dealing with human volunteers who 
inevitably form a more heterogenous group than laboratory rats! These problems will 
be discussed in greater detail below. Finally this discussion will end by suggesting 
future areas of research which could build on these preliminary findings whilst 
hopefully avoiding many o f the pitfalls into which studies in this thesis fell.
4.1 Study design
This study was inevitably restricted by the fact that it was carried out mainly by one 
investigator with finite time. It was also limited by the number of diabetic 
pregnancies which occurred in the unit during the period of research. As the studies 
required time and prolonged commitment from the volunteers, not all pregnant IDDM 
women were suitable and willing for recruitment.
174
Study protocol
Previous work done in our department (Bisson, 1992) had made a serendipidous 
discovery of differences between iPTH levels in normal (n=18) and IDDM (n=16) 
pregnant volunteers. At the time (1993-4) when this study was designed there was 
great interest in the use o f calcium supplementation to prevent the development o f PE. 
Initial studies on this had shown significant changes in BP produced by calcium 
supplementation in small groups of women. For example Belizan reported results 
from Guatemala in 1983 in which 14 women received placebo and 22 women 
received either lg  or 2g calcium supplementation per day (Belizan et al, 1983a). 
Knight & Keith (1992) showed a reduction in DBP in 10 American women with PIH 
who received lg  calcium compared with 10 women with PIH on placebo. The 
problem with these initial studies is that “treatment” of a very small number of 
heterogenous subjects will always produce suspect results as so many other factors 
besides the “treatment” could be responsible for the observed differences. However 
further work with larger numbers o f non-European women did seem to support the 
hypothesis that calcium supplementation reduced the incidence o f hypertensive 
complications o f  pregnancy (Villar et al, 1987 [1.5g calcium, 52 women]; Lopez- 
Jaramillo et al, 1989 [2g calcium, 106 women]; Belizan et al, 1991 [2g calcium, 1194 
women]).
Other studies have shown an association between hyperparathyroidism and 
hypertension as reviewed in the introductory section of this thesis (section 1.2H, p26). 
In summary this link was first described in 1957 by Hellstrom et al, who found that 
70% of patients with hyperparathyroidism were hypertensive at some stage of the 
disease. Initially this association was though to be due to impaired renal function in 
patients with hyperparathyroidism. A study in 1981 found that in 42 hyperparathyroid 
patients with hypertension only 4 had raised serum creatinine levels. As increases in 
serum creatinine only occur once there has been a significant fall in glomerular 
filtration rate in was unfortunate that this study did not use a more sensitive marker of 
renal function (Lafferty, 1981). Subsequently a Dutch group looked at intact PTH and 
showed that this is increased in young (20-39 year old) primary hypertensive subjects 
(Grobbee et al, 1988). McCarron et al (1980) suggested that hyperparathyroidism 





Whilst a large, multicentre, prospective, randomized controlled trial was obviously 
needed to establish whether or not calcium was o f use in preventing PE it was felt that 
it would be useful to study calcium handling and iPTH, comparing normal pregnant 
women with IDDM pregnant women who would be at increased risk o f developing 
PE (Gamer et al, 1990). The study was designed to be prospective and it was felt 
from the outset that it was important to follow as many o f the women as possible into 
the post-partum period and beyond so that each woman could act as her own control. 
The calcium load experiments were designed to look at the short-term changes in 
semm electrolytes and intact PTH ,and urinary electrolyte excretion rates induced by 
oral calcium whilst the double-blind randomized allocation to either calcium 
supplements or placebo would look at the longer term effects o f oral calcium. Whilst 
not looking primarily for an effect o f calcium supplementation on BP it was thought 
prudent to record BP on a regular basis throughout the time the women received 
therapeutic intervention.
1.5g o f calcium was chosen as the supplementary dose having considered several 
other trials which had used amounts which varied from lg  to 2g (Belizan et al, 1983a; 
Villar et al, 1987; Lopez-Jaramillo et al, 1989; Belizan et al, 1991; Knight & Keith, 
1992). It was also a dose in line with the recommended intake for pregnancy of 
1250mg calcium daily (Committee On Medical Aspects of food policy, 1991).
lg  o f elemental calcium was chosen for the oral calcium tolerance load in accordance 
with work described by Broadus, Dominguez and Bartter (1978) on non-pregnant 
women and subsequent work by Kent, Price, Gutteridge, Allen, Blakeman, Bhagat, St 
John, Barnes, Smith & Evans (1991) on pregnant women. Broadus kept his 
participants as in-patients which allowed their calcium intake prior to the oral load to 
be strictly controlled, this was not felt to be practical for this study. He measured 
urinary calcium excretion for 6 hours after oral calcium and found that it increased 
within 2 hours, plateaued for 2 hours and then decreased. During the whole o f this 6 
hour period his patients were not allowed other food. Kent et al (1991) described a 
study period of four hours after oral calcium. This was long enough to show rises in 
serum iCa2+ and UCE and a fall in iPTH but not long enough to show a return to 
normal values. It was felt that, for this thesis, reducing the test to four hours made the 
test more acceptable to pregnant women whilst not losing much information. It also
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avoided the need for intravenous dextrose and insulin in the IDDM group which again 
made the test more acceptable to pregnant women.
PRC and PRS were measured in the same women as increasing evidence o f an 
interaction between the RAS and the calcium/PTH system is being amassed in non­
diabetic subjects both outside and during pregnancy. Subjects with essential 
hypertension and a low-renin profile respond well to calcium channel blockers while 
those with a high-renin profile are relatively insensitive to this class of drugs 
(Resnick, Nicholson & Laragh, 1986). Elderly hypertensive patients with low plasma 
renin and high levels of aldosterone have been shown to have low serum iCa2+ and 
high iPTH levels (Zozaya & Viloria, 1997). Infusion o f magnesium sulphate in 
pregnant women with PE has also been shown to reduce PRA (Sipes, Weiner, 
Gellhaus & Goodspeed, 1989). Also although virtually nothing is known about the 
RAS in IDDM pregnancy, it is known to be disordered in non-pregnant diabetic 
subjects (see section 1.3H, p48).
Numbers and characteristics o f recruited women
Our hospital looked after approximately 16 IDDM pregnant women per year, 
excluding those gestational diabetic women who required insulin treatment. We felt 
that we had a realistic chance of recruiting 20 reliable IDDM women who would be 
prepared to embark on a prospective study in the time available and as this number 
was of the same order as the studies described above we hoped to be able to detect 
significant differences between them and normal controls in calcium metabolism. 
There were o f course potentially more normal pregnant women who could be enrolled 
into the study. However as this was quite a complicated study involving three 
complete morning sessions in the laboratory, 24 hour urine collections, therapeutic 
intervention and numerous visits for BP recording in the end it proved quite difficult 
to recruit even 20 normal women within the allocated time. Only one normal woman 
who was not a member o f staff at the hospital agreed to take part. Inevitably this 
meant that the control group was significantly different from the IDDM group in 
terms o f occupation. However as all 40 women were Caucasian and lived in the same 
area it seemed unlikely that the occupation bias in the control group would be large. 
If  anything the high proportion of doctors, nurses and midwives in the control group 
should have helped increase the accurate collection o f tests such as the 24 hour
177
collection of urine. It also probably increased their motivation towards the study 
which was high, judging by both their compliance with calcium or placebo 
supplementation, and their willingness to return for repeated studies. The IDDM 
group were also well motivated and demonstrated high compliance, reflected in their 
strict adherence to a tight diabetic regime during the pregnancy. Diabetic control was 
significantly less good post-partum (a classical feature) and it is likely that 
compliance with supplementation would also have been less good outside pregnancy.
More IDDM women (14 out of 20) in the study were primigravid, compared with 9 of 
20 in the control group. Ideally it would have been best to recruit only primigravid 
women or else a larger number o f women of mixed parity so that the women could 
have been subdivided into primigravid and multigravid patients and analysed 
separately. The subgroup o f 6 multiparous IDDM patients was really too small a 
group for meaningful statistical analysis. Nevertheless the results were analysed by 
parity as indicated in the results chapters in an attempt to reduce any bias caused by 
the unequal parity distributions in the two groups o f women. Predictably the 
multiparous patients were significantly older than the primigravid patients in both 
groups but only by a few years. Although renal function deteriorates with age one 
would not have expected this small age difference to produce a detectable effect and 
this was confirmed by the lack of parity difference in baseline serum biochemistry, 
creatinine clearance and fractional excretion rates in both normal and IDDM women. 
The parity differences which were found are discussed in greater detail below but 
must be regarded with caution because of the small numbers involved.
IDDM women with hypertension or nephropathy, defined as an abnormal urinary 
albuminrcreatinine ratio, were not recruited for this thesis. This sub-set of IDDM 
women is known to be at particularly high risk of developing PE, probably because of 
pre-existing vascular endothelial dysfunction. As this thesis was looking specifically 
at disorders in either calcium homeostasis or the RAS it was decided that the inclusion 
of a complicated sub-set o f women would only confuse the issues under investigation.
Timing o f the post-pregnancv studies
Calcium metabolism is affected by lactation. Kent et al (1991) found that lactating 
women had very significantly reduced UCE following oral calcium loading compared
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with either pregnant or non-pregnant women. There is no evidence that serum iCa2+ 
concentrations are affected by lactation but iPTH appears to be raised in lactating 
women (Specker, Tsang & Ho, 1991; Ardawi, Nasrat & A’Aqueel, 1997). For these 
reasons it was necessary to wait until the participating women had finished lactating 
before carrying out the last calcium load experiment. Inevitably this produced great 
variation in the timing of the post-pregnancy studies. However, almost all were 
performed within one year and there was no significant difference between the timing 
of the normal and IDDM post-pregnancy studies so comparisons are still likely to be 
valid. The prolonged wait also reduced compliance with the post-pregnancy study, 
and one woman in each group moved away from the area before stopping lactation. 
Post-pregnancy data are also compounded by the women being at different phases of 
their menstrual cycle or using oral contraception. It was impossible to prevent the use 
of oral contraception and it also proved difficult to try to bring up all the women 
during the same phase of the menstrual cycle because of the constraints of childcare 
and the women’s work. For example they might only be able to come on a specific 
day when their partner or another person was available to provide babysitting. It was 
decided that it was more important to get the women to reattend at any time rather 
than lose their participation as a non-pregnant control.
Earlier work had shown that there was no significant difference in urinary sodium, 
potassium or calcium excretion between the two phases o f the menstrual cycle and 
also that the concentration of iPTH was unchanged (Bisson, 1992). Plasma 
concentrations of renin, Aogen, Ang II and aldosterone are all known to fluctuate 
during the menstrual cycle with peak activity after ovulation (Brown et al, 1964 and 
Kaulhausen et al, 1978). More recent work looking at women on modem, low dose 
oestrogen (30mcg), combined oral contraceptives (COC) and women in the third 
trimester o f pregnancy compared to controls has shown that both pregnancy and the 
COC produce a similar 3-4 fold rise in PRS (Derkx et al, 1986). Despite having a few 
women in each non-pregnant group on the COC this study was still able to shown a 
similar magnitude o f rise in PRS between the non-pregnant women and the pregnant 
women. The same study by Derkx showed lower plasma concentrations of renin 
measured by an immunoreactive method in the women using COC compared with 
control women. In this thesis PRC was measured by reacting the renin in the sample 
with excess (heterologous) Aogen under standard pH and temperature conditions.
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Therefore the differences in PRS between COC users and non-users was not relevant 
and the same applies to the increased PRS in pregnancy. In addition the main purpose 
o f this study was to compare normal women with IDDM women and as both were 
rather disparate groups outside of pregnancy the effects o f COC use and progesterone- 
only pill use may have cancelled each other out leaving the main difference of 
diabetic status.
Fasting before the study
Glucose ingestion is known to increase both UCE and UMgE (Lindeman, Adler, 
Yiengst & Beard, 1967; Lemann et al, 1970). In the same paper Lindeman et al 
showed that glucose ingestion decreased potassium excretion and that dietary protein 
led to similar increases in UCE and UmgE, whereas eating fat had no effect. For all 
these reasons it was important that the patients were fasted before the study. This 
could potentially have produced problems in the IDDM group; as it was only two 
women were hypoglycaemic prior to the start o f one o f the studies with plasma 
glucose values of 2.0mmol/L and 1.9mmol/L. One woman had to eat a slice o f toast 
90 minutes before the start o f the 21 week experiment. The experiment was continued 
in this case because it was impossible for the woman to rearrange another morning for 
the study within the appropriate time frame. This particular woman did have higher 
than average IDDM values of FEK, FECa and FEMg at 21 weeks but her values were 
not the highest measured and did not significantly affect the study results overall.
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4.2 Dietary study results
The gold standard for assessing dietary intake of a specified nutrient is to weigh all 
food and drink consumed over a given time period and then calculate amounts using a 
reference volume for the composition o f foods. Studies such as these which are 
usually carried out on in-patients are highly disruptive to normal life and also 
extremely expensive. For these reasons it was decided to use a food frequency 
questionnaire to evaluate calcium intake. The questionnaire selected had previously 
been validated in 25 subjects, who not only completed the questionnaire with a 
dietician, but also kept a food diary over 8 days in which they recorded the weights o f 
food and drink consumed, having previously been instructed in how to do this. The 
mean daily intake estimated from the questionnaire was 1134mg calcium and that 
derived from the diaries was 1173mg (Ryan et al, 1994). During this study the 
questionnaire was administered by the researcher, after training by a dietician. To 
increases accuracy food portion models were used.
Food frequency questionnaires have also been used to assess nutrient intake in 
pregnant women with similar backgrounds to the volunteers in this study (Robinson, 
Godfrey, Osmond, Cox & Barker, 1996; Rogers & Emmett, 1998). The former 
showed closest agreement between the questionnaire and food diaries for calcium 
intake while the latter found that pregnant women in the South West o f England 
tended to consume slightly more calcium daily than the national daily 
recommendation for non-pregnant women.
The majority o f studies on calcium supplementation in pregnancy have attempted to 
make some assessment of baseline calcium intake although this was not done in the 
largest o f the South American studies (Belizan et al, 1991), nor in that of Lopez- 
Jaramillo et al (1989) who studied women in the Andes. Others used either food 
frequency questionnaires (Crowther et al, 1999) or 24 hour dietary recall methods 
(Belizan et al, 1983a; Villar et al, 1987; Knight & Keith, 1992; Levine et al, 1997). 
Average daily calcium intakes during pregnancy in this study were 1316mg in the 
normal women and 1574mg in the IDDM women with wide standard deviations in 
both. These values are very close to the American data presented by Levine et al 
(1997) whose calcium and placebo groups had intakes of 1113mg and 1135mg
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respectively before supplementation, and again standard deviations were in the region 
of ± 700mg. The Australian study, which again looked at women from a developed 
country, had similar results o f 1144mg in the calcium group and 1268mg in the 
placebo group, although, surprisingly, just over a quarter of all the women in this 
study reported intakes o f less than 800mg per day (Crowther et al 1999). 
Unfortunately the Australian study did not report on the racial mix of their recruited 
women which could have accounted for this dietary discrepancy. This figure is closer 
to the South American dietary results quoted by Belizan et al, 1983a where average 
daily calcium intake was only 700mg.
Calcium intake in pregnancy in this thesis was in line with the Committee on Medical 
Aspects of Food Policy’s, 1991 recommendations of at least 1250mg daily. Outside 
pregnancy, women in this study also took in more than the minimum 
recommendation. Therefore the women in this study are very different to the South 
American women, studied by Belizan’s group, who have calcium deficient diets as 
defined by the British standard (Belizan et al, 1983a, 1983b, 1988 & 1991).
182
4.3 Blood pressure results
Measurement of blood pressure
It has been known for many years that BP has a diurnal variation (Brown, 1930). BP 
in pregnancy is also affected by the position of the patient; if it is taken with the 
mother lying supine 70% have at least a 10% fall compared to seated values, and in 
8% it falls by 30-50% (Holmes, 1960). To minimize these differences our readings 
were all taken between 09.00hr and 12.00hr and with the patients sitting. BP 
recording in pregnancy is made even more problematic by the fact that Korotkofif 
sounds may persist to zero because of peripheral vasodilation. For this reason it was 
once recommended that Korotkoff IV should be used to measure the DBP in 
pregnancy (Petrie, O’Brien, Littler & de Sweit, 1986; World Health Organization, 
1987; Davey & MacGillivray, 1988)) and this was used in this study. However while 
this study was on-going this advice changed and it is now recommended that 
Korotkoff V be generally used, with Korotkoff IV being recorded in the very rare 
cases when Korotkoff V does in fact persist to zero (de Swiet & Shennan, 1996). To 
minimize inter-observer error most o f  the BP measurements were taken by the same 
observer with a minority being carried out by one midwife who had been instructed in 
the technique to use. As neither o f these observers was blind to the diabetic status of 
the woman this could have biased the results. This would have been unacceptable if 
the primary purpose o f this thesis had been to look at BP measurements in IDDM and 
normal women. However, as this was only done as a minor part of the study, and 
there was no funding to provide an unbiased person to take BP readings it was the 
best that could be achieved. Alternatives would have been to use either an automated 
sygmomanometer or the Hawksley random zero sphygmomanometer to reduce 
observer error or bias. Unfortunately neither of these machines is problem free. 
Automated machines tend to underestimate the DBP, especially during pregnancy, 
because o f the discrepancy between Korotkofif IV and V mentioned above. The 
random zero monitor has also been shown to be more inaccurate than standard 
sphygmomanometers (O’Brien, Mee, Atkins & O’Malley, 1990).
Results
Whilst this study did not have the statistical power to comment on the incidence of PE 
in IDDM pregnancy it was interesting that none of the normal women developed PE
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but three o f the IDDM women did. This gives an incidence o f 15% for PE in IDDM 
pregnancy, similar to 14.4% found by Brudenell (1982) and 9.9% reported by Gamer 
et al (1990), and higher than the incidence reported in non-diabetic women which 
varies from 1% to 5%, or more depending on the definition used.
This study did not show any effect o f a daily 1.5g calcium supplement on BP. This 
contradicted several reported studies (Belizan et al, 1983a; Villar et al, 1987; Lopez- 
Jaramillo et al, 1989; Belizan et al, 1991; Knight & Keith, 1992). This study was 
very small with only 10 normal and 10 IDDM women assigned to each arm of the 
trial. However, two of the studies listed above were also extremely small with 
Belizan’s work of 1983 showing an effect of both lg  and 2g calcium supplements on 
11 women each and Knight & Keith’s work looking at 20 women with PIH half o f 
whom received lg  calcium. This thesis looked at women o f mixed parity with 17 out 
o f 40 being multiparous and therefore at reduced risk o f  PE. In this respect this study 
was compatible with Belizan’s initial report of 1983 which also studied women of 
mixed parity. The remaining studies mentioned above only considered primigravidae.
The women in this study were all receiving a good diet with an adequate intake of 
calcium for pregnancy as suggested by the United Kingdom Committee on Medical 
Aspects o f Food Policy (1991); that is at least 1250mg/day. In contrast the papers 
cited above had looked at women with below average calcium intakes; the 1983 paper 
from Belizan’s group looked at urban Guatemalan women on a average diet 
containing 700mg calcium per day. Knight & Keith (1992) looked at women from 
Mississippi but the hypertensive white women in this trial were only taking 810mg 
calcium daily and the black women with PIH even less -  351 mg per day on average. 
This dietary difference is the most likely reason why the women in this study did not 
benefit from calcium supplements.
Four years after work on this thesis began the results of the National Institutes of 
Health o f the USA trial o f calcium supplementation to prevent PE were published and 
showed no beneficial effect o f 2g/day calcium supplements for normal, healthy, 
nulliparous women whose diet already contained adequate calcium (Levine et al, 
1997 (table 4.1).
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Table 4.1 Incidence of hypertensive disorders during pregnancy according to 







Pre-eclampsia: 158(6.9) 168 (7.3) 0.94 (0.76-1.16)
- mild 108 (4.7) 109 (4.8) 0.99 (0.76-1.28)
- severe 50 (2.2) 59 (2.6) 0.85 (0.58-1.23)
Pregnancy-associated
hypertension:
351 (15.3) 397(17.3) 0.88 (0.78-1.01)
- mild 335 (14.6) 381 (16.6) 0.88 (0.77-1.01)
- severe 16(0.7) 16(0.7) 1.00 (0.50-1.99)
All hypertensive 
disorders
509 (22.2) 565 (24.6) 0.90 (0.81-1.00)
Results are given as numbers (%) of women and relative risks with 95% confidence 
intervals. The relative risks are those for a woman in the calcium group compared to 
a woman in the placebo group
In 1999, Crowther et al published their results which showed a beneficial effect of 
1.8g daily calcium supplementation in preventing PE in 456 nulliparous, Australian 
women (relative risk 0.44[95%CI 0.21-0.90]). This appears to contradict the much 
larger American trial but the Australian trial was halted because of a lack of funding 
when they had recruited less than half of the women suggested by their original power 
calculations and therefore their results need to be interpreted with caution. A 
surprisingly large number of women in the Australian trial had low calcium intakes 
with 29.3% in the calcium group and 27.7% in the placebo group consuming less than 
800g calcium per day. Unfortunately no comment was made on the ethnicity of the 
subjects in the Australian trial which may have contained large numbers of women of 
aboriginal origin who may well have a less good diet than Australians of European or 
Asian descent.
The results for normal women presented in this thesis are in keeping with the bigger 
prospective, randomized, double-blind, placebo-controlled trial from America which
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has shown that the prevention o f PE is not easily obtained with this simple dietary 
manipulation in women who are already calcium-replete (Levine et al, 1997).
When normal and IDDM women were compared in this study the normal women had 
a fall in DBP during the second and early third trimester with a gradual rise towards 
the end of pregnancy as first described by MacGillivray, Rose & Rowe (1969). This 
“mid-trimester” fall was not apparent in the IDDM women. Similar findings were 
reported by the ‘Diabetes in early pregnancy study’ which enrolled 312 IDDM 
women and 356 control women within 3 weeks of conception and found no difference 
in either SBP or DBP between the groups at 6 weeks’ gestation. Although not all the 
women in this study had their BP measured at each time point almost 250 IDDM 
women and 300 normal women did have their BP measured during the second 
trimester; the normal women showed the expected fall but the IDDM women did not 
(Peterson, Jovanovic-Peterson, Mills, Conley, Knopp, Reed, Aarons, Holmes, Brown 
& Van Allen, 1992).
This fall in DBP in the middle trimester of normal pregnancy is likely to be the result 
o f peripheral vasodilation which reduces the peripheral vascular resistance more than 
can be compensated for by the pregnancy-induced rise in cardiac output. Thus the 
failure of the IDDM women to show such a fall in DBP could either be as the result of 
an increased cardiac output or because of a reduced fall in peripheral resistance.
Cardiac output is a function of left ventricular stroke volume and the heart rate. In 
1986 Airaksinen, Ikaheimo, Salmela, Kirkinen, Linnaluoto & Takkunen performed 
echocardiography on 17 pregnant women with IDDM and 11 normal pregnant women 
who acted as controls. The mean duration of diabetes was 14 years, exactly the same 
as in this thesis. The women were studied prospectively in each trimester and post­
partum. The authors found that the IDDM women had slightly smaller left ventricles 
than the normal women when not pregnant and that they also had less o f a pregnancy- 
induced increase in left ventricular size and stroke volume. As they also had a smaller 
increase in heart rate during pregnancy the overall pregnancy associated rise in 
cardiac output was only 1.3L/min in the IDDM women compared to 3.4L/min in the 
normals. Therefore the failure o f DBP to fell mid-trimester in the IDDM women 
appears not to be caused by an increased cardiac output.
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Peripheral resistance is controlled by both the autonomic nervous system and by 
various substances which act directly on the blood vessels. Ang II is the most potent 
vasoconstrictor known and the role o f iCa2+ in vascular contraction and relaxation has 
been discussed already in the introductory section o f this thesis. Other substances 
which produce local vasodilation are the end-products o f tissue metabolism such as 
hydrogen ions, potassium, lactate, carbon dioxide and prostacyclin. As discussed in 
greater detail later (Section 4.6, p i97) this thesis found decreased PRC in IDDM 
pregnant women. If all other considerations were equal this would tend to produce 
lower levels o f Ang II in the IDDM women and therefore vasodilation and a fall in 
BP. This thesis also did not show any change in serum iCa2+ concentrations in IDDM 
women.
Prostaglandins were not measured in this thesis. As mentioned above it is likely that 
the fall in DBP which occurs in normal pregnancy in caused principally by ‘flooding’ 
o f the circulation by vasodilators -  chief among these being prostacyclin. The urinary 
excretion o f prostacyclin, which equates directly to the its serum concentration but is 
technically easier to measure, rises four-fold by 20 weeks in normal pregnancy and 
remains at this level until delivery. In contrast it only rises two-fold in pregnancies 
which subsequently become complicated by PIH (Fitzgerald, Entman, Mulloy & 
Fitzgerald, 1987). There is now increasing evidence that prostacyclin production is 
impaired in diabetic pregnancy (Kuhn, Botti, Cherouny & Demers, 1990). This will 
result in reduced peripheral vasodilation and hence less o f a fall in BP.
The blood vessels o f pregnant IDDM (n=10) women have also been shown to be 
‘stififer’ than those o f normal pregnant women (n=20) in a study which used 
ultrasound to determine a stiffness index and hence the elasticity o f the maternal aorta 
and carotid arteries (Hu, Bjorklund, Nyman & Gennser, 1998). This difference could 
also limit peripheral vasodilation and lead to a failure o f BP to fall as much in IDDM 
pregnancy as in normal pregnancy.
The failure o f the pregnant IDDM women to show the usual mid-trimester fall in DBP 
may also be because o f impaired autonomic nervous system activity. Recent use o f 
24 hour ambulatory blood pressure monitoring (ABPM) has shown that non-pregnant 
IDDM subjects with normal BP by conventional recording and no evidence of renal
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impairment, defined by no microalbuminuria, are less likely than control subjects to 
have an overnight fall in BP (Spallone, Gambardella, Maiello, Barini, Frontoni & 
Menzinger, 1994; Gilbert, Phillips, Clarke & Jerums, 1994; Khan & Couper, 1995). 
In one of these studies a score for autonomic dysfunction was determined (Spallone et 
al, 1994) and there was a positive correlation between this score and the degree of 
abnormality in the 24hr ABPM profile. Autonomic nervous function was not studied 
in this thesis. In a study reported in 1987 autonomic function was measured during 
and after pregnancy in 25 IDDM women and 10 control women. No differences were 
found between the groups outside of pregnancy but autonomic function was impaired 
in the IDDM group during pregnancy (Airaksinen, Salmela, Ikaheimo, Kirkinen, 
Linnaluoto & Takkunen, 1987). Loss of diurnal variation in BP in pregnant women 
with PE has recently been reported (Halligan, Shennan, Taylor & de Swiet, 1997) and 
raises interesting possibilities about the increased incidence of PE in IDDM 
pregnancies.
It was disappointing that although, on initial inspection o f the data, calcium 
supplementation appeared to lower both SBP and DBP in the IDDM women this 
affect disappeared when the data were reanalysed as percentage changes from the BP 
at 20 weeks when the women were randomized to calcium or placebo. Although the 
IDDM women in this study were all taking diets adequate in calcium as defined above 
it had been hypothesized, prior to starting the study, that intestinal absorption of 
calcium might be impaired in IDDM making these women effectively calcium- 
deficient and therefore more likely to have shown an effect o f calcium 
supplementation.
Calcium absorption, as discussed in the introductory section o f this thesis (Section 
1.2A, pl2) is regulated by 1,25-DHCC, production o f which is regulated by iPTH. 
Levels o f 1,25-DHCC rise in normal pregnancy (Kumar, Cohen, Silva & Epstein, 
1979). To our knowledge vitamin D levels have not been studied in IDDM pregnancy. 
In 1972 Schneider & Schedl reported decreased absorption of calcium in the 
duodenum of diabetic rats compared to normal rats; they did not directly measure 
either iPTH or 1,25-DHCC. Subsequent work found plasma levels of 1,25-DHCC to 
be low in diabetic rats (Hough, Russell, Teitelbaum & Avioli, 1982). Human studies 
have shown conflicting results: in 1982, Christiansen, Christensen, McNair, Nielsen
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& Madsbad found normal levels of 1,25-DHCC in adult male IDDM subjects, 
although levels of 25-HCC and 24,25-DHCC were reduced. A few years later the 
finding o f normal levels o f 1,25-DHCC in Caucasian IDDM subjects was confirmed 
although the same workers found reduced levels of 1,25-DHCC in poorly-controlled 
Bantu IDDM subjects (Nyomba, Bouillon, Bidingija, Kandjingu & de Moor, 1986). 
The IDDM women in our trial were well controlled, especially during the pregnancy 
arm of the study and therefore likely to have normal levels o f 1,25-DHCC. It was 
extremely unfortunate that promised funding was withdrawn so that 1,25-DHCC 
could not be measured in this study. It was interesting that in the tiny group of 
women in whom it was measured at 31 weeks gestation there was no difference 
between the normal and IDDM women but obviously this finding would need to be 
validated in larger numbers.
1,25-DHCC is also produced from 25-HCC in the placenta (Weisman, Harell, 
Edelstein, David, Spirer & Golander, 1979; Whitsett, Ho, Tsang, Norman & Adams, 
1981). 1,25-DHCC levels have been found to be low in PE (August, Marcaccio, 
Gertner, Druzin, Resnick & Laragh, 1992 and Graves, Wood, Brown & Seely, 1994) 
and it has been suggested that this is due to impaired placental production of the 
vitamin, yet another sign o f the inadequate placentation which occurs in pregnancies 
which are complicated by PE. 1,25-DHCC was not measured in any of the three 
women who developed PE in this study. However, their iCa2+ levels were not low, 
suggesting that they were not calcium deficient.
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4.4 Biochemistry results
In the non-pregnant women fasting serum Mg, PO4, urate and albumin concentrations 
were all significantly less in the IDDM women; at 21 weeks gestation these variables 
were identical in the two groups. This implies that the IDDM women do not respond 
to pregnancy in a similar way to the normal women. Concentrations of albumin are 
known to fall during normal pregnancy because of changes in plasma volume which 
rises progressively during pregnancy, plateauing during the last 8 weeks or so (Pirani, 
Campbell & MacGillivray, 1973). Robust experimental data on the plasma volume in 
IDDM pregnancy is not available but the consensus of opinion is that it probably does 
not increase to the same extent. The concentrations o f other plasma electrolytes are 
also known to fall in normal pregnancy, partly because of dilution due to the increased 
plasma volume and partly as a result o f increased renal excretion. The GFR increases 
soon after conception, reaching 60% above non-pregnant levels by 16 weeks and 
remaining there for the rest of the pregnancy (Davison, 1974). Tubular function is 
also affected with some substances being less efficiently reabsorbed during 
pregnancy. In 1977, Dunlop & Davison reported the excretion o f urate was increased 
in normal pregnancy leading to a fall in plasma levels.
This thesis found an increase in creatinine clearance and falls in serum sodium, 
potassium, creatinine, Mg, PO4, urate and albumin in normal pregnancy, compared to 
the non-pregnant state, which is in keeping with the finding o f others mentioned 
above. In contrast in the IDDM women there was no fall in serum sodium, Mg, PO4 
or urate and although creatinine clearance increased from the non-pregnant value this 
was not significant. One explanation for this is that the IDDM women have some 
degree o f impaired renal function compared to the normal women and that this 
difference is exacerbated when their kidneys are presented with the increased renal 
plasma flow which occurs in pregnancy as described by Davison & Dunlop, 1980. 
However, only one of the IDDM women studied had a second trimester urinary 
albumin:creatinine ratio outside the normal range and when creatinine clearances 
were compared outside pregnancy there was no difference between the normal and 
IDDM women. Also the results of this study showed the fractional excretion rate of 
sodium was not affected by diabetic status outside pregnancy and during pregnancy it 
was raised in the IDDM women compared to normal. Therefore the failure of the
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concentration o f serum sodium to fall in IDDM pregnancy must be caused by a 
smaller increase in plasma volume rather than impaired renal excretion of sodium.
There were also no differences in the 24hr excretion o f PO4 between the normal and 
IDDM women at any gestation and in fact during pregnancy the FEPO4 was 
increased in the IDDM women compared to the normal women implying yet again 
that serum PO4 concentration did not fall in IDDM pregnancy because o f less increase 
in plasma volume. Phosphate excretion will be discussed in greater detail below in 
the subsection relating to iPTH results.
When serum Mg is considered the situation is more complicated. In normal 
pregnancy serum Mg has been shown to fall progressively between 6 and 38 weeks 
(p<0.001) and as this fell parallels the fall in serum proteins it is likely to be due to 
haemodilution (Seydoux, Girardin, Paunier & Beguin, 1992). This thesis showed a 
similar fall. Outside pregnancy McNair, Christiansen, Madsbad, Lauritzen, Faber, 
Binder & Transbol (1978^ reported very significantly lower (pO.OOl) levels of 
serum Mg in IDDM subjects compared to normal controls. This finding was 
subsequently confirmed by Mather, Nisbet, Burton, Poston, Bland, Bailey & 
Pilkington (1979) and they showed a significant (p<0.001) negative correlation 
between serum Mg and plasma glucose. Other workers went on to confirm low serum 
Mg in diabetic subjects and to show that the worse the degree of diabetic control the 
lower the serum Mg (Sjogren, Floren & Nilsson, 1986).
It appears that serum Mg is low in IDDM subjects because of increased renal loss of 
Mg (McNair, Christensen, Christiansen, Madsbad & Transbol, 1982; Olukoga, 
Adewoye & Erasumus, 1989) and in anaesthetized rats treatment with insulin has 
been shown to reduce the renal loss of Mg (Anwana & Garland, 1990). Recently a 
group o f Danish workers showed that a 3 month period of improved glycaemic 
control in 49 subjects, achieved by frequent outpatient review and adjustment of 
insulin dosage, similar to the intensity o f treatment given to the pregnant IDDM 
women in this study, reduced the urinary loss of Mg but did not change the average 
serum Mg concentration (Djurhuus, Henriksen, Klitgaard, Blaabjerg, Thye-Ronn, 
Altura, Altura & Beck-Nielsen, 1999).
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The results presented in this study of lower concentrations of serum Mg and raised 24 
hour urinary Mg excretion in the non-pregnant IDDM volunteers compared to non­
pregnant controls are in keeping with the findings described above. Inevitably there is 
much less published data on Mg levels in IDDM pregnancy. In 1985 Wibell, Gebre- 
Medhin & Lindemark reported lower serum Mg in IDDM pregnant women compared 
with normal pregnant controls; Kuoppala (1988) found similar levels o f serum Mg in 
pregnant controls and IDDM women and also in a small (n=14) number o f women 
with gestational diabetes. A different study found no difference between extracellular 
total Mg in normal and diet-controlled gestational diabetic pregnancies but reduced 
intracellular free Mg in the gestational diabetic group (Bardicef, Bardicef, Sorokin, 
Altura, Altura, Cotton & Resnick, 1995).
In view o f this small number of studies on serum Mg concentrations in IDDM 
pregnancy and the discrepancies in their results, this thesis, looking both prospectively 
and longitudinally at serum Mg, in 20 IDDM women, is valuable. This thesis has 
found that serum Mg was the same in both the second and third trimesters in normal 
and IDDM pregnancy and although the 24 hour excretion o f Mg was higher in the 
IDDM women at both 21 and 31 weeks this difference was not significant. As 
mentioned above others groups have found a significant negative correlation between 
plasma glucose and serum Mg and this study also showed this association both during 
and outside of pregnancy. During pregnancy the IDDM women in this study had 
better glycaemic control and this is likely to explain the lack of difference between 
them and the normal women when serum Mg and urinary Mg excretion are compared.
Outside pregnancy approximately 30% of .filtered Mg is reabsorbed in the PCT, 50- 
60% in the Loop o f Henle and the remainder is excreted. The mechanism of Mg 
reabsorption is not understood but iPTH is not though to be involved (Hosking, 1998). 
This study showed no correlation between the FEMg and iPTH concentration in the 
normal non-pregnant women but significant negative correlations between these 
variables at both 21 weeks (p<0.01) and 31 weeks (p<0.01) were observed. Similar 
negative correlations were observed between these variables in the IDDM women 
when not pregnant and at 21 weeks gestation. Although these results initially appear 
to contradict the established view that iPTH is not involved in the physiological 
control of Mg excretion it is more likely that the correlations reported in this thesis are
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a spurious association produced by the confounding effect of the standard meal and 
oral calcium load. This study clearly showed a very significant effect (p<0.001) of 
the standard meal and oral calcium on the FEMg which increased by approximately 3- 
fold over the 4 hours from the meal in both groups of women at all three gestations 
(table 3.39 and fig. 3.41). Over the same time the oral calcium load markedly 
suppressed levels o f iPTH (see next section). Therefore, in this particular study, it is 
not surprising to find negative correlations between concentrations of iPTH and the 
FEMg.
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4.5 iPTH results and the effect of the oral calcium load on serum concentrations 
of iPTH, iCa2+ and POi and the FE rates of these ions
As discussed in detail in the introduction to this thesis (section 1.2C, p i4) the 
concentration of iPTH is known to be controlled predominantly by the concentration 
of serum iCa2+. iPTH acts to increase levels o f serum iCa2+ by two main mechanisms. 
Firstly, via 1,25-DHCC, the proportion of dietary calcium which is absorbed in the 
gut is increased and secondly iPTH acts directly on the PCX of the kidney to increase 
calcium reabsorption while PO4 excretion is increased. This study did not look at gut 
absorption o f calcium but it did study the relationship between serum iCa2+ and the 
concentration of iPTH and also the effect of altering both these variables on the 
excretion o f calcium and PO4. Pregnancy-induced changes in these factors and 
differences between normal and IDDM subjects during and outside pregnancy are 
discussed in this section. Relationships between iPTH and the RAS are discussed in 
the following section.
Several studies have found reduced levels of serum iCa2+ in subjects with IDDM 
(McNair, Fogh-Anderson, Madsbad & Christensen, 1983; Schwarz, Sorensen, 
Momsen, Friis, Transbol & McNair, 1992). However, the data are not all in 
agreement with Witt, White, Santiago, Seino & Avioli, (1983) reporting normal levels 
of serum iCa2+ in IDDM although the individuals in this study were not directly 
compared with controls. Fasting non-pregnant serum iCa2+ levels in this study were 
the same in both IDDM and normal women.
There is no consensus as to what happens to serum iCa2+ during pregnancy. Some 
report it as falling slightly (Tan et al, 1972; Pitkin & Gebhardt, 1977; Pitkin et al, 
1979), others have found that it rises (Reitz et al, 1977) and further studies have found 
no change (Gertner et al, 1986; Roelofsen et al, 1988; Dahlman, Sjoberg, Bucht, 
1994; Seely et al 1997). Another group reported a more complex picture with an 
overall rise in pregnancy compared with 12 months post-partum but a slight fell in the 
latter part of the third trimester (Rasmussen et al, 1990). Only four o f these studies 
(Pitkin et al, 1979; Rasmussen et al, 1990; Dahlman et al, 1994; Seely et a/,1997) 
used the same women throughout the study so that each woman gave repeated blood 
samples and acted as her own non-pregnant control; the others used groups of
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different women at different gestations and this may partly account for the 
discrepancy in their results. Although the longitudinal studies are likely to give a 
more accurate picture of pregnancy-induced changes in serum iCa2+ the post-partum 
data in the studies of both Pitkin et al (1979) and Seely et al (1997), are confused by 
the fact that some of the women were still lactating (20 of 30 women and 8 o f 23 
women respectively) when the blood samples were drawn. Pitkin compared ionized 
calcium levels in the lactating and non-lactating women and found no difference 
between the groups but this work has not been repeated with larger numbers (Pitkin et 
al 1979). The studies by Rasmussen et al (1990) and Dahlman et al, (1994) did not 
mention whether or not the women were lactating when they gave blood samples.
The study described in this thesis was a longitudinal, prospective trial in which each 
woman acted as her own non-pregnant control, only after she had discontinued breast­
feeding, and thus the criticisms mentioned above do not apply although there were 
considerable time delays between the pregnant and not pregnant samples (median 40 
weeks in the normal group and 29 weeks in the IDDM group). However it is unlikely 
that levels o f serum iCa2+ change significantly over this sort o f time period. The 
results presented earlier confirm that serum iCa2+ does not change in pregnancy. The 
little published work on serum iCa2+ in IDDM pregnancy indicates that concentrations 
are not altered by pregnancy (Cruikshank, Pitkin, Reynolds, Williams & Hargis, 1980; 
Cruikshank et al, 1983). Results in this thesis agree with this. Since a stable 
extracellular concentration of iCa2+ is important for many physiological functions, as 
described in the introductory section, it makes sense that this stability is maintained in 
both normal and IDDM pregnancy as demonstrated in this thesis. However it seems 
that the homeostatic mechanisms to maintain stable serum iCa are different m 
pregnancy.
Pregnancy was once though to be a “state of physiological hyperparathyroidism” but 
this was before assays which measured iPTH were available. Now different groups 
have reported either no change in pregnancy (Mimouni, Tsang, Hertzberg, Neumann 
& Ellis, 1989; Saggese, Baroncelli, Bertelloni & Cipolloni, 1991) or lower values 
during pregnancy, compared to postpartum (Rasmussen et al, 1990; Ardawi et al, 
1997) with none finding increased iPTH. This study showed that iPTH tended to be 
lower in normal pregnancy than in the same women outside pregnancy but this
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difference failed to reach statistical significance. It found no difference between 
values at 21 and 31 weeks gestation and showed no effect of chronic calcium 
supplementation on iPTH concentration. If, as all these studies and this thesis, 
suggest iPTH is not increased during pregnancy then there must be another 
mechanism by which the mother is able to obtain the 700mmol o f calcium required to 
create a healthy term baby especially as the UCE increases markedly during 
pregnancy as mentioned in section 1.2F, p i 8. The most likely explanation is that the 
proportion of dietary calcium absorbed rises during pregnancy because o f the 
increased levels o f 1,25-DHCC which have been shown to occur in pregnancy 
(Kumar et al, 1979; Whitehead et al, 1981; Reddy et al, 1983; Gertner et al 1986; 
Verhaeghe & Bouillon, 1992; Ardawi et al, 1997; Seely et al 1997).
Much o f the additional vitamin D found in pregnancy is produced in the placenta. 
The ability o f human decidual tissue to generate 1,25-DHCC and of human placenta 
to generate both 1,25-DHCC and 24,25-DHCC in vitro was first reported in 1979 
(Weisman et al). Subsequently Whitsett et al (1981) showed that human placenta 
could also synthesize 1,25-DHCC in vitro. As well as directly producing vitamin D 
the placenta secretes a protein hormone, PL, which increases in vitro renal 1-alpha- 
hydroxylase activity (Spanos et al, 1981). Additionally PL stimulates the production 
of insulin-like growth factor 1 (IGF-1) in the mother and the fetus and this also 
increases renal 1,25-DHCC production (Caverzasio et al 1990). Oestrogen, as 
mentioned above (section 1.2B, p i3) also stimulates renal 1-alpha-hydroxylaSe 
activity and is a further cause of the raised levels o f vitamin D found in pregnancy.
Levels o f 1,25-DHCC are known to be reduced in pregnancies complicated by both 
PIH (Frolich, Rudnicki, Storm, Rasmussen & Hegedus, 1992) and PE (August, 
Maracaccio, Gertner, Druzin, Resnick & Laragh, 1992). It has been hypothsized that 
this is caused by reduced 1,25-DHCC production by the abnormal placentae found in 
hypertensive pregnancies. Placentation in IDDM pregnancy is likely to be somewhat 
different to normal placentation and it would have been interesting if this thesis had 
been able to show low levels of 1,25-DHCC in IDDM pregnancy thus demonstrating 
a similar impairment in calcium metabolism in IDDM and PE pregnancies. Although 
the results presented earlier show an 11% reduction in levels of 1,25-DHCC in IDDM 
pregnancy in the third trimester, as only 7 women were analysed in each group
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because o f financial problems, this result was not significant and so conclusions 
cannot be drawn from it. Very little is known about vitamin D levels in human IDDM 
pregnancy; in 1988 Kuoppala published a cross-sectional study which found lower 
levels o f both 25-HCC and 1,25-DHCC in IDDM pregnancy compared to normal 
pregnancy. Later prospective studies found reduced levels o f 1,25-DHCC (Mimouni 
et al, 1989) and 25-HCC in IDDM pregnancy (Martinez, Catalan, Balaguer, 
Lisbona, Quero, Reque & Pallardo, 1991). The findings o f this thesis appear to agree 
with these studies.
The findings of lower levels o f iPTH in IDDM pregnancy reported in this thesis were 
very interesting. As with 1,25-DHCC little work has been done on levels of PTH in 
IDDM pregnancy. Using a C-terminal assay for PTH Cruikshank, Pitkin, Varner, 
Williams & Hargis (1983) reported reduced concentrations of PTH in IDDM 
pregnancy and a later study, which like this thesis, measured iPTH (Mimouni et al,
1989) found low-normal concentrations of iPTH in IDDM pregnancy compared to 
normal pregnancy. Others have suggested that the reduced values of iPTH found in 
IDDM pregnancy could be caused by reduced concentrations o f serum Mg (Mimouni 
et al, 1989). Severe Mg deficiency is known to impair iPTH secretion (Anast et al, 
1976) but more physiological reductions in serum Mg do not appear to have this 
effect (Toffaletti, Cooper & Lobaugh, 1991). This thesis did not find either reduced 
concentrations o f serum Mg in IDDM pregnancy or a positive correlation between 
serum Mg and iPTH levels in either the normal or IDDM women. There were 
significant negative correlations between serum Mg and iPTH at 21 weeks and 
outside pregnancy in the IDDM women (fig. 3.49, p i51); when serum iCa2+ was 
controlled for using partial correlation analysis this apparent negative correlation 
disappeared in the non-pregnant IDDM women. However at 21 weeks the negative 
correlation remained highly significant after controlling for serum iCa2+. No 
correlation between serum Mg and serum iPTH was demonstrable at 31 weeks in the 
IDDM patients regardless o f whether or not serum iCa concentrations were 
considered. In renal dialysis patients chronic hypermagnesaemia has been shown to 
decrease PTH secretion (Navarro, Mora, Jimenez, Torres, Macia & Garcia, 1999). 
IDDM patients, as discussed above, tend to be in a state of chronic Mg deficiency 
which was reversed in the patients in this study during pregnancy when their 
glycaemic control improved. Therefore for IDDM women pregnancy is a state o f
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relative hypermagnesaemia and this could cause the significantly reduced iPTH levels 
found at 21 weeks. By 31 weeks the correlation between these variables had 
disappeared possibly because the parathyroid glands had reset to higher levels o f  
serum Mg by receptor down-regulation.
Oral calcium loading
As expected the oral calcium load produced a significant increase in serum iCa2+. 
This increase was similar in the normal and IDDM women and was of the same order 
o f magnitude at all three gestations studied. The UCE also increased as expected in 
both groups of women at all three gestations. Both variables plateaued at four hours 
after the oral calcium. Work done by others has shown similar increases in both o f 
these variables which persist up to four hours after oral calcium (Broadus, et al, 1978; 
Kent et al, 1991). Broadus (1978) extended his experiments to six hours and showed 
a later fall in UCE.
It was mentioned above that PO4 excretion is increased by iPTH. When the overall 
amount o f PO4 excreted per 24 hours was compared this was the same in the normal 
and IDDM women and was not affected by pregnancy. However the fasting 
fractional excretion of PO4 was markedly raised in the IDDM women at both 21 
(p<0.05) and 31 (p<0.01) weeks gestation (fig. 3.18). This difference between the 
two groups of women was maintained during the calcium load experiments with 
IDDM FEPO4 being higher than normal FEPO4 at all times. As iPTH was generally 
lower in the IDDM women in this study an additional factor must be involved to 
explain their raised FEPO4. Ingestion of both glucose and galactose is known to 
increase urinary PO4 excretion within an hour (Lindeman et al, 1967) possibly 
because raised plasma glucose levels produce an osmotic diuresis and more PO4 is 
filtered in the kidney. The standard breakfast in this study contained both glucose and 
galactose and therefore inevitably this had a confounding effect on the FEPO4. This 
study showed strong positive correlations between plasma glucose and the FEPO4 in 
the IDDM women at all times and this is likely to be the cause o f their raised FEPO4.
Following the oral calcium load in the non-pregnant women the FEPO4 fell steadily 
(fig. 3.39) in both the normal and IDDM women with the IDDM women having 
higher values at all times as described above. During pregnancy the FEPO4 also fell
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after the oral calcium load although values for hour 1 were actually higher than the 
basal hour; this pattern was identical in both groups of women and at both study 
gestations (fig. 3.39). This fall in FEPO4 corresponds with suppression o f iPTH and a 
rise in FECa and was to be expected after the oral calcium.
As mentioned above ingestion of both glucose and galactose is known to increase 
urinary PO4 excretion within an hour (Lindeman et al, 1967). During pregnancy the 
plasma glucose rises more, at one hour, in response to a glucose load than in non­
pregnant individuals (Hatem, Anthony, Hogston, Rowe & Dennis, 1988). The 
standard breakfast in this study contained both glucose and galactose and therefore 
inevitably this had a confounding effect on the FEPO4 and may have accounted for 
the initial rise in FEPO4 in the pregnant women. Beyond this time plasma glucose 
tended to fall back towards fasting levels and therefore other factors such as the FECa 
and the suppressed serum iPTH were quantitatively more important in controlling the 
FEPO4 for the remainder of the calcium load experiments.
Ca supplementation
The calcium supplements which half o f the women were receiving by 31 weeks did 
not affect serum iCa2+or the UCE during either the fasting hour or in the four hours 
after the oral calcium load. This was not unexpected as the women did not take their 
supplements on the morning of the experiment. As this study and those o f Broadus, 
et al (1978) and Kent et al (1991) have shown the changes induced by acute calcium 
loading are immediate but last only a few hours and so effects o f the calcium 
supplements on either serum iCa2+ levels or UCE would not be expected to persist 
after an overnight fast.
Unexpectedly the subgroup o f women receiving the calcium supplements did not 
show a significant increase in the 24 hour urinary excretion of calcium. This is likely 
to be because the 24 hour excretion of calcium was measured in mmol/24 hours 
whereas the increases in UCE produced by the oral calcium loading were at maximun 
only 8mcmol/min, equivalent to 1 mmol/24 hours. Small differences like this can be 
easily lost in an inaccurate 24 hour urine collection. As was pointed out in the 
Introduction the majority o f ingested calcium is excreted in the faeces; had this study 
measured faecal excretion of calcium one would have expected this to be raised in the
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supplemented group. The failure of calcium supplements to alter the concentration of 
serum iCa2+ tends to support the hypothesis that calcium supplementation will not 
alter BP in women who are already receiving a diet adequate in calcium as it is 
difficult to suggest a mechanism for and effect on BP when serum iCa2+ is unchanged.
Serum iCa2+ in the IDDM women who developed PE was the same as in the other 
IDDM women. As none o f the 3 future pre-eclamptic women were hypertensive at 
the time when the blood samples were taken it is impossible to comment about levels
0 4 *of serum iCa in PE pregnancy.
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4.6 Plasma renin concentration and plasma renin substrate results
The results presented in this thesis confirm numerous earlier studies showing that both 
PRC and PRS are increased in normal pregnancy compared with data from non­
pregnant individuals (Skinner et al, 1972; Weir et al, 1975; Baker et al, 1990). 
However this study was more concerned with differences between normal and IDDM 
subjects. An overview of the RAS in IDDM has been given in the introductory 
section of this thesis (section 1.3H, p48). In summary levels of PRS appear to be 
unaltered in IDDM but overall PRC levels are low with a greater proportion of 
inactive prorenin to active renin being found in diabetic subjects.
PRC results
Fasting PRC in the IDDM women studied was not lower than in the normal women 
outside pregnancy and this contradicts established work on non-pregnant subjects 
(Day et al, 1975; Luetscher et al, 1985). This could be a type II error caused by small 
numbers and, as not all of the 40 volunteers could be persuaded to return after 
pregnancy, numbers in the non-pregnant group are smaller than in the pregnant 
groups. Renin levels have been shown to be normal in young IDDM subjects with 
short (3-5 yrs) duration o f disease (Wilson & Leutscher, 1990) but this does not 
account for the findings in this study as the average duration of disease in those who 
returned after their pregnancies was 13 years. However the IDDM subjects recruited 
to this study were relatively young, well-controlled and had very few diabetic 
complications and it is likely that there will be less differences between a diabetic 
group like this and non-diabetic subjects. After the standard breakfast PRC was 
lower, although not significantly so, in the IDDM subjects, compared to the non­
diabetic women, and this is in agreement with the findings of others.
During pregnancy this study did show reduced PRC in the IDDM women compared to 
the normal group. Very little work has previously been done on PRC in IDDM 
pregnancy. In 1982, Broughton Pipkin, Hunter, Oats & 0,Brien reported reused levels 
o f PRC in 7 normotensive diabetic patients of whom 6 had been insulin-dependent 
before the pregnancy and compared them to 9 normal pregnant women. The 
discrepancy between these results may be explained by smaller numbers in the latter 
study and differences in patient selection. The women studied by Broughton Pipkin et
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al 1982 were all primigravidae whereas in this study 6 o f 20 IDDM women were 
multigravid. As multigravid women tend to have a greater increase in plasma volume 
during pregnancy they would be expected to have greater suppression o f their RAS. 
However more of the normal women studied in this thesis were multigravid (11 out of 
20) and still PRC was higher in the normal than IDDM women.
Higher plasma glucose concentrations are an obvious difference between groups of 
normal and IDDM subjects. However, as discussed in the introductory section of this 
thesis, reasons for low renin in IDDM are likely to be multifactorial and it would be 
simplistic to expect a strong correlation between PRC and plasma glucose. Therefore 
it was not surprising to find no relationship between these two variables in either 
group of women at most of the study gestations. What was surprising was the 
apparently very significant (p<0.01) correlation between PRC and plasma glucose in 
the normal women in the third trimester. It has been shown that the plasma glucose 
response to a 75g oral glucose tolerance test is greater in women in the third trimester 
compared with either women in the second trimester or with women outside 
pregnancy (Hatem et al, 1988). Extrapolating from this women in the third trimester 
of pregnancy will have higher plasma glucose levels than “normal” after meals and 
this could produce an osmotic diuresis. I f  this situation remained unchecked plasma 
volume would fall with serious consequences for the mother and fetus. The rise in 
PRC in response to rising plasma glucose which we have demonstrated would act to 
conserve plasma volume.
Chronic calcium supplementation did not affect PRC. This is in agreement with work 
done on dogs (Kotchen et al, 1974). Theoretically calcium could stimulate renin 
production by inhibiting sodium reabsorption in the kidney tubules but, as there was 
no difference in either serum sodium or the fractional excretion of sodium between 
the supplemented and non-supplemented women in this study, it is not surprising that 
PRC was unaffected too.
In this study there was a negative correlation (p=0.01) between serum iCa2+ and PRC 
in the normal women outside pregnancy which confirms the findings o f others that a 
fall in extracellular iCa2+ concentration leads to an increase in renin secretion. This is 
discussed in detail in the introductory section of this thesis and so is merely
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summarized here. Early experiments showed that the infusion o f both calcium 
chloride and calcium gluconate into anaethetized dogs reduced the rate of renin 
secretion (Kotchen et al, 1974; Watkins et al, 1976). This inhibition o f renin release 
was thought to occur via a direct action of calcium on the JG cells, not via the renal 
nerves or the baroreceptors. Further experiments have increased the evidence in 
favour of calcium having an inhibitory effect on renin release, in contrast to the more 
typical findings in exocrine and endocrine cells, where the calcium concentration is 
usually positively correlated with the secretion rate. In 1977 Baumbach & Leyssac 
looked at isolated preparations of rat glomeruli. They found that decreasing the 
extracellular concentration of iCa2+ increasd renin secretion, while increasing the 
intracellular concentration of iCa2+ using a calcium ionophore which facilitated 
calcium influx into the cells inhibited renin release. Others found that chelating 
extracellular iCa2+ with EDTA which subsequently produced a fall in intracellular 
iCa2+ increased renin release (Park & Malvin, 1978). The mechanism(s) by which 
raised intracellular calcium concentrations inhibit renin release remains hypothetical. 
One possibility is that calcium may activate chloride channels allowing chloride to 
flow out o f cells followed by potassium, thus the osmotic pressure o f the cell falls and 
water is lost by the JG cell and its renin-containing organelles which therefore are less 
able to secrete renin. Another hypothesis is that the secretory granules and the cell 
membrane are separated by a network of myofilaments which contract as the 
intracellular concentration of calcium is raised, this decreases contact between them 
and so secretion cannot occur.
This negative association between serum iCa2+ and PRC was not apparent in the 
IDDM women in this study probably because there are other, quantitatively more 
important, factors acting to suppress renin secretion in IDDM. The most important of 
these is likely to be that prostacyclin production is impaired in IDDM pregnancy 
compared with normal pregnancy (Kuhn et al, 1990) and prostacyclin is known to be 
an important stimulator o f renin release (section 1.3C, p38). Other factors probably 
also play a part, for example chronic glycosylation inactivates the prorenin-processing 
enzyme cathepsin B (Coradello et al, 1981) resulting in higher levels o f prorenin and 
low PRC. Another possibility is that the neuroendocrine processes involved in renin 
production and secretion are affected by IDDM. In 1979, Tuck et al demonstrated 
decreased sympathetic activity and impaired p-receptor mediated responsiveness of
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renin release in IDDM patients with peripheral neuropathy. None of the IDDM 
women in this study had obvious peripheral neuropathy, although nerve conduction 
studies were not done to look for the condition. However, as mentioned above, the 
IDDM women as a group failed to show a mid-trimester decrease in DBP and it was 
postulated that this might be a result o f some degree o f autonomic neuropathy. It is 
therefore not unreasonable to postulate that their renin release be impaired by 
sympathetic nerve dysfunction.
This thesis also found no correlation between serum iCa2+ and PRC in the normal 
pregnant women where basal levels of PRC were two- to three-fold higher than non- 
pregnant values. The main stimulus to renin release in pregnancy is thought to be the 
progesterone-driven increased renal excretion of sodium which would rapidly result in 
sodium depletion if it were not countered by increased renin, and hence aldosterone, 
production. During normal pregnancy progesterone rises about seven fold from levels 
found during the luteal phase o f the menstrual cycle (Aspillaga, Whittaker, Taylor & 
Lind, 1983). In IDDM pregnancy levels are even higher (Stewart, Whittaker, Persson, 
Hanson & Lind, 1989). In the face of such a strong stimulus it is not surprising that
•  'J -Lthe correlation between serum iCa and PRC was lost.
Compared with calcium less work has been done on Mg and renin secretion. In 
isolated, perfused rat kidneys (Fray, 1977; Ettienne & Fray, 1979) and in dog kidneys 
(Wilcox, 1978) increases in the extracellular concentration of Mg do appear to 
stimulate renin release. Infusion of Mg to increase basal levels by approximately 50% 
has also been shown to increase PRA in man (Ichihara, Suzuki & Saruta, 1993). This 
agrees with this study’s findings for the normal non-pregnant women but in the 
pregnant and IDDM women the situation was confused probably reflecting the fact 
that in these conditions Mg is not a physiological stimulus for renin release.
This study was unable to find any correlation outside pregnancy between iPTH and 
PRC in either the normal or IDDM subjects. In contrast to this, in 1992, Grant et al 
provided evidence for a direct stimulatory effect o f 1,34-PTH on PRA in non­
pregnant human volunteers. Although PRC and PRA are not identical, in the absence 
of factors known to influence PRA such as treatment with ACE inhibitors, one would 
expect them to respond to stimuli in similar ways. However it possible that iPTH has
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a different effect to 1,34-PTH on renin secretion. To the author’s knowledge the 
influence o f iPTH on PRC has not been studied before during pregnancy. This thesis 
found no relationship between the two variables in normal pregancy
PRS results
The results presented earlier confirm that PRS is unchanged in IDDM women 
compared to normal women outside o f pregnancy. At 21 weeks of pregnancy the 
IDDM women studied showed pregnancy-induced rises in PRS similar to the normal 
women (fig. 3.53). Broughton Pipkin et al (1982) also found that PRS rose in IDDM 
pregnancy compared to the normal (non-IDDM), non-pregnant range but they found 
lower values of PRS in their pregnant IDDM women. It is thought that the rise in
PRS, which occurs in pregnancy, is oestrogen-driven, paralleling rises found in
women taking oestrogen containing oral contraceptives (Derkx et al, 1986). In 1989, 
Stewart et al studying two groups, one English and one Swedish, of pregnant IDDM 
women, reported that serum oestradiol concentrations were higher at 28 weeks in one 
group (n=25) of IDDM women compared to normal controls although not in their 
other group (n=15); by 36 weeks both groups o f IDDM had raised oestradiol 
compared to normal. In this study PRS continued to increase significantly (p<0.05) 
between the second and third trimesters in the normal women, again confirming work 
by Baker et al, 1990; however there was no significant trimester difference in the 
IDDM women. This suggests that an additional factor may be opposing the
stimulatory effect of oestrogen in late IDDM pregnancy so that the rise in PRS is
reduced.
What this inhibitory factor might be remains unresolved. This thesis has shown 
reduced iPTH in pregnant IDDM women and iPTH is known to increase renin 
secretion as discussed in the introductory section (section 1.3C, p37). However iPTH 
does not appear to affect PRS (Smith et al, 1979) outside pregnancy. The effect of 
iPTH on pregnant PRS has not been studied before; the results in this study suggest a 
negative relationship between concentrations of iPTH and PRS in pregnancy. HCG 
probably increases PRS (Bramfield et al, 1990) but again this appears to be raised 
rather than lowered in IDDM compared to normal pregnancy (Stewart et al, 1989). 
Plasma glucose concentrations were higher in the IDDM women compared to the
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normal women but, although this study found a significant negative correlation 
between plasma glucose and PRS in non-pregnant IDDM women, there was no such 
association during pregnancy in either normal or IDDM women.
Previously published work does not suggest any role for glucose in the control o f PRS 
so the negative correlation mentioned above was surprising. This study also found an 
unexpected positive correlation (p=0.002) between plasma glucose and PRS in the 
normal non-pregnant women (fig. 3.59). Closer inspection of the data reveal that 
there are only five data points for values of PRS of greater than 2.75mcgAngI/ml in 
the non-pregnant normal women and in fact all o f these refer to one woman. If  this 
woman’s results are excluded then there is no correlation between PRS and plasma 
glucose. However, there are no a priori reasons for excluding this woman, a normal, 
normotensive multigravida who delivered a healthy child after an uncomplicated 
pregnancy. Similarly, there is no reason to suspect laboratory error as these samples 
were analysed along with approximately 500 others and only the five belonging to this 
woman were abnormally high. This illustrates the difficulty of studies which involve 
relatively few subjects as one outlier has a disproportionate effect on results. The 
negative correlation in the non-pregnant IDDM women cannot be explained away by 
looking in a similar way at the results o f a single woman but again it should be 
remembered that numbers in the non-pregnant group were less than 20 (n=13) 
because of the difficulty in persuading women with a young baby to return to the 
laboratory and caution is needed in interpreting apparently significant results.
During normal pregnancy this study showed a significant (p<0.05 at 21 weeks and 
p<0.01 at 31 weeks) negative correlation between iPTH and PRS. This was 
unexpected as when analysed separately the data showed an increase in PRS but no 
change in iPTH. It is difficult to explain this apparent association physiologically and 
it may just be a statistical error. Correlations were performed on many variables 
during this study and, even at a significance level of p<0.01, 1% of these “significant” 
results will have occurred by chance.
When parity was considered as a separate issue in this thesis is was interesting to find 
that at 21 weeks’ gestation the primigravid IDDM women did not have significantly 
lower PRC compared to the primigravid normal women but that PRC was reduced in
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the multiparous IDDM women compared to the normal multiparae. Multiparous 
preganancy is associated with a greater increase in plasma volume than a first 
pregnancy (McFadyen, 1989). It is likely that IDDM women do not respond to 
pregnancy with such a large rise in plasma volume as normal women and this 
difference may be more apparent in first diabetic pregnancies which could explain 
why there is less suppression o f PRC in the primigravid IDDM subjects. Why there 
should be a difference between 21 and 31 weeks gestation is not clear. It should also 
be remembered that as there were only 5 IDDM multiparous women included in the 
analysis (the sixth was one of the subgroup who developed PE) these parity 
differences should be interpreted with caution.
PRC and PRS results in the women who developed PE
The PRC values in the IDDM women who developed PE were extremely varied. D3 
had undetectable PRC outside pregnancy and in the third trimester, three weeks before 
she was admitted with PE. In the second trimester although PRC rose from zero it 
remained low. This IDDM woman had suffered from IDDM for 33 years, the longest 
disease duration amongst the volunteers, and she had also required laser treatment for 
diabetic retinopathy. Therefore, out of the 20 IDDM women studied, she was 
probably the worst case and the low renin levels found in her plasma are in keeping 
with low PRC reported by others in subjects with complicated IDDM. Notably her 
renal function, as assessed by micro albumin: creatinine ratio was not abnormal during 
the pregnancy although it was abnormal when she returned afterwards (at 
14mg/mmol). As mentioned in the Results section she should probably be regarded 
as a case of PE superimposed on IDDM renal disease.
D5 raises extremely interesting possibilities; at 22 weeks she had low levels o f PRC 
and normal levels o f PRS. When next studied at 31 weeks, just one week before her 
admission with PE, her levels of PRC were three- to four-fold higher than those of the 
non-pre-eclamptic IDDM subjects and her levels of PRS were approximately double 
theirs. It is possible that these very high levels o f PRC were responsible for her rapid 
rise in BP. D5 was unwilling to give blood samples after her pregnancy which was 
unfortunate as it would have been interesting to see if her PRC returned to normal.
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DIO’s results were inconclusive; in the second trimester and outside pregnancy she 
had relatively normal values of PRC and PRS but in the early third trimester PRS fell 
and PRC became undetectable. She did not develop PE until 37 weeks gestation and 
as this study’s protocol did not include PRC estimation in the latter part o f the third 
trimester it is not possible to draw any conclusions from this.
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4.7 Summary of findings
This thesis has confirmed the findings of others by showing a mid-trimester fall in 
diastolic blood pressure in normal pregnancy. Following work from South America 
on women with calcium deficient diets there was great hope in the 1980s and early 
1990s that simple dietary manipulation with calcium supplementation might reduce 
the incidence of pre-eclampsia and pregnancy-induced hypertension. This now seems 
not to be the case, at least in women with already adequate calcium intakes, and this 
thesis supports the latter opinion. The dietary results presented here show that both 
normal and insulin-dependent diabetic women in the South West of England have 
dietary calcium intakes in line with the 1991 recommendations of the Committee on 
Medical Aspects o f Food Policy.
This thesis was designed to compare insulin-dependent diabetic pregnancy with 
normal pregnancy. Inevitably therefore the results presented for normal pregnancy do 
little but confirm previous work. For example serum concentrations o f electrolytes 
and creatinine are known to fall in pregnancy whilst creatinine clearance and urinary 
calcium excretion are known to rise. It is also well-established that serum urate 
concentrations rise with increasing gestation. This thesis also confirms that serum 
ionized calcium concentrations are stable during normal pregnancy. Recent work on 
serum concentrations of intact parathyroid hormone in normal pregnancy has 
contradicted the long-held view o f pregnancy as a state of physiological 
hyperparathyroidism. The results of this thesis confirm that intact parathyroid 
hormone concentrations do not rise in normal pregnancy. This thesis is in agreement 
with previously published work showing that both plasma renin concentration and 
plasma renin substrate rise in normal pregnancy.
Similarly, much work has been done on calcium and magnesium homeostasis in 
diabetic individuals outside pregnancy. Thus the findings in this thesis, outside 
pregnancy, of low serum concentrations of magnesium and an increase in the 
fractional excretion of magnesium in diabetic subjects compared to controls are not 
new. The consensus o f opinion is that this urinary loss of magnesium is reversed with 
improved diabetic control and in this thesis this was certainly the case with the 
improved diabetic control achieved by the women during pregnancy. Existing data on
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serum concentrations o f ionized calcium in diabetic subjects outside pregnancy are 
conflicting; this thesis shows that they are identical to values in non-diabetic subjects.
When normal and insulin-dependent diabetic women were compared during 
pregnancy this thesis confirmed the previously noted trend for an increased incidence 
of pre-eclampsia in diabetic pregnancy. It also showed that pregnant diabetic women 
do not have the normal mid-trimester fall in blood pressure; in this respect the 
pregnant diabetic women in this thesis are similar to non-diabetic pregnant women 
who develop pre-eclampsia. A further new finding was that calcium supplementation 
has no effect on blood pressure in diabetic pregnancy.
This thesis has extended existing knowledge in the field of calcium, magnesium and 
phosphate homeostasis in insulin-dependent diabetic pregnancy. It has shown that in 
well-controlled pregnant diabetic women serum concentrations o f ionized calcium, 
phosphate and magnesium are the same as in normal pregnant women and that they 
respond similarly to an oral calcium load. It has also shown no difference in the 
fractional excretion rates of either calcium or magnesium between normal and 
diabetic pregnancy. The fractional excretion of phosphate was increased in diabetic 
pregnancy.
The response o f serum intact parathyroid hormone to oral calcium loading has not 
been studied before in insulin-dependent diabetic pregnancy. This thesis showed 
significantly lower fasting levels o f intact parathyroid hormone at 21 weeks in 
diabetic, compared with normal, pregnancy and there was a similar trend at 31 weeks. 
Following oral calcium intact parathyroid concentrations were suppressed within an 
hour in both the normal and diabetic subjects and there was a trend towards greater 
suppression in the diabetic group. Vitamin D has also not been studied adequately in 
insulin-dependent pregnancy. This thesis only measured 1,25-dihydroxy- 
cholecalciferol in a very small number of women but did show a trend towards lower 
levels in the diabetic women which warrants further investigation (section 4.8, p208).
Other positive new findings in this thesis were that plasma renin concentration is not 
increased in diabetic pregnancy as it is in normal pregnancy, and that plasma renin 
substrate rises in diabetic pregnancy as it does in normal pregnancy. The rise in
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plasma renin concentration which occurs in normal pregnancy is thought to be a 
response to the progesterone-driven natriuresis o f pregnancy. This thesis showed no 
reduction in sodium excretion in diabetic pregnancy which raises the question that an 
additional factor may be acting to suppress plasma renin in pregnant diabetic subjects. 
The similar rise in plasma renin substrate in normal and diabetic pregnant women was 
not unexpected as there was no a priori reason for thinking that plasma renin substrate 
levels are affected by insulin-dependent diabetes.
This thesis also found a trend towards reduced plasma renin concentration in 
multigravid diabetic women compared to diabetic primigravidae which has not been 
reported before. This raises interesting questions but may in fact be merely an error 
resulting from the small numbers o f multigravid diabetic women in the study.
Finally the findings of extremely high levels o f both plasma renin concentration and 
plasma renin substrate in one of the diabetic women just one week before the onset of 
clinically apparent pre-eclampsia, whereas her levels earlier in the pregnancy were 
indistinguishable form those of the other pregnant diabetic women, raises interesting 
possibilities about the role o f the renin-angiotensin system in the aetiology of pre­
eclampsia.
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4.8 Suggestions for further research
Although this thesis has answered many o f the questions posed initially regarding 
both calcium homeostasis and the RAS in IDDM pregnancy it has also raised more 
queries and highlighted areas of deficiency in the current understanding of the 
pathophysiology of IDDM pregnancy. Before discussing some of these areas in 
greater detail a few general points are worth considering.
The greater value o f prospective, longitudinal research compared to both retrospective 
and cross-sectional studies is not disputed. Whilst it is relatively easy to study women 
longitudinally during pregnancy, a time when frequent visits to hospital are well- 
tolerated, it is much harder to continue a study into the puerperium. It is also difficult 
to recruit large numbers of pregnant women with IDDM over a short time in a small 
area. This study managed to follow 20 normal and 20 IDDM women during 
pregnancy but less were willing to return after delivery, especially because of the 
prolonged wait for breast feeding to be discontinued. Numbers recruited would have 
been higher had the study not involved the randomization to either calcium or placebo 
as some women approached declined to accept this. As this thesis has shown no 
effect o f calcium supplementation on the women studied, who already had a diet 
adequate in calcium, any future study could leave out the calcium supplement part of 
this work and recruitment would therefore be easier. Recruitment could also have 
been improved by extending the study to neighbouring hospitals, thus achieving 
higher numbers without jeopardizing the prospective, longitudinal aspect o f the study.
Women with pre-existing hypertension or renal disease were not recruited for this 
thesis. If a larger study were being undertaken it would be interesting to deliberately 
recruit such a sub-group for comparison with the uncomplicated IDDM women.
Analysis o f the results in this thesis, and comparison of them with the results of 
others, was potentially complicated by the fact that the women recruited were of 
mixed parity, although in many cases this did not significantly alter findings. In 
general any study on pregnancy should involve either only primigravid patients or 
large and equal numbers o f primigravidae and multigravidae to facilitate statistical 
analysis.
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This study found that serum concentrations o f iPTH are low in IDDM pregnancy and 
this immediately raises questions about differences in other calciotrophic hormones. 
The limited number o f 1,25-DHCC assays which were performed suggest that this too 
is reduced in IDDM pregnancy and it would be interesting to measure this in a larger 
number of women. Outside pregnancy 1,25-DHCC is produced in the kidneys; during 
pregnancy the placenta acts as an additional source of the vitamin as well as 
producing 24,25-DHCC (Weisman et al, 1979; Whitsett et al, 1981). It is likely that 
the IDDM placenta differs from the normal placenta and may therefore not produce so 
much 1,25-DHCC. It would be extremely interesting to compare in vitro production 
of the various forms of vitamin D in normal and IDDM placental preparations and 
also to measure circulating concentrations of the same substances in vivo.
This thesis has shown that PRC is reduced in IDDM pregnancy as it is in non­
pregnant IDDM individuals (Day et al, 1975; Luetscher et al, 1985). However in 
normal pregnancy PRC is raised (Skinner et al, 1972; Oats et al, 1981; Baker et al,
1990) and in order to compensate for this sensitivity to infused Ang II is reduced 
(Talledo et al, 1967). Subsequently increased sensitivity to infused Ang II has been 
shown to be predictive of the development o f PE (Morris et al, 1978; Oney & 
Kaulhausen, 1982; Nakamura et al, 1986; Dekker et al, 1990). Having demonstrated 
alterations in components of the RAS in IDDM pregnancy further work should now 
be done on the sensitivity o f pregnant IDDM women to infused Ang II.
The blood pressure results presented in this thesis showed that the IDDM women did 
not have a “mid-trimester fall” in diastolic blood pressure and it was suggested that 
this was because o f autonomic dysfunction leading to a reduced fall in peripheral 
resistance compared to normal pregnant women. Recent use of 24 hour ambulatory 
blood pressure monitoring has shown that non-pregnant IDDM subjects, who are 
apparently normotensive on conventional measurement and who have no evidence of 
renal impairment, are less likely to have an overnight fall in blood pressure and that 
this correlates with their degree o f autonomic nerve impairment (Spallone et al, 
1994). Pregnant women with PE similarly have no overnight fall in blood pressure 
(Halligan et al, 1997). A future study performing prospective 24 hour ambulatory 
blood pressure monitoring on a group o f pregnant IDDM women and simultaneously 
looking at their autonomic nervous function might well produce interesting results.
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APPENDIX I
Patient information sheet and consent form (see over) signed by volunteers before 
participating in study.
PATIENT INFORMATION SHEET FOR RESEARCH STUDY ON CALCIUM 
IN NORMAL AND DIABETIC PREGNANCY
Calcium is an important part of the human body. It forms the major part of bone and is 
also found circulating in the blood where it is involved in the process o f muscle 
contraction. It is also important for the contraction and dilation of blood vessels and 
so has an effect on blood pressure.
It is very important that mothers take enough calcium in their diet during a pregnancy 
so that the baby is provided with all that it needs especially for the development o f its 
skeletoa
There seem to be differences in the ways in which the bodies of pregnant diabetic 
women deal with calcium compared to non-diabetic women. For example, babies bom 
to mothers with diabetes may have low levels o f calcium in their blood. Diabetic 
women are also more likely to have problems with high blood pressure during a 
pregnancy and this may be related to the way in which their body handles calcium.
This research study is planning to look at levels of calcium and related substances in 
the blood and urine of pregnant diabetic women and also in some non-diabetic 
pregnant women so that we can compare results and see why the diabetic group is 
more likely to have high blood pressure.
If you agree to take part in this research you will either be given calcium supplements 
or a placebo (ie. a look-alike tablet which does not contain any calcium) from 20 
weeks of pregnancy. Neither of these tablets will have any harmful effects on your 
baby. Your blood pressure will be measured every two weeks in the normal way.
In order to study more closely the effects of the calcium tablets on substances in your 
blood and urine you will be asked to participate in two short studies during the 
pregnancy and in one after your baby is bom. This will involve collecting urine at 
home for 24 hours. The next day you come up to hospital for a morning during which 
some blood and urine samples will be taken. You will be given breakfast and a drink 
containing calcium. After lunch, which will be provided, you will be free to go home.
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CONSENT FORM
RESEARCH STUDY ON CALCIUM IN NORMAL AND DIABETIC 
PREGNANCY
Have you read the patient information sheet? YES/NO
Have you had the opportunity to ask questions and discuss
the study? YES/NO
Have you received satisfactory answers to all your questions? YES/NO
Have you received enough information about this study? YES/NO
Do you understand that you are free to withdraw from this study
- at any time
- without having to give a reason
- and without affecting your future medical care? YES/NO
Do you agree to take part in this study? YES/NO
Signed:____________________________  Date:
Name (in block letters):_____________________________
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APPENDIX II
Questionnaire used to assess dietary calcium intake.
1) What sort of milk do you use?
eg. whole, skimmed, semi-skimmed, fortified eg. Calcia, evaporated
2) How much milk do you use daily including tea and coffee?
3) Which bread do you use?
eg. white, brown, wholemeal, high fibre white eg. Mighty White
4) Do you use small or large loaves? or rolls?
Do you use thin, medium or thick sliced?
How many slices per day?
5) Do you drink bottled (what brand) or tap water?
How much?
6) How many drinks do you have per day made with water?
7) Do you use a water filterer or softener?
8) Do you eat yoghurt (Greek / natural / fruit) or fromage frais?
How much per week?
9) Which hard cheeses do you eat?
How much per week? (a food portion model was used)
10) Which soft cheeses do you eat?
How much per week? (again a model was used)
Using food portion models where appropriate the amount o f the following foods eaten 
per day / week / fortnight / month was then recorded:
Ice cream 
Eggs








Fresh orange juice 
Dried fruit
Dark green vegetables 
Milk pudding / custard 
Pastry (white or wholemeal)
Cakes (specify)
Pizza
Beans - baked 
kidney 
other
Soups (cream variety or home-made with milk)
Milky drinks eg. milkshakes 
White sauce
The subjects were also asked if they took calcium or mulitvitamin supplements, and 
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